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Abstract 
Background 
Eczema is an important condition as it affects 20% of children in the UK and is 
associated with significant morbidity for children and their families. Although some 
progress in understanding factors associated with the occurrence of eczema has been 
made, very little is known about factors associated with disease worsening. Most 
textbooks and review articles quote long lists of exacerbating factors but with very little 
scientific data to support them. Before I could begin to study this topic, I first had to 
define a disease flare in eczema, systematically review the literature on flare factors in 
eczema and review available outcome measures for eczema. 
Objectives 
The objectives of the main study described in this thesis were to assess the role of 
various environmental factors on the severity of eczema in a cohort of children with 
eczema. 
Hypotheses 
1. In hot weather, the combination of heat, sweating and grass pollen precipitates 
increased severity in children with eczema in the UK. 
2. In cold weather, the combination of cold weather, indoor aeroallergen exposure 
and reduced relative humidity from central heating lead to increased severity in children 
with eczema in the UK. 
These first two hypotheses were informed by previous research which proposed 
"summer" and "winter" types of eczema. 
3. Detergents (soap, shampoo) increase the propensity to disease flares triggered 
by other factors at all temperatures, but more in cold weather due to impaired skin 
barrier function. 
4. UK children with filaggrin mutations are more prone to the effects of climatic 
factors such as cold and heat than individuals who are wild type for filaggrin. 
5. Any combination of greater than or equal to three exposures at any time is 
associated with worsening of eczema. The exposures assessed included: dust, 
exposure to pets, shampoo, sweating, swimming, nylon clothing next to the skin and a 
change in mean temperature of more than 3°C from the previous weekly average. 
Methods 
Pilot study 
30 children with moderate to severe eczema aged 0 to 15 years participated in a panel 
study over a one month period in June 2003 in Cork, Ireland. This study involved daily 
completion of a paper diary recording eczema severity and exposures. Feasibility of a 
panel study design was assessed and associations between exposures and disease 
severity were analysed. 
Main study 
A prospective cohort study (n=60) of children aged up to 15 years with moderate to 
severe eczema was studied for between six and nine months with overlapping start 
dates to allow study of seasonal factors. Exposures studied included: temperature, 
relative humidity, sun exposure, sweating, clothing, cleansing products/ washing, 
outdoor pollen level, extent and nature of exposure to household pets, dusty 
environments and swimming. Children or their parents completed daily novel electronic 
diaries recording eczema severity and exposures. Portable dataloggers were used to 
record indoor temperature and relative humidity. External meteorological data was 
obtained from a local monitoring centre. 
The primary outcome was a daily "bother" score and the secondary outcomes were 
daily "scratch" scores and flares of eczema. Autoregressive moving average models 
(ARMA) were used to model the impact of each exposure on eczema severity for each 
individual. Standard random effects meta-analysis techniques were used to pool 
estimated coefficients across participants. Heterogeneity of responses as detected 
using Chi-squared tests represented inter-individual variation. The body site-specificity 
of reactions was also examined as was the interaction between filaggrin mutations and 
disease worsening with exposures. 
Findings 
Pilot study 
The pilot study highlighted the issue of drop outs and missing data during the study. 
83% (n=25) returned the diaries at the end of the study period, and within these, 
recording of disease severity was good (97% complete). However, there was variability 
in recording of exposures (65% to 83% complete). Preliminary findings suggested a 
temporal association between eczema severity and heat (lag 0, i.e. the day of 
exposure, p=0.04), damp (lag day 2, p=0.03), sweating and stress (lag day 3, p=0.03 
and p=0.02 respectively) and damp (lag day 4, p=0.001). 
Main study 
Primary outcome: "bother scores" 
Increased disease severity was associated with direct contact with nylon clothing 
(pooled regression coefficient 0.23, 95% CI 0.03 to 0.43), increasing exposure to dust 
(pooled regression coefficient 0.53, 0.23 to 0.83), exposure to unfamiliar pets (pooled 
regression coefficient 0.22, 0.10 to 0.34), sweating (pooled regression coefficient 0.24, 
0.09 to 0.39) and shampoo exposure (pooled regression coefficient 0.07, 0.01 to 0.13). 
-' 
The association between shampoo use and worsening of eczema was enhanced in 
cold weather (pooled regression coefficient 0.30, 0.04 to 0.57). Body site specificity was 
observed for the reactions to nylon clothing, which was greater on covered sites (trunk 
p=0.02, limbs p=0.03), reactions to wool clothing on truncal covered sites (p=0.03) but 
not limbs (p=0.62), while worsening of hand eczema was associated with exposure to 
pets (p<0.001). The only interaction with filaggrin mutations was observed for the 
2282del4 mutation and worsening of eczema in summer. Significant heterogeneity of 
responses between individuals was observed for exposure to grass pollen and outdoor 
temperature. In regard to the final hypothesis, a combination of any three of seven likely 
variables was associated with worsening of eczema (pooled regression coefficient 0.41, 
0.20 to 0.63). 
Secondary outcome: "scratch" scores 
Increased disease severity was seen associated with swimming (pooled regression 
coefficient 0.14,0.00 to 0.28), exposure to wool clothing (pooled regression coefficient 
0.28, 0.11 to 0.45), sweating (pooled regression coefficient 0.15, 0.04 to 0.26), 
shampoo (pooled regression coefficient 0.07, 0.01 to 0.13), dust (pooled regression 
coefficient 0.36, 0.12 to 0.59) and high grass pollen levels (pooled regression coefficient 
0.10, 0.01 to 0.73). 
Secondary outcome: flares of eczema 
Only swimming was clearly associated with worsening of eczema using this outcome 
measure (pooled regression coefficient 0.42, 0.05 to 0.80). 
Conclusions 
The following factors were shown to be associated with disease worsening in children 
with eczema in this UK study: clothing (wool and nylon), sweating, shampoo, swimming, 
dust, contact with unfamiliar pets and high grass pollen levels. Relative to the study 
hypotheses, the association between shampoo exposure and eczema worsening was 
shown to be increased in cold weather. There was also evidence showing an 
association between various combinations of exposures and disease worsening. There 
was insufficient evidence to support the other hypotheses tested in this study but this 
may be explained by low prevalence of these exposures. The implications of the 
findings of this study for clinical practice are that for the first time, it has been shown 
that shampoo exposure may be associated with eczema worsening and that this is 
more pronounced in cold weather. This study also suggests that worsening of eczema 
may be more complicated in that multiple exposures acting in concert may be 
associated with worsening of disease. Future research with increased participant 
numbers is required to specifically study possible gene-environment interactions with 
filaggrin mutations and their relevance in relation to disease flares and to look at 
shampoo formulations in relation to worsening of eczema. 
Introduction 
Eczema affects around 20% of UK schoolchildren and can have a significant 
detrimental effect on the quality of life of children and their families. 
The prevalence of the disease is increasing and at present it is the commonest reason 
for referral of a child to a dermatology clinic in the UK (Williams 1992; Williams, Stewart 
et al. 2008). Eczema causes significant morbidity including hospital admissions. social 
exclusion, missed school days, failure to thrive and sleep loss. It necessitates parental 
time and financial outlay for treatment. Investigators have shown costs per patient to 
vary between US$71 in the Netherlands and US$2,559 in Germany (Rathjen G 2000; 
Verboom, Hakkaart-Van et al. 2002). The constant itch of eczema results in bleeding 
and secondary skin infection, as well as sleepless nights for the sufferer and family 
members. 
Possible exacerbating factors are one of the primary concerns of parents of children 
with eczema. In some cases, the cause of disease flares is obvious to parents, but most 
of the time it is not, leading to avoidance behavior such as restrictive diets and missed 
recreational activities. Yet, there is very little objective analytic scientific data to support 
the roles of these potential triggers in provoking flares of eczema. Analytical studies are 
now required to clarify the confusion and some of the myths about possible flare factors 
and to establish whether flare factors work in concert as in a complex disease model or 
independently. 
Filaggrin 
It is well established that eczema is a multifactorial disease with a clear genetiC 
component. The focus of genetic research into eczema has been mainly on the 
immunological basis for disease. A key shift in the understanding of the genetics of 
eczema has been the discovery of mutations which affect skin barrier function. 
(-, 
Recently two null mutations in the gene (FLG) encoding the skin barrier protein filaggrin 
(filament-aggregating protein) have been shown to strongly predispose to eczema, 
acting in a semi-dominant genetic model (Palmer, Irvine et al. 2006; Smith, Irvine et al. 
2006; Sandilands, Terron-Kwiatkowski et al. 2007). The two FLG null mutations, R501 X 
and 2282del4 have been shown to be strongly associated with eczema, with odds ratios 
for risk of eczema between 3.7 and 7.1. These mutations are also highly prevalent, 
seen in approximately 10% of white European populations (Smith, Irvine et al. 2006). 
The association between filaggrin mutations and eczema have been repeatedly 
demonstrated in case-control and association studies (>20) from a variety of European 
populations and a number of other mutations have been identified,S of which are highly 
prevalent. FLG is located in the epidermal differentiation complex (EDC) on 
chromosome 1 q21. Profilaggrin, a filaggrin precursor is found in the keratohyalin 
granules in the epidermal granular layer (Figure 0-1). 
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Figure 0-1 Filaggrin staining in normal human skin 
Diagram of the epidermis Filaggrin staining in normal kin 
Strarum granulosum 
Epidermis 
Stratum pinosum 
Dennis 
Legend to figure 0-1 
This figure shows intense filaggrin staining in the stratum granulosum of normal human epidermis. 
Permission to use this image given by Dr Alan Irvine 
Profilaggrin is cleaved producing filaggrin which allows keratinocytes to flatten by 
aggregating their keratin cytoskeleton and producing squames. When filaggrin is 
subsequently degraded, its degradation products are composed of hygroscopic amino 
acids. Thus filaggrin may be important in two ways : to maintain barrier function of the 
skin and to keep the skin moisturised . It is estimated that up to 50% of children with 
eczema may carry one or two mutations in the gene encoding filaggrin (Palmer. Irvine 
et al. 2006). Individuals carrying one null-allele for filaggrin make only 50% of the 
normal amount of filaggrin. Often these individuals have a mild form of Ichthyosis 
vulgaris and are at risk for eczema. Individuals who have two null-alleles make no 
filaggrin and have a more severe form of ichthyosis vulgaris and are at greater risk of 
eczema (Palmer, Irvine et al. 2006; Smith, Irvine et al. 2006). Recent case-control 
studies have also highlighted an association between FLG null mutations and eczema 
phenotype, suggesting probable associations with early onset persistent severe 
eczema and asthma in association with eczema. 
As part of this study, the role of filaggrin mutations in the response to environmental 
factors will be assessed to determine if this is an important source of heterogeneity 
between individuals. 
Terminology 
Throughout this study, I will use the term, eczema (using the new World Allergy 
Organisation term to denote what was previously described as atopic eczema or 
dermatitis) (Johansson, Bieber et al. 2004). The reasons for this are that studies 
suggest that the majority of children with eczema, particularly in community settings, 
are not atopic, as defined by positive skin prick tests or serum IgE antibodies to 
common allergens (Flohr, Johansson et al. 2004). 
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Background: 
Chapter 1: What is meant by a uf/are" in eczema? 
1.1 Why is defining a flare an issue? 
Defining a flare is clearly a key component of a thesis that seeks to establish the 
possible causes of flares of eczema. Eczema is a chronic relapsing and remitting 
disease characterised by flares or exacerbations over years. Despite this, most trials in 
eczema have been of short duration (4 to 6 weeks), thereby concentrating on short-
term disease control (Hoare, Li Wan Po et al. 2000). More recent trials have begun to 
consider the issue of long-term control, with particular emphasis on the prevention of 
flares or relapses (Kapp, Papp et al. 2002; Wahn, Bos et al. 2002; Meurer, Fartasch et 
al. 2004; Papp, Staab et al. 2004; Gollnick, Kaufmann et al. 2008). This shift in focus 
has highlighted methodological issues regarding the definition of a flare, for which there 
is currently no clear guidance or agreement. 
The aim of this Chapter is to systematically review the current literature relating to the 
definition of disease flares for eczema and other chronic intermittent diseases, and to 
make preliminary recommendations regarding the most appropriate definition of a flare 
for use in clinical research based on the literature review and experience of trying to 
define an eczema flare in cohort studies and clinical trials. 
1.2 Materials and methods 
A detailed electronic search of Medline biographic database was done in April 2005 and 
updated in May 2008 using the following possible search terms "flare$"; 
"exacerbation$"; "relaps$"; remission$; worse$ and *recurrence". The search was 
restricted to all prospective studies of eczema in humans; using the Cochrane search 
terms for eczema (Appendix 2, 1-9) and prospective studies (Hoare. Li Wan Po et al. 
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2000). This included case series, case controlled trials and randomised controlled trials. 
The search resulted in 499 articles and was supplemented by reference checking of 
articles found in the primary search. Articles not written in English were first translated. 
An additional search of flare definitions in other chronic relapsing diseases such as 
asthma and rheumatoid arthritis was conducted to explore how other specialists had 
tackled the problem of defining flares and relapses. 
1.3 Results: 
1.3.1 How other researchers have defined flares in prospective studies 
The outcome of the search strategy is outlined below (Figure 1-1). 
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Figure 1-1 Outcome of search strategy for definitions of flares in eczema 
AD 
n = 14,891 
Legend to figure 1-1 
Flare 
n = 235,366 
Combined 
n = 499 
Papers examined 
n = 55 
Flare discussed 
n = 18 
(17 studies) 
Prospective 
n = 2,861,905 
Excluded: 
Not eczema 
Review 
Not prospective 
Flare not defined 
Flare not defined 
n = 37 
(n = 68) 
(n = 72) 
(n = 175) 
(n=139) 
This figure shows that while 499 papers were identified by the search strategy, only 18 (17 studies) defined flares 
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Most papers were either not relevant, or did not attempt to define disease flares. In 
total, 18 papers (17 studies) measured disease exacerbation or flare. The criteria used 
in defining a flare varied widely, but generally included some measure of worsening 
symptoms (8/17); the application of treatment (5/17); or duration of symptoms and / or 
treatment (7/17). All of the papers which provided a definition of disease flares were 
reports of clinical trials. No study was designed for the purposes of validating a 
definition of a disease flare in eczema. Definitions of disease flare or relapse in the 17 
trials could be categorised into 3 broad themes: i) composite definitions - describing a 
definition which includes at least two different factors (e.g. symptoms, severity, duration 
or treatment) (4 trials); ii) score thresholds or changes in severity scores (9 trials) and 
iii) behavioural definitions, i.e. defining a flare based on an action such as recourse to 
additional therapy or medical consultation (4 trials). A detailed summary of the 17 
studies which have defined a disease flare is given (Appendix 1) and discussed in more 
detail below according to the three broad categories. 
Composite definition of flare: 
Four articles used a composite definition of eczema flares; three of these articles derive 
from the same investigative group (the Multicentre Investigator Study Group) and the 
definitions are identical. Papp, Kapp and Wahn defined flares as an Investigator Global 
Assessment score (IGA) of ~ 4 4 (range 0 to 5) requiring corticosteroid therapy to begin 
within 3 days of the visit (either scheduled or unscheduled and prompted by a flare) and 
preceded by seven days without corticosteroid use (Kapp, Papp et al. 2002; Wahn, Bos 
et al. 2002; Papp, Staab et al. 2004). Thomas et al defined relapse as a scratch score 
(range 1 to 5) of more than 2 for at least three consecutive days (Thomas, Armstrong et 
al. 2002). 
Arbitrary score threshold or change in score: 
Nine articles provided a definition of disease flare based on a change in disease 
severity. Four groups of investigators used varying levels of change in the SCORAD 
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score to define disease exacerbation (European Task Force 1993; Akatan N 1998; 
Bunikowski, Gerhold et al. 2001; Ehlers, Worm et al. 2001; Granlund, Erkko et al. 2001; 
Salo, Pekurinen et al. 2004). Other investigators have used the three item severity (TIS) 
score, the total body disease activity score, the investigator global assessment score 
(IGAS) and a modified Costa scoring system (Appendix 1) (Costa, Rilliet et al. 1989; 
Sowden, Berth-Jones et al. 1991; George, Bilsland et al. 1993; Granlund, Erkko et al. 
1995; Wolkerstorfer, de Waard van der Spek et al. 1999; Hanifin, Gupta et al. 2002; 
Berth-Jones, Damstra et al. 2003; Siegfried, Korman et al. 2006). 
Behavioural definition: 
Three articles used operational definitions of relapse based solely on behavioural 
responses. The CASM-DE-01 study group defined relapse in their three papers as a 
period of at least three consecutive days during which moderately potent topical 
corticosteroid application was considered necessary (a named corticosteroid was 
selected for use in each participating country). In this group's second paper in 2004, 
they specified that the corticosteroids must be considered necessary by the investigator 
in their definition of flare, a point that was not clear in the 2002 paper (Meurer, Folster-
Holst et al. 2002; Meurer, Fartasch et al. 2004; Gollnick, Kaufmann et al. 2008). Zaki et 
al stated that the need to use potent topical steroids, or further systemic treatment 
constituted a relapse (Zaki, Emerson et al. 1996). 
1.3.2 Lessons from other chronic diseases 
The need to define flares and what constitutes disease control within the context of 
clinical research has been faced by those researching other chronically relapsing 
diseases. In some cases, consensus agreement had been achieved. For example, the 
Global Initiative for Asthma / National Institutes of Health guidelines have been adopted 
as a suitable definition of disease control for use in clinical trials of asthma (1997; 
(GINA) 1998). Similarly. the American College of Rheumatology has issued guidelines 
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on the definition of disease improvement for use in trials of rheumatoid arthritis (Felson, 
Anderson et al. 1995). 
In asthma, the definitions include totally and well controlled asthma weeks (TCAW and 
WCAW); based on symptoms, use of treatment and peak expiratory flow rate (PEFR), 
emergency room visits or medication related adverse events over a one week period 
(1997; (GINA) 1998; Bateman, Boushey et al. 2004) . Exacerbations are defined as 
deterioration in asthma requiring treatment with an oral corticosteroid, an emergency 
room visit, or hospitalisation. If the patient needs to use oral corticosteroid treatment for 
> 10 consecutive days, the eleventh day is considered to be a second exacerbation 
(Aalbers, Backer et al. 2004). Thus, the definition of control incorporates duration, 
symptoms, medication use, peak expiratory flow rates (PEFR) and need for further 
treatment. For investigators the options include using single composite measures such 
as TCAW and WACW or multiple outcome measures, such as PEFR and medication 
use. Both options have advantages and disadvantages, the former being simpler to 
analyse but at the cost of possible loss of statistical power. 
In rheumatoid arthritis, the American College of Rheumatology (ARC) and other groups 
have formulated well established definitions of remission (Pinals, Masi et al. 1981; 
Scott, Spector et al. 1989; Prevoo, van 't Hof et al. 1995; Eberhardt and Fex 1998; 
Makinen, Kautiainen et al. 2005). The concept of a "flare" of rheumatoid arthritis does 
not appear to have been agreed as a consensus; the focus in research being mainly on 
levels of disease activity. The definition of exacerbation or relapse in relation to 
rheumatoid arthritis as used in trials is usually based on a cut off on an arbitrary 
remission score, but in some studies descriptive terminology has been used (Yazici, 
Erkan et al. 2002; Verstappen, van Albada-Kuipers et al. 2005). In relation to multiple 
sclerosis, investigators have studied the concept of flares and a definition coined by 
Schumacher et al is widely used (Schumacher GA 1965; Panitch, Goodin et al. 2002; 
Schwid, Thorpe et al. 2005). This definition of relapse incorporates symptoms, signs 
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and duration. Some investigators have added arbitrary cut offs on disability scales to 
this definition in an effort to incorporate an objective scoring system and improve the 
clarity of the definition (Kurtzke 1983; 1998; Barbero, Verdun et al. 2004). 
1.4 Discussion 
1.4. 1 Strengths and limitations of different approaches to defining flares 
Composite definitions: 
Composite scales have emerged in the literature recently. Their main advantage is the 
use of a multi-dimensional scale incorporating several factors, such as duration, 
symptoms, signs and/or treatment. However, their increased complexity can lead to 
difficulties in interpretation, classification and high proportions of missing data. 
To illustrate some practical difficulties of using composite scales, data from previous 
research has been used (Thomas, Armstrong et al. 2002). An exacerbation of disease 
(relapse) was defined as a daily itch score of >2 for 3 consecutive days (Figure 1-2). 
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Figure 1-2a Schematic representation of typical pattern of eczema relapse and rem ission (relapse 
defined as 3 consecutive days with a scratch score of >2) 
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Figure 1-2b Typical problem of brief unsustained remissions- is this one or two relapses? 
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Figure 1-2c Typical problem of constant exacerbations but never for three consecutive days yet this 
would not fit the definition of relapse 
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This definition generally worked well as illustrated in Figure 1-2a. However, during data 
analysis it became clear that rules were required for occasional cases. A further 
example (Figure 1-2b) illustrates a situation where a lengthy relapse was broken by a 
brief remission (2 days)1. Should this be classed as a single relapse, or two relapses 
separated by a period of remission 1? Similarly, if there is high disease activity 
throughout, but this never persists for three consecutive days, is this a relapse? (Figure 
1-2c)2. 
The application of topical therapy was not required to define a flare in this study. Some 
participants recorded raised itch scores but did not use treatment. The opposite was 
also true, i.e. some participants documented low scores but used active treatment on a 
daily basis. In other words, does the behaviour represent habit or genuine disease 
activity which is not articulated in questionnaires or interview? 
Arbitrary score threshold 
Most of the papers which used an arbitrary threshold to define a relapse used the 
patient's disease severity compared to baseline. The advantage of this system is the 
clarity of the definition. However, in reality the baseline in a relapsing disease such as 
eczema will fluctuate. If the patient's disease is severe at baseline, they are unlikely to 
experience the percentage increase in score necessary for a relapse, due to a "ceiling 
effect". A further assumption is that baseline represents 'normal' or 'stable disease', 
which may not be the case unless the patient's disease is deliberately stabilised prior to 
enrolment in the trial. Inclusion criteria, study population and the use of a washout 
period will all impact on baseline scores. 
I Single relapse (remission had to he sllstained for at least .3 days for it to signify the end of a flard. 
: No, r e l a p ~ e e was ddined as.3 COI1SeCUllh' days with an itch Sl'()re >2 (1-:'), 
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A further important issue with definitions of disease flare based on arbitrary score 
definitions is that it involves little or no input from the patient. Whilst SCORAD does 
incorporate patient symptoms (itch and sleep loss), some of the other scoring systems, 
such as TIS and SASSAD, rely entirely on signs (Berth-Jones 1996; Wolkerstorfer, de 
Waard van der Spek et al. 1999). For a concept such as disease flare, the patient may 
be best placed to judge whether or not his/her disease is well controlled. 
Behavioural definition 
A definition of disease flare based on a behavioural response to disease activity 
includes actions such as applying a potent topical corticosteroid or a visit to a health-
care professional appears attractive. Such a definition incorporates the patient's 
reaction to the status of their skin and may be less subjective than concepts such as 
reporting itch in a questionnaire. However, the decision to treat is governed by many 
more factors than simple disease activity. Habit often plays a large part, as does 
anxiety, parental instructions, personality and treatment expectation. The side effects of 
topical corticosteroids are a particular concern for eczema patients, which means that 
those patients who are worried about using topical corticosteroids (or their carers in the 
case of children), may choose not to treat, despite increased disease activity (Charman 
and Williams 2003). 
1.5 Recommendations 
This review highlights the lack of consensus on how to definite flares and capture long-
term control in eczema. In relation to this particular thesis, it has lead to the proposal of 
novel definitions of what constitutes a flare in eczema which can be used as an 
outcome measure for the formal cohort study. It has also lead to the proposal of 
definitions of totally and well controlled eczema weeks, the usefulness can be 
compared against other measures of disease control in the formal study. 
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Definition of flare 
A "flare" of eczema is defined as an episode requiring escalation of treatment or 
additional medical advice. This should be pre-defined by investigators at the outset of a 
study. For instance, in a study of participants with mild eczema, escalation to the use of 
topical corticosteroids might constitute a "flare", in studies of moderate or severe 
eczema, the need to use potent or super-potent topical steroids or to attend a primary 
care physician or dermatologist for disease worsening might be more appropriate. It is 
not possible to develop an entirely standardised definition for "flare" as the true meaning 
is in relation to the individual patient and his/her perception of disease worsening above 
baseline. This definition will require validation in clinical trials. 
Totally and well controlled weeks (lCW and WCW) 
As a disease model, asthma has many similarities with eczema and the work of the 
Global Initiatives for Asthma / National Institutes of Health guidelines provides a useful 
model to follow. The concepts of totally controlled weeks (TCW) and well controlled 
weeks (WCW) should be considered for adoption in eczema research and some simple 
definitions have been outlined (Figure 1-3). 
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Figure 1-3 Summary of recommendations for totally controlled and well controlled weeks 
Totally controlled week (TCW) 
Rescue treatment not required * 
Plus 
Zero days with symptoms** above a pre-specified level *** 
Well controlled week (WCW) 
Rescue treatment used for ~ 2 2 days * 
Plus 
~ 2 2 days with symptoms** above a pre-specified level*** 
*Rescue treatment is defined as any additional treatment which has been specified in 
the study protocol to deal with disease deterioration. Standard co-treatment such as 
emollients can be allowed if specified in the treatment protocol. I n some study designs, 
study treatment is used as an "as required" treatment in response to disease worsening 
and therefore study treatment could be considered as rescue treatment. 
** Valid symptom assessment tools include either: 
i) Patient global assessment, or ii) Self reported itch/scratch 
***Pre-specified symptom level: 
5-point Likert scale (0-4) > 1 
VAS (0-10cm) >4 
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These definitions provide an intuitive means of assessing long-term disease control and 
are appropriate for use in a variety of clinical trial settings, as well as for epidemiological 
research. 
Using these definitions, a TCW is one in which no rescue treatment has been applied 
and in which symptoms are well controlled every day. Rescue treatment is defined as 
any treatment (other than emollient) which is applied in response to a worsening of the 
disease. Within the confines of a clinical trial, this would usually be "rescue treatment" 
as defined by the study protocol, but could also be the study treatment itself if it is 
applied in response to changes in disease activity. 
A WCW is one in which treatment has been applied for a period of :52 days and 
symptoms are controlled most of the time. These definitions are based on assessments 
over consecutive seven day periods. 
Choosing treatment, symptoms and duration as the components of these definitions, 
rather than signs, is pragmatically chosen to suit clinical research where daily or weekly 
patient review is often impractical. 
Potential limitations 
This is a retrospective review of studies which were not primarily devised to define 
flares of eczema. These recommendations will therefore require validation in clinical 
studies of eczema. 
Factors to consider when choosing this outcome measure for use in a 
clinical trial 
In relation to this study, it was decided to use flares as a secondary outcome measure 
as it captures meaningful outcomes that are understood by patients and clinicians. This 
measure was not used a primary outcome as it has not been validated and there were 
some concerns that it might not be sufficiently sensitive and might be associated with a 
loss of statistical power. It was also decided to assess the performance of totally and 
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well controlled weeks against monthly measures of severity. Using the latter measures 
as an outcome would have been inappropriate in this study where the focus is on short 
term disease flares. In order to inform this decision process, a possible decision 
pathway has been outlined. (Figure 1-4) 
"'\ ' 
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Figure 1-4 Decision process for choosing appropriate outcome measures in clinical trials 
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Include concept of 
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I 
1 No 
I No I 
Use existing 
validated 
scales at fixed 
time points 
.Or study treatment if applied "as required" in response to disease activity. TCW= totally 
controlled week, WCW= well controlled week 
Legend to figure 1-4 
This figure provides guidelines for when it might be appropriate to incorporate definitions of flares, TCW and WCW in 
clinical research. 
The use of a single categorical variable may lead to a loss of power; this needs to be 
weighed against the inherent simplicity of the measure. For the purposes of this 
thesis, this issue led to the use of this measure as a secondary, not a primary 
outcome. 
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Chapter 2: What causes flares in eczema? 
2.1 Introduction 
Having defined what is meant by a "flare" in eczema, I performed a systematic review 
of the literature to identify what evidence there is to support the roles of commonly 
blamed "flare factors" in eczema. This area needed more examination in order to 
inform the best exposure measures for use in this study and to confirm the suspected 
research gap this study was designed to counter. 
2.2 What causes flares in eczema? A systematic review of the 
literature 
2.2.1 Background 
"Flare factors" for eczema are frequently quoted in anecdotal lists and accepted as 
"facts" (Dahl 1990). However little scientific evidence is available to support the role 
of many of these factors as causes of disease exacerbations. As discussed in 
Chapter 1, several definitions of what constitutes a flare in eczema exist, 
predominantly for use in clinical trials. Most incorporate a combination of an increase 
in the severity of symptoms and/ or signs over a period of time requiring medical 
intervention. The ideal means by which the role of a "flare factor" in causing a flare of 
disease is established is to demonstrate a temporal relationship between exposure 
and disease worsening, a dose-response effect and, ideally, remission of the flare 
following withdrawal of the relevant factor. 
Cross-sectional studies and case series have assessed patients' beliefs regarding 
factors causing disease exacerbations. The list of beliefs is surprisingly uniform 
worldwide. Factors such as sweating, heat, sunlight, wool fabrics, grass intolerance, 
dust, stress, seasonality, holidays and hormonal influences are quoted as causing 
worsening in series from the UK, Germany, Finland, Japan and Nigeria, despite 
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cultural, climatic and racial variation (Schudel and Wuthrich 1985; Kemmett and 
Tidman 1991; Lammintausta, Kalimo et al. 1991; Turner, Devlin et al. 1991; Kissling 
and Wuthrich 1993; Katayama, Taniguchi et al. 1997; Tay, Khoo et al. 1999; Mattila, 
Kilpelainen et al. 2003; Nnoruka 2004; Williams, Burr et al. 2004). Such questionnaire 
studies suffer from the major potential for response bias. Cross-sectional studies are 
also unable to distinguish the temporal relationship between a factor and subsequent 
flare. Randomised controlled trials, e.g. of reduction of house dust mite (HOM) 
around the house, can imply that factors such as HOM may generally have 
something to do with overall eczema activity in groups of individuals, however, they 
rarely provide enough direct data to evaluate the relationship between specific 
factors and disease flares in individuals (Friedmann 1999). There is also an issue of 
whether studies of exposure reduction actually succeed in reducing exposure. I have 
therefore not included HOM reduction studies in this review as demonstrating 
improvement on HOM reduction does not confirm worsening on exposure. In relation 
to ultraviolet radiation, while this is proposed as a possible "flare factor", natural 
sunlight can improve eczema and ultraviolet radiation is also used in the treatment of 
severe eczema (Green, Oiffey et al. 1992). The focus of this review is therefore not 
on therapeutic trials of withdrawal of exposures but on prospective observational and 
experimental studies such as double-blind provocation studies since these are best 
placed to answer questions about what contributes to flares in eczema. 
2.2.2 Materials and methods 
A systematic review of the literature was carried out using Medline between 1950 
and May 25th 2008 to address the following question: What causes flares of 
eczema? 
Criteria for study inclusion 
Type of study 
A range of study types was included and ranked according to potential to minimise 
bias. Included studies were restricted to provocation and observational studies that 
evaluated worsening of disease after exposure to a potential flare factor. As 
discussed, studies looking at the impact of removing a potential provocation factor 
such as HOM were not included in this review as disease improvement on withdrawal 
of an exposure does not confirm worsening on exposure. Experimental or 
provocation studies were restricted to those with a prospective double blind design 
due to the high degree of potential information bias associated with open studies. 
Randomised controlled trials were included if they involved a provocation. Open or 
unblinded studies were excluded. 
Types of participants 
Only studies involving participants with eczema as defined by a physician were 
included (Johansson, Bieber et al. 2004). Studies concerning all age groups were 
assessed. 
Types of outcome measures 
The main outcome measures were worsening of disease, if relevant using severity 
scoring systems, for instance the SCORAO (European Task Force 1993). Studies 
which did not assess the impact of a challenge or provocation on the severity of 
eczema were excluded. 
Search terms 
The Cochrane Skin Group search strategy for eczema was used and combined with 
search terms for potential flare factors and disease exacerbations (Appendix 2) 
(Hoare, Li Wan Po et al. 2000). The online search was supplemented by an 
extensive hand search of the literature identified from retrieved articles and by 
contact with experts in the field. Searching was not restricted by language and where 
required, translation and/or interpretation services were used. 
2.2.3 Results 
The Medline search identified 29 relevant studies (Figure 2-1). 
Figure 2-1 Outcome of search strategy for flare factors in eczema 
Cochrane search 
terms for eczema 
14,891 
Potential "flare factors" 
See table 1 
2,122,985 
I 
Combined search 
terms and flare 
factors 
Terms for flare or 
exacerbation 
235,366 
Additional papers 
following reference 
checking 17 
Flare factors in 
eczema and 
definition of 
flares 
397 
I 
Excluded: 
-
Review articles 
89 
Relevant papers 
308 
Final relevant 
papers 29 
Exclusions following review: 
1. Treatment, not disease flares 61 
2. Sensitisation, not severity 35 
3. Not eczema 57 
4. Review articles 23 
5. N ~ h u m a n n 28 
6. Not "flare factors" 24 
7. Aetiology not flares 24 
8. Questionnaire studies 19 
9. Not blinded 25 
Total 296 
Meta-analysis was not considered appropriate due to the heterogeneity between 
studies in terms of study population, design, duration and outcomes. The summary 
assessment was therefore qualitative and results are presented in tabular form by 
factor studied. 
The results of studies of various "flare factors" are discussed in detail in Appendix 3. 
Briefly, thirteen studies assessed the role of foodstuffs in causing eczema flares. Of 
these, eleven studies were double blind placebo controlled food challenges 
performed after exclusion diets of possible foods associated with worsening of 
eczema. In these studies, skin status is assessed before, during and after exposure 
to either food or placebo given in a double blind placebo controlled fashion. In most 
of these studies, an elimination diet is given prior to the double blind placebo 
controlled food challenge (DBPCFC) and in some of the studies the double-blinded 
challenge is only given to those who improve following the elimination diet. Seven 
studies were carried out on participants with severe eczema and none incorporated a 
control group (Sampson and McCaskill 1985; Pike, Carter et al. 1989; Van Bever, 
Docx et al. 1989; Devlin and David 1992; Vieluf, Wieben et al. 1999; Worm, Ehlers et 
al. 2000; Breuer, Wulf et al. 2004). Nine studies included children only; the other 
studies involving either only adults or a mixture of age groups. Only three studies did 
not show a relationship between the exposure (sugar, tartrazine and various 
foodstuffs) and skin reactions although in most instances it was not clear if this was 
worsening of eczema (Pike, Carter et al. 1989; Devlin and David 1992; Ehlers, Worm 
et al. 2001). The two studies which were not DBPCFCs used a method called the 
skin application food test (SAFT) whereby the possible "flare foodstuff' was applied 
to the forearm under experimental conditions to determine if it was associated with 
the development of eczema at the site (Oranje, Aarsen et al. 1992; Oranje, van 
Toorenenbergen et al. 1992). 
Three studies assessed the role of dust mite, two using topical and one an inhalant 
approach (Norris, Schofield et al. 1988; Tupker, De Monchy et al. 1996; Shah, Hales 
et al. 2002). Only one of these studies had a control group (Norris, Schofield et al. 
1988). All three showed a worsening of eczema in at least 30% of participants. Two 
small studies looked at other aeroallergens using the atopy patch tests; the results of 
these studies are difficult to interpret (Wananukul, Huiprasert et al. 1993) (Bygum, 
Mortz et al. 2003). Briefly patch tests involve the application of potential allergens to 
the skin for a 48 hour period followed by examination of the skin at 96 hours to look 
for evidence of a delayed hypersensitivity reaction in the form of eczema at the site of 
application. 
Two studies looked at the effects of seasonal and climatic factors on eczema (Vocks, 
Busch et al. 2001; Kramer, Weidinger et al. 2005). The more recent study by Kramer 
et a/ was a prospective panel study of 39 children where daily observation of skin 
status was correlated with environmental and seasonal factors to determine if there 
was an association (Kramer, Weidinger et al. 2005). This study proposed that there 
are winter and summer types of eczema where the former flare in cold weather while 
the latter flare in hot weather with high grass pollen levels. 
2.2.4 Discussion 
Eczema is a chronic disease with a relapsing and remitting course and, due to 
frequent and unexplained fluctuations in disease severity, it is difficult to assess the 
roles of potential trigger factors scientifically. This systematic review has focussed on 
the evidence to support or refute the roles of commonly quoted "flare factors" on 
eczema. 
Strengths and limitations of this study 
This systematic review has critically appraised the evidence on the basis of study 
design and quality and has included non- English language papers. However, some 
relevant papers may have been missed despite a comprehensive search strategy as 
the data may be concealed within other studies, especially those with a primary focus 
on asthma or allergy. Another major limitation is that while the main interest of the 
study is the clarification of evidence for the causes of clinically relevant flares, the 
included studies focus on disease worsening which is not an equivalent concept 
(Langan, Thomas et al. 2006). Few if any of the studies have sufficient statistical 
power to establish definitive conclusions; no author has directly addressed this issue. 
Implications for this thesis 
Food Food allergy may be important in a subgroup of children with eczema, e.g. 
those with severe recalcitrant disease with a high suspicion of food allergy. Two 
caveats need to be mentioned. The first is that the clinical relevance of small 
changes in severity score is sometimes difficult to interpret. Second, nearly all of the 
studies have been undertaken on people with severe eczema in a hospital setting, 
thereby limiting the generalisations to people with milder disease in the community. 
Many RCTs have assessed the impact of food exclusion in eczema; the level of proof 
provided by this type of study is not direct evidence of causation since an 
improvement on removal of an exposure is not the same as flaring following 
exposure. 
House dust mite and aeroallergens The three provocation studies suggest an 
association between exposure and flares; this evidence is somewhat supported by 
the patch test studies (Norris, Schofield et al. 1988; Wananukul, Huiprasert et al. 
1993; Tupker, De Monchy et al. 1996; Shah, Hales et al. 2002; 8ygum, Mortz et al. 
2003). Other supportive indirect evidence is derived from atopy patch test (APT) 
studies, some of which show a correlation between positive test results and eczema 
in an air-exposed pattern; this association has not been confirmed in other similar 
studies (Darsow, Vieluf et al. 1996; 8ygum, Mortz et al. 2003; Darsow, Laifaoui et al. 
2004). These provocation studies may not equate to real life exposure to house dust 
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mite. A patient's history of flares on exposure to dust mite, which is used as a gold 
standard in APT studies, may not be a good indicator of the relevance of a factor 
, 
particularly if there is a lag period between exposure and reaction and/ or the 
presence of confounders. 
A number of investigators have studied the impact of house dust mite reduction 
measures in eczema and on the basis of three blinded RCTs, they concluded that 
there was some evidence that HDM reduction measures might be of benefit in 
eczema (Hoare, Li Wan Po et al. 2000). Four subsequent double-blind placebo 
controlled studies have addressed this issue with mixed results (Gutgesell, Heise et 
al. 2001; Oosting, de Bruin-Weller et al. 2002). 
Effects of irritants No study addressing this factor fulfilled the pre-determined 
criteria for this review, as investigators did not actually study the impact of irritants on 
severity of eczema. This does not mean that irritants are not an important cause of 
eczema flares as suggested by clinical anecdotal experience, but simply that the 
impact of irritants on eczema have not been studied sufficiently using appropriate 
study designs (Tupker, Coenraads et al. 1995; Seki, Morimatsu et al. 2003). 
Seasonality In the study by Kramer et at, post hoc analysis was the basis for 
conclusions regarding seasonality; this seasonality needs to be confirmed in new 
datasets designed to test an a priori hypothesis (Kramer, Weidinger et al. 2005). In 
the study by Volks et at, inferences drawn at a group level cannot be interpreted to 
be relevant at an individual level (ecologic fallacy) (Vocks, Busch et al. 2001). Some 
other issues related to this particular study were the selection of a group of inpatients 
(thereby reducing generalisations of findings) and the frequent population changes 
within the group. Thus both studies do not allow conclusions to be drawn regarding 
the impact on individual patients. 
Detergents and textiles The studies do not support advocating the use of cotton 
clothing and enzyme-free detergents to all parents of children with eczema, in the 
absence of a definite history of worsening following exposure to textiles or detergents 
(Diepgen, Stabler et al. 1990; Diepgen T J 1995). 
Stress The two case series identified in the review correlated stress but not , 
life events, with severity of eczema (Gil, Keefe et al. 1987; King and Wilson 1991). 
Indirect evidence from other types of studies adds weight to this association. Kimata 
et al has studied the impact of road traffic (n=26), video games (n=25) and ringing 
mobile telephones (n=27) on wheal responses and neuropeptides in eczema (not 
eczema severity) in two provocation case-control studies. In all three groups, 
increased wheal responses, substance P, vasoactive intestinal peptide and nerve 
growth factor was increased in the eczema group but not in controls (Kimata 2003; 
Kimata 2004). 
Ultraviolet radiation The clinical relevance to unselected patients with eczema is 
not clear (Deguchi, Danno et al. 2002). 
Infections Other indirect evidence supporting the importance of bacterial 
infections is the correlation between the presence of staphylococcal enterotoxin-
specific IgE antibodies (SEA and/ or SEB) and severity of eczema. This association 
has been tested in cross-sectional studies only and not in prospective cohort studies 
(Bunikowski, Mielke et al. 1999; Breuer, Wittmann et al. 2000; Ide, Matsubara et al. 
2004). 
Pets Exposure to furry pets is also frequently blamed for causing eczema flares. 
Such assertions have been based mainly on anecdote, the finding of high serum IgE 
levels to purified animal allergen in children with eczema and on positive atopy patch 
tests. These positive tests may simply be an epiphenomenon of the atopic state. I 
failed to find any high quality studies addressing the question of whether having furry 
pets in the home may be responsible for disease flares. Clearly, in clinical scenarios 
where there is a definite relationship between exposure to pets and severe disease 
flares, avoidance may be warranted. However, it is likely that exposure to a family pet 
will lead to tolerance even in those with pet allergy. Therefore, an individual is more 
likely to react following exposure to an unfamiliar pet. Further high quality studies are 
required to elucidate this relationship. 
2.2.5 Conclusion 
Good scientific evidence for the roles of "flare factors" in eczema is limited despite 
frequent anecdotal lists in review articles and textbooks. Further scientific study is 
required to elucidate the relative impact of these factors in studies of longitudinal 
design over longer study periods and whether combinations of factors rather than 
single factors are important, ideally in unselected groups of people with eczema. 
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Chapter 3 What are the best outcome measures for eczema? 
3.1 Introduction 
In Chapters 1 and 2 I have reviewed what is meant by a flare of eczema, I have 
reviewed the evidence to support the roles of various "flare factors" in eczema. In 
summary, no consensus exists between investigators regarding the definition of 
flares in eczema and, despite the high prevalence of the disease there is minimal 
scientific evidence to support the roles of "flare factors" in eczema. I have proposed 
recommendations of definitions for flares and totally and well controlled eczema 
weeks for use in future clinical research in the field. The definition of flares will be 
used as a secondary outcome for this study. Thus, the identification of a primary 
outcome measure, a further secondary outcome measure and measures which can 
assess overall disease control, against which the performance of totally and well 
controlled weeks can be tested, are essential. 
When carrying out epidemiological studies, it is critical that outcome measures which 
are validated for use in clinical research are utilised. A systematic review of the 
outcome measures currently used in eczema was therefore carried out (study carried 
out with Dr Jochen Schmitt (lead author) and Professor Hywel Williams) to determine 
which measures were adequate to use for the formal study. An outline of this review 
is described in Chapter 3. 
3.2 Background 
No laboratory test is available to assess disease severity in eczema (Chren 2000). 
Therefore clinical outcome measures are relied upon for clinical practice and 
research. This means that standardized and valid outcome measures are needed. 
Charman et at in a systematic review of outcome measures used to assess the 
impact of therapeutic interventions in eczema found that only 27% of the 
investigators used an "objective outcome measure that had been published before 
(Charman, Chambers et al. 2003). 56 different objective measures of disease 
severity were found in 94 trials. 
Another issue is the lack of validation of outcome measures. Charman et al also 
identified 13 named outcome measures of disease severity in eczema and reported a 
lack of validation studies for most of these measures (Charman and Williams 2000). 
Their review focused on whether published outcome measurements had been tested 
at all and not whether they performed sufficiently well when tested. 
The objectives of this systematic review were to update the review by Charman et at 
and to extend the previous review by assessing the validity, reliability, sensitivity to 
change, and ease of use of these measures (Charman and Williams 2000). 
3.3 Methods 
3.3.1 Literature search 
A systematic literature review was carried out using multiple search strategies to 
identify all named outcome measures of disease severity specific to eczema. 
Searches were undertaken for inauguration articles (Le., articles in which an eligible 
outcome measurement was published first), as well as subsequent validation studies 
of eligible outcome measures. 
MEDLINE and EMBASE were searched from inception until July 2006 using different 
combinations of the medical subject terms "atopic dermatitis," "atopic eczema," 
"severity of illness index," and "severity". Additional electronic searches were 
performed in MEDLINE and EMBASE for eligible outcome measures to search for 
data on validity, reliability, and sensitivity to change. Free internet searches were also 
performed for psychometrics, sensitivity to change, and acceptability data using 
http://www.google.co.uk. The researchers who created the outcome measures were 
also contacted for additional data relevant to validity. The literature search was 
restricted to articles with abstracts, articles on human partiCipants, and articles 
including original data. No language restrictions were imposed. Two reviewers (JS 
and SL) independently performed the literature search. Independent double 
assessment of eligibility was performed on a set of randomly chosen abstracts (10% 
of all abstracts identified). Agreement between the reviewers was 100%. Data 
abstraction was performed independently by 2 reviewers (SL and JS). 
3.3.2 Assessment of psychometric properties from the literature 
Before adopting an outcome measurement into clinical practice, it should be tested 
for reliability, validity, sensitivity to change, and acceptability (Streiner DL 1995). 
Validity means that the measurement truly measures what it is supposed to, whereas 
reliability means the confidence with which we can be sure that random error does 
not affect the measurement.(Kline 2005) Published data was assessed relating to 
construct validity, internal consistency, interobserver reliability, test-retest reliability, 
sensitivity to change, and acceptability. Definitions of these properties are 
summarized in Appendix 4 (Streiner DL 1995; Rosner 2000; Kline 2005). Criteria 
were also defined for "adequate" and "acceptable" psychometric properties prior to 
carrying out the literature review or extracting data (Rosner 2000). These criteria are 
also summarized in Appendix 4. 
Criterion validity is the extent to which a measurement relates to an external (gold) 
standard. One of the reasons this study was carried out that there is no gold standard 
to assess objective disease severity in eczema. Therefore it was not possible to look 
at criterion validity in this review. 
3.3.3 Assessment of content validity of outcome measures 
Content validity was not adequately described in the published studies; therefore, this 
issue was assessed in a separate study. 12 consumers (either individuals with 
eczema or their parents) were selected from the two centres involved in this study, 
Nottingham, UK and Dresden, Germany. These comprised 2 patients aged ~ 1 8 8
years, 2 patients aged 8-14 years and 2 caregivers of patients aged 1-7 years. Six 
international dermatology experts who were not involved in developing any of the 
relevant outcome measures scale were also selected. 
Experts and consumers rated content validity of all domains (e.g., intensity of lesion 
and extent of disease) and items (e.g., erythema, papulation, and scaling) included in 
named outcome measurements on a 5-point Likert scale ("very important," 
"important," "indifferent," "may not be important," and "unimportant"). Consumers and 
experts were blinded to the name of the outcome measurement and assessed the 
individual domains and items without knowing to which measure or measures they 
belonged. In other words, the name of the scale that the domain was a component 
of, e.g. SCORAD, was not stated when content validity was assessed. A median 
score of "important" or "very important" was required to rate a domain or item as 
adequate. More than 50% of the items used a particular outcome measurement to 
describe a domain needed to be rated as "important" or "very important" to conclude 
that the domain was measured adequately (Figure 3-1). 
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Figure 3-1 Content validity of domains and items used in outcome measures of eczema 
assessed by consumers (n=12) and experts (n=6) 
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Legend to figure 3-1 
This figure shows ratings of domains of scales assessing eczema severity rated by experts and consumers on a 
Likert scale . Experts and consumers considered intensity of lesions and extent of disease as "very important" criteria . 
Course of disease and symptoms were also judged to be "important" or "very important" by both groups, whereas 
epidermal function was considered as "may not be important" by the experts and "indifferent" by the consumers . 
Experts tended to rate items that are less specific for eczema as less important when assessing disease severity. 
Although consumers considered crackinglfissuring, vesicles, bleeding , and erosions as "very important," experts were 
"indifferent" or judged these items as "may not be important". 
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3.3.4 Criteria applied for recommendation of outcome measurements 
The recommendation on whether to apply an outcome measure is based on the 
following eight characteristics: content validity by expert, content validity by 
consumer, convergent construct validity, divergent construct validity, internal 
consistency, inter-observer reliability, test-retest reliability, and sensitivity to change. 
Full credit (100%) was given for characteristics "adequately met," half credit (50%) for 
those "acceptably met," and no credit (0%) for those "not acceptably met," not 
assessed, or both. Weighted mean ratings (weighted by the number of study 
participants) were used for characteristics that have been assessed in more than one 
study.-For each outcome measure, a total relative score was calculated ranging from 
100%, indicating that all criteria were adequately met, to 0%, indicating that none of 
the criteria were acceptably met. 
3.3.5 Statistical methods 
All data concerning validity and reliability of outcome measures was identified without 
reanalysing individual patient data. 
3.4 Results 
A total of 45 eligible articles were found, 21 of which were retrieved by searching 
MEDLINE and EMBASE, 17 by hand-searching reference lists, and 6 by free internet 
searches; 1 article was provided by a contacted person (list of references for studies 
in Appendix 5). The 45 articles reported on 20 different objective outcome measures 
for severity of eczema. 
Most validation studies were performed on the Severity Scoring of Atopic Dermatitis 
index (SCORAD, n = 14)*, Eczema Area and Severity Index (EASI, n = 5), and 
Nottingham Eczema Severity Score (NESS, n = 5) (Tofte 1998; Emerson, Charman 
et al. 2000; Hanifin, Thurston et al. 2001; Hon, Ma et al. 2003; Barbier, Paul et al. 
2004; Breuer, Braeutigam et al. 2004; Hon, Leung et al. 2004; Jenner, Campbell et 
al. 2004; Belloni, Pinelli et al. 2005; Staab, Kaufmann et al. 2005; Hon, Kam et al. 
2006). No data was identified on the validity of 5 published outcome measures 
(Atopic Dermatitis Severity Index, Four Step Severity Score [FSSS], Skin Intensity 
Score, Six-area Total Body Severity Assessment, and atopic dermatitis severity 
score [WAZ-S]) (Kagi, Joller-Jemelka et al. 1992; van Joost, Heule et al. 1994; Van 
Leent, Graber et al. 1998; Mastrandrea, Pecora et al. 2005; Silny, Czarnecka-
Operacz et al. 2005). Appendix 6 describes the study settings and populations of the 
validation studies for each outcome measure. 
"(European Task Force 1993; Kunz, Oranje et al. 1997; Oranje, Stalder et al. 1997; Schafer. Dockery et al. 1997; 
Wolkerstorfer, de Waard van der Spek et al. 1999; Hon, Ma et al. 2003; Ben-Gashir, Seed et al. 2004; Breuer, 
Braeutigam et al. 2004; Angelova-Fischer, Bauer et al. 2005; Charman, Venn et al. 2005; Pucci, Novembre et al. 
2005; Staab, Kaufmann et al. 2005; Hon, Kam et al. 2006; Hon, Leung et al. 2006) 
3.4. 1 Domains and items of outcome measures for eczema 
Full details of domains studied by the different outcome measures are available in 
the published paper (Schmitt, Langan et al. 2007). In the 20 outcome measures, five 
distinct domains were identified: intensity of lesion, extent of disease/body sites 
affected, symptoms, course of disease, and epidermal function. Substantial 
heterogeneity between the outcome measures was found for domains being included 
in the summary score, items used to measure domains, relative weights of the 
domains, scales used to measure the items, and persons performing the 
assessment. Disease intensity was assessed in 17 outcome measures using 13 
different items. In most outcome measures, physicians are asked to grade intensity 
on Likert scales, whereas others (e.g., SA-EASI) use visual analog scales marked by 
the patient or caregiver. Disease intensity contributed 33% to 100% of the summary 
score (Bahmer, Schafer et al. 1991; Wolkerstorfer, de Waard van der Spek et al. 
1999). An assessment of disease extent was included in 16 outcome measures and 
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contributed between 19% and 100% of the total summary score. A paper by 
Charman et a/ has recently highlighted the difficulties with measuring body surface 
area in eczema which leads to problems including this as a component of composite 
measures.(Charman, Venn et al. 1999) An estimation of the involved body surface 
area was required by 9 measures and involvement of special body sites by 7 
outcome measures. Body surface area is measured heterogeneously, with some 
outcome measures applying the "rule of nines" (e.g., SCORAD), others using tick 
boxes (e.g., NESS), and others using a silhouette on which the patient marks 
involved body sites (e.g., SA-EASI) (European Task Force 1993; Emerson, 
Charman et al. 2000; Housman, Patel et al. 2002). Disease symptoms like pruritus 
were assessed in 11 outcome measures attributing up to 33% to the total score. 
FSSS, NESS, and RL score included an assessment of the course of disease within 
the past year (Rajka and Langeland 1989; Emerson, Charman et al. 2000; 
Mastrandrea, Pecora et al. 2005). 
3.4.2 Assessment of content validity of outcome measures 
Both experts and consumers considered intensity of lesions and extent of disease as 
"very important" criteria for the assessment of the severity of eczema (Figure 3-1). 
Course of disease and symptoms were also judged to be "important" or "very 
important" by both groups, whereas epidermal function was considered as "may not 
be important" by the experts and "indifferent" by the consumers. 
Experts tended to rate items that are less specific for eczema as less important when 
assessing disease severity. Although consumers considered cracking/fissuring, 
vesicles, bleeding, and erosions as "very important," experts were "indifferent" or 
judged these items as "may not be important". Experts and consumers rated content 
validity on a 5-point Likert scale ("very important," "important," "indifferent," "may not 
be important" and "unimportanf). 
3.4.3 Validity of outcome measures and recommendations 
Appendix 7 outlines the results of validation studies on all outcome measures 
identified. Content validity, as assessed by the consumer, is adequate for all 
outcomes except the OSMD. Based on the experts' rating, OSMD, Patient-oriented 
Eczema Measure [POEM], and WAZ-S do not have acceptable content validity. Only 
EASI, SCORAD, and the Three Item Severity Score (TISS) have been shown to have 
adequate convergent and divergent construct validity. Evidence for adequate internal 
consistency was found only for the POEM. Eighteen outcome measures had either 
unacceptable internal consistency (n = 4; Atopic Dermatitis Area and Severity Index, 
SSS, SCORAD, and RL score) or had not been validated for internal consistency (n = 
14). There is convincing evidence to conclude that BSCC; NESS; OSAAD; Six Area, 
Six Sign Atopic Dermatitis severity score [SASSAD]; and SCORAD have adequate 
inter-observer reliability, whereas adequate test-retest reliability has been shown only 
for the POEM. For most of the outcome measurements, identified inter-observer 
reliability and test-retest reliability have not been evaluated adequately yet. 
Sensitivity to change is adequate for EASI, Investigators' Global Atopic Dermatitis 
Assessment (IGADA, investigator global assessment with descriptive terms), and 
SCORAD; acceptable for Leicester index, OSMD, POEM, SA-EASI, SASSAD, and 
SSS; not acceptable for the RL score; and has not been adequately assessed for the 
remaining 10 measures. The time needed to perform disease severity assessment 
ranges from 1 minute up to 10 minutes. 
Based on the existing evidence, none of the 20 outcome measurements can be 
highly recommended. EASI, POEM, and SCORAD have been shown to meet most 
validity criteria and are recommended for use. Although the validity criteria are only 
partly met, IGADA, NESS, SA-EASI, SASSAD, and TIS appear to be acceptable until 
further validation studies are available. Because of a lack of evidence for their 
validity, the remaining 12 outcome measurements are not recommended (Appendix 
7). 
3.5 Discussion 
3.5.1 Main findings 
Currently, investigators can select from 20 different named measurements of disease 
severity. Of these, only EASI, POEM, and SCORAD have been validated adequately 
enough at present to recommend their use in clinical trials and everyday practice. 
The reason 17 of the 20 outcome measurements identified are not recommended is 
primarily that data on their validity is missing. Since the review by Charman and 
Williams in 2000, 7 new outcome measurements have been introduced (FSSS, 
IGADA, OSMD, POEM, SA-EASI, TIS, and WAZ-S) (Charman and Williams 2000; 
Housman, Patel et al. 2002; Sugarman, Fluhr et al. 2003; Charman, Venn et al. 
2004; Mastrandrea, Pecora et al. 2005; Schachner, Lamerson et al. 2005; Silny, 
Czarnecka-Operacz et al. 2005). Of these, however, only the POEM has been 
adequately validated (Appendix 7). 
Most outcome measurements analyzed are assessed by a physician (e.g., EASI and 
SASSAD) and are therefore sometimes referred to as "objective," whereas others 
(e.g., POEM, SA-EASI) are more "subjective" because they are scored directly by the 
patient or caregiver. In reality, of course, both measurements require subjective 
judgment of categories within domains by physician and patient. The disadvantage of 
"subjective" outcome measurements is that reporting bias may be due to coping 
strategies, quality-of-life or comorbidity. The advantage of a subjective measurement 
like the POEM, however, is that it truly measures what is important to the patient 
(Charman, Venn et al. 2004). Although some of the items included in the POEM were 
not considered adequate by the experts in this study, the POEM was shown to be 
highly valid from the consumers' perspective (Appendix 7). 
3.5.2 Study strengths and limitations 
Based on objective criteria, recommendations were made on which outcome 
measurements to apply. These were informed by a systematic and comprehensive 
literature search. The cut-offs used to judge whether the validity criteria studied are 
"adequate" or "acceptable" are consistent with the literature and were defined a priori 
(Rosner 2000; Kline 2005). 
Another potential limitation of this study is that acceptability was not considered (i.e., 
time needed to perform measurement) in this recommendation. This was not 
included because the amount of time needed depends on the experience of the 
person doing the assessment. It was also not clear from most of the articles whether 
the time needed was actually measured rather than just estimated. 
By including content validity from both a consumer's and expert clinician's 
perspective, content validity has been included twice in the overall grading system. 
This approach might have given disproportionate weight to content validity. It is likely 
that consumer and expert perspectives are measuring slightly different elements. 
Combining both content validity perspectives into one overall composite score did not 
alter the overall conclusions or choice of instruments in this review (data not shown). 
To assess content validity, different consumer groups were surveyed, which raise the 
question of whether the responses were homogeneous across those groups. The 
median responses of adult patients, children aged 8 to 14 years, and parents of 
.+7 
younger patients were almost identical (data not shown). This finding provides good 
evidence for the validity of this approach to assess content validity. 
Some authors have used the Investigators' Global Assessment (IGA) as a gold 
standard and assessed criterion validity of other outcome measurements by 
correlating them with the IGA. The IGA is not stable enough to be a gold standard as 
it is influenced by response to treatments, compliance, and the patient-physician 
relationship. The IGADA is a variant of the IGA in which objective rules on how to 
rate severity are defined, unlike the IGA. The IGADA gives verbal descriptions for 
disease severity, such as "almost clear" or "very severe," which seems to be useful 
for clinical practice. Future research is necessary to evaluate the reliability of the 
IGADA. 
3.5.2 Implications for this research 
SUbstantial heterogeneity was found in the domains included in the different 
outcomes, the items used to measure the domains, the relative weights of the 
domains on the summary score, the scales used to measure the items, and the 
person performing the assessment. This leads to the conclusion that the 20 named 
outcomes identified do not measure the same aspects. The EASI or (objective) 
SCORAD are recommended as a valid and unbiased estimate of "objective" disease 
severity plus the POEM as a measurement of eczema severity from the patient's 
perspective. 
For the purposes of this thesis, two different types of outcome measure were 
required, a simple daily measure which could be posed as a single question, that 
would not pose too much respondent burden and monthly standard outcome 
measures as discussed in detail in this chapter. Two daily measures were selected 
after intensive debate and discussion, bearing in mind that this literature review has 
not identified any recommended measure suitable for use on a daily basis that 
equates to a single question. The first of these was a "bother" score which is a score 
derived from the POEM score. The POEM score is a recommended score and has 
been shown to be valid as previously discussed. The "bother" score assesses how 
much bother the eczema has caused (0-10) and is a response to a single question. 
"Scratch" scores were selected as a second primary outcome as this group has 
experience of its use in the context of clinical trials in eczema and previous research 
has shown good correlation to scratching as measured using accelerometers. 
More guidance on the monthly measures was obtained from this review. The POEM 
and TIS scores were both selected as the former has been shown to have adequate 
validity and the latter is considered acceptable pending further research. 
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Chapter 4 A pilot study to assess the effects of 
environmental factors in eczema 
4.1 Introduction 
A major research gap has been identified in the scientific evidence regarding causes 
of flares in eczema in Chapter 2. Proposals have been made regarding how flares 
should be defined in eczema and new concepts including totally and well controlled 
weeks have been suggested for use in clinical research (Chapter 1). Furthermore, 
the recent discovery of the high prevalence of filaggrin mutations in children with 
eczema has led to a hypothesis that patients with filaggrin mutations are more 
susceptible to environmental trigger factors which may help to explain the 
heterogeneity between individuals in their response to exposures (Introduction). 
Chapters 4 describes in detail how the research gap highlighted in Chapter 2 in 
relation to the scientific study of possible exacerbating factors for eczema was 
addressed in this pilot study with a view to planning the methods of the subsequent 
formal study described in Chapter 5. 
4.2 Objectives 
This study was designed to assess the feasibility of performing a panel study of 
exacerbating factors in eczema with the express objective of informing the planning 
of a focussed study with specific a priori hypotheses over a longer duration. In terms 
of feasibility issues, the main areas to explore were the willingness of parents and 
their children to take part, the percentage completion of data, the design of the 
diaries and methods for data analysis. 
4.3 Methods 
4.3.2 Participants 
Parents of 30 children aged 0 to 15 years with eczema fulfilling UK modified Hanifin 
and Rajka's criteria attending outpatients in the South Infirmary-Victoria Hospital, 
Cork, Ireland were invited to partiCipate (Williams, Burney et al. 1994). 
4.3.3 Study duration 
This study took place over four weeks in 2003. Duration was based on allowing 
sufficient time to assess feasibility. 
4.3.4 Severity Assessment 
Severity was assessed using the Children's Dermatology Life Quality Index (Lewis-
Jones and Finlay 1995) (CDLQI) and the SCORAD (SCORing atopic dermatitis) at 
baseline and study completion (European_ Task_Force 1993) by the lead investigator 
(SL). Parents or patients recorded daily symptom severity in paper diaries using 
scratch (1-5) and sleep (1-5) scores. In-depth explanations were given to participants 
regarding diary completion and severity assessment. Older children completed the 
diaries themselves (usually >8 years). 
4.3.5 Exposures studied 
Fourteen variables were included in the analysis based on previously published 
studies, some of which have been discussed in detail in Chapter 2. These included 
exposure to dust, exposure to pets, sweating, stress, damp (assessed by patients 
based on exposure to damp in buildings), central heating, foods, infection, teething 
(where appropriate), clothing, cleansing products, hot or cold weather and holidays. 
4.3.6 Primary outcome 
The primary outcome was a daily scratch score (1-5). 
4.3.7 Sample size 
In the absence of knowledge of the variability and lag times of purported risk factors, 
a formal power calculation was not realistic in this exploratory study. 
4.3.8 Statistical analysis and ethics 
A range of analyses were explored. An episode was defined as a day where the 
patient's scratch score was 4 or greater. At patient level, the total number of episodes 
were modeled in relation to overall exposure using Poisson regression with 
correction for overdispersion. Secondly, random-effects ordinal logistic regression 
was used to model the relation between exposures and scratch scores, with robust 
variance estimates to account for the error covariance (generalized linear latent and 
mixed models (gllamm) module in Stata. This relationship was examined on all days 
whether an "episode" occurred or not with the specific focus being the relationship 
between exposures and severity of eczema. Gllamm is a Stata program that can fit 
latent-variable models; the generalized linear mixed model is a special case of latent-
variable model) (corporation 2003).The lag time between exposures and worsening 
was explored (Le. lag O=same day, lag 1 = one day after exposure etc). Ethical 
approval was obtained from the local research ethics committee and informed 
consent was obtained from parents. 
4.4 Results 
4.4.1 Demographics 
25 Irish white children, eleven girls (44%) and fourteen boys (56%) completed the 
study. Five participants did not complete the one month study or failed to complete 
the diary. The age range was 2 months to 14 years with a mean age of 4.6±4.26 
years. The study period was a 28 day period in June 2003. The average 
temperatures and relative humidity were 13.3°C and 83.6% respectively and 
maximum temperature and relative humidity were 20.1)C and 98% respectively. 
4.4.2 Disease severity 
The initial mean ± SO SCORAO was 20.37±11.94; the final was 22.23±10.62. Most 
participants/parents attributed worsening to high temperatures. The majority of 
patients had mild (44%) or moderate (44%) eczema; only 12 % had severe disease 
(assessed globally at study outset). Mean COLOI scores before and after were 
7.04±3.91 and 7.8±4.72 respectively. Severity scores did not significantly change 
during the period. 
4.4.3 Feasibility objectives 
Twenty five of 30 diaries (83%) were available for analysis; the other diaries were 
either lost (4) or not completed (1). This equates to 83% of participants completing 
the study. The completeness of recording of exposures ranged from 65% to 83%; 
measures of outcome were 97% complete in the diaries available for analysis. This 
highlights differential completion of different aspects of the paper diaries. 
4.4.4 Diary data 
12 (48%) experienced flares with an average 3.6 flares per child (range 1 to 8). 
Eczema severity using SCORAO (p=0.025, r=0.446), and COLOI scores (p<0.001, 
r=O. 734) at review correlated with the number of flares. 
At episode level using random effects logistic regression, on the day of exposure (lag 
0), heat (high outside ambient temperatures) correlated to increased scratch scores 
(p=0.043) as shown in Figure 4-1. 
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Figure 4-1 Correlation between maximum temperature and mean scratch scores 
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Legend to figure 4.1 
This graph shows maximum daily temperatures against mean scratch scores across participants. 
At a lag of 2 days, damp (wet outside) was associated with raised scratch scores 
(p=0.027). Three days after exposure, sweating and stress were associated with 
elevated scratch scores (p=0.029 and 0.019 respectively). At lag 4, damp outside 
was associated with elevated scores (p=0.001). Analysis of significant variables 
using robust variance estimates revealed only damp at lag 4 was significantly 
associated with disease flares (p=0.039). 
4.5 Discussion 
4.5. 1 Main Findings 
Analysis of diary data suggests a temporal association between eczema severity and 
four variables . These included heat (lag 0), damp (lag 2) , sweating and stress (lag 3) 
and damp (lag 4). Robust variance analysis of the data supported a correlation only 
with damp. However, that may be due to the short duration of the study and a lack of 
statistical power to confirm other associations given the number of possible 
explanatory variables. 
4.5.2 How this pilot study has provided key information for the main 
study 
Few studies have sCientifically evaluated the impact of environmental factors on the 
severity of eczema. Most authors have documented patients' perceptions of "flare 
factors" (Williams, Burr et al. 2004). One longitudinal panel study has studied 
seasonality in a scientific fashion and described "winter" and "summer" categories of 
eczema (Kramer, Weidinger et al. 2005). This study confirms the feasibility of 
performing a formal panel study to address the possible roles of environmental 
factors in worsening of eczema. It gives information regarding likely participation and 
completion rates in order to determine the sample size for the formal study and how 
best to measure exposures and outcomes. It also suggests that environmental 
factors may be important in eczema worsening. 
In terms of exposures, damp was very crudely measured by asking participants if 
they had been exposed to damp that day. Previous research suggested that the 
important component was actually relative humidity rather than household damp. It 
was therefore decided in the main study to focus on the measurement of indoor and 
outdoor relative humidity. The main outcome measure in this study was a "scratch" 
score (1-5). As this scale has only 5 points, it must be analysed using methods for 
ordinal data and normal distribution cannot be assumed. This makes analysis more 
complex (requiring ordinal logistic regression rather than normal time series 
methods) and therefore it was decided for the main study to incorporate "scratch" 
scores with a greater range (0-10) as a secondary outcome measure and to select a 
further measure as a primary outcome measure. Data collection for the pilot study 
was done using paper diaries which participants completed daily for a one month 
period. I was suspicious, but unable to confirm, that there was some "parking-lot" 
compliance based on some respondents showing rows of completed entries with the 
same colour pen and the same values. This prompted the search for data collection 
methods which would reduce recall bias which lead to the use of electronic diaries in 
the main study. In this study, lagged responses were also used assessing the impact 
of exposures on the study outcomes in the days following exposure. This greatly 
increases the number of variables in the study, i.e. each variable is included five 
times if a lag of up to four days is used. The problems with that are the issues of the 
complexity of the analyses and multiple testing whereby the findings could be 
significant by chance. I decided for the main study not to include lagged responses 
for these reasons but to adjust for the fact the response on one day is related to the 
responses on the surrounding days by using measures to adjust for autocorrelation. 
4.5.3 Strengths and limitations of this study 
This study prospectively assessed several factors utilising daily recording of 
exposures and disease severity. This is particularly relevant in a complex disease 
such as eczema, where several factors may combine to cause flares. The population 
was well defined and the response rate was very good. 
The small sample size, range of variables and weather conditions limit the validity of 
conclusions, reflecting the exploratory nature of the study. Studying a smaller range 
of putative flare factors could lead to clearer outcomes but this approach could be 
associated with the risk of missing a key factor. Finding only one significant variable 
after robust variance estimates may reflect the duration and low numbers rather than 
a true lack of association with other variables or indeed this may represent a chance 
finding due to multiple testing. 
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4.5.4 Implications for clinical practice and the main study 
During consultations with a patient with eczema, health care professionals should 
ask about environmental factors in order to assess their relevance to the individual 
patient. In general, studies have suggested that heat may be a major factor in 
disease flares. Therefore it would appear sensible to advise parents to use simple 
measures to try to keep children with eczema cool. A larger prospective study over a 
longer period with independent objective recording of exposures, ideally in a fashion 
that limits the differential recording of outcomes and exposures is required to 
definitively establish the impact of these factors on disease status. 
57 
Chapter 5 
Main cohort/panel study 
5.1 Introduction 
Chapter 2 and the pilot study results described in Chapter 4 suggest that 
environmental conditions are likely to influence disease status in children with 
eczema and may be associated with disease flares. The mechanism underlying 
environmental triggers of "flares" in eczema is poorly understood. It is not clear why 
people seem to respond differently to environmental factors. Specifically, some 
eczema sufferers appear to flare when the weather is hot; others seem to flare during 
the winter when the outdoor temperature is low and indoor temperature is high with 
low relative humidity. This Chapter describes the formal study of the effect of 
environmental factors on eczema severity in a cohort of children with eczema. 
5.2 Hypotheses 
1. In hot weather, the combination of heat, sweating and grass pollen 
precipitates increased severity in children with eczema in the UK. This hypothesis is 
based on a combination of the findings of the study by Kramer et al and the 
discussions of the research team (Kramer, Weidinger et al. 2005). 
2. In cold weather, the combination of cold weather, indoor aeroallergen 
exposure and reduced relative humidity from central heating lead to increased 
severity in children with eczema in the UK. This hypothesis is based on the clinical 
experience of investigators and follows intensive discussion of the study by Kramer 
et al (Kramer, Weidinger et al. 2005). 
3. Detergents (soap, shampoo) can heighten the propensity to increased 
severity (triggered by other factors) at all temperatures but possibly more in cold 
weather due to impaired skin barrier function. This hypothesis was informed by 
research which proposed seasonal variation in responses to irritant exposure and 
clinical experience(Tupker, Coenraads et al. 1995). 
4. Patients with filaggrin mutations are more prone to the effects of climatic 
factors such as cold and heat than individuals who are wild type for filaggrin. 
5. Any combination of greater than or equal to three exposures at any time is 
associated with worsening of eczema. The exposures assessed were: dust, 
exposure to pets, shampoo, sweating, swimming, nylon clothing next to the skin and 
a change in mean temperature of more than 3°C from the previous weekly average. 
5.3 Methods 
5.3.1 Description 
Summary of study design 
This was a 2 year hypothesis-testing, prospective observational study. Outcome and 
exposure measures were chosen with the aim of keeping assessments simple, non-
invasive yet meaningful. 
Study duration 
Patients were recruited over a 6 month period and studied for up to nine months. 
Entry into the study was staggered to analyse seasonal effects. 
Primary outcomes: 
Primary outcomes (Figure 5-1) were defined by global scores recorded daily in the 
patient's diary. Global scores were graded from 0 (no bother at all) to 10 (the most 
bother you can imagine) as a response to the question, "How much bother did your 
(your child's) eczema cause today? This measure was chosen because it is valid 
(derived from the Patient Orientated Eczema Measure), sensitive to change and it is 
appropriate to use every day as discussed in detail in Chapter 3 (Charman, Venn et 
al. 2004). 
Figure 5-1 Outcome measures for this study 
Primary outcome measure 
• "Bother" score: Global scores were graded from 0 (no bother at all) to 10 (the most 
bother you can imagine) as a response to the question, "How much bother did 
your (your child's) eczema cause today? 
Secondary outcome measures 
• "Scratch" scores: Scratch was graded from 0 to 10 (0= not scratched at all; 10= 
scratched all of the time) as a response to the question: "How much did you (your 
child) scratch today? " 
• Disease flares: Binary outcomes were recorded in respect of the question" Have 
you had to step up your treatment today because your (your child's) eczema was 
worse?" What is meant by stepping up treatment was defined at the outset for 
each child 
The use of daily itch scores was considered as the primary outcome measure, but 
flares are composed of more facets than purely itch and, parental perception of a 
child's itch levels may not be accurate. The use of totally and well controlled weeks 
(TCW and WCW) was contemplated also but due to the nature of a panel study 
(intensive study of a relatively smaller group), the loss of statistical power would be 
too great and these measures would be likely to give a better measure of overall 
disease control than shorter term disease worsening, as in disease flares. Using 
flares as defined by the preliminary work (Chapter 1) was deliberated as the primary 
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outcome measure; however, as this measure has not yet been validated, this was 
used as a secondary outcome measure rather than the primary outcome and its 
performance was tested in comparison to "bother" scores. 
Secondary outcomes: 
Daily scratch scores were recorded in the patient's electronic diaries. Scratch was 
graded from 0 to 10 (0= not scratched at all; 10= scratched all of the time) as 
a response to the question: "How much did you (your child) scratch today? ". This 
measure focuses on day time itching and does not reflect nocturnal scratching. A 
further secondary outcome was the occurrence of flares as assessed by the need 
to "step up" treatment. Binary outcomes were recorded in respect of the question" 
Have you had to step up your treatment today because your (your child's) eczema 
was worse?" What is meant by stepping up treatment was defined at the outset for 
each child, e.g. move to potent topical corticosteroid from weak corticosteroid. As this 
is a patient centred outcome, it needed to be individually defined rather than using a 
fully standardized approach. If participants responded that they had stepped up their 
treatment that day, they were asked to specify the site of the flare through a series of 
follow on questions. Clinical disease severity scoring was assessed monthly using 
the 3 item score, which is published and validated in eczema and the patient 
orientated eczema measures (POEM score). All clinical disease severity scoring 
using the TIS score was done by the lead investigator (SL). Quality of life was 
assessed using the Children's Dermatology Life Quality Index (CDLQI) (Lewis-Jones 
and Finlay 1995). Severity scoring was repeated at each monthly review (TIS and 
POEM) and quality of life (CDLQI) was assessed every three months by an 
examining dermatologist. The TIS, POEM score and COLQI provide background data 
regarding severity and therefore would not be appropriate methods to assess daily 
fluctuations in severity. This combination of assessments was chosen to reflect on 
both "objective" and "subjective" outcomes. The TIS score, as discussed in Chapter 3 
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has not been thoroughly assessed for validity as the criteria defined in Chapter 3, 
were only partly met. However, this score was selected for its acceptability and ease 
of use in view of the fact that it was being used to reflect the overall severity rather 
than relating to the main study outcome measures. 
5.3.2 Participants 
Setting: 
60 patients were recruited consecutively from the Queen's Medical Centre paediatric 
dermatology outpatient department, Nottingham over a 6 month period. Participants 
were also recruited from primary care Nurse Consultant lead eczema clinics. Further 
participants were recruited following a presentation at the Nottingham support group 
for carers of children with eczema (NSGCCE). Parents and patients were offered the 
possibility of separately consenting to opt into the genetic arm of the study. No 
participant was enrolled until informed consent was obtained. All participants were 
treated in accordance with the Helsinki accord. Nottingham is located 117 metres 
above sea level and is located in the East Midlands. 
Inclusion criteria: 
Patients aged 0 to 15 years with moderate to severe eczema, fulfilling UK 
modified Hanifin and Rajka criteria where parents consented to partake and they/ 
their parents were able to complete the symptom diary.(Wiliiams, Burney et al. 1994) 
Baseline severity was determined using the TIS score and the patient orientated 
eczema measure (POEM score) (Wolkerstorfer, de Waard van der Spek et al. 1999; 
Charman, Venn et al. 2004). Entry criteria also required that participants must have 
had a minimum of three significant disease flare ups in the preceding 6 months. The 
definition of a disease flare up was that proposed in Chapter 1, i.e. escalation of 
treatment or the need for additional medical advice for increased disease severity. 
Exclusion criteria: 
Patients 16 or over (These patients have a different disease profile and may not 
accurately reflect patterns in the childhood eczema cohort); those with diagnoses 
other than eczema; patients with mild disease; patients/ parents who were either 
unable to or did not consent to complete the diary; children with concurrent severe 
asthma requiring oral corticosteroids for treatment of asthma flares. 
5.3.3 Procedures 
Baseline interview 
Avoidance behaviour in relation to types of clothes, detergents and household pets 
was assessed so that analysis could be stratified by prior belief. Patients/their 
parents were also asked whether their disease flared more in summer or winter and 
whether they perceived that cold or hot temperatures played a role in disease flares. 
Parents and their children were asked some basic questions regarding their housing; 
including whether there were carpets/ rugs or furry toys in the child's room, frequency 
of cleaning and use of mattress and pillow covers. These questions were posed 
discreetly in a standardized questionnaire, avoiding the issue of leading questions 
which might bias answers (Appendix 8). An investigator was present to clarify any 
unclear questions. Socioeconomic status was assessed using two methods: parental 
occupation as assessed using the Standard occupational classification and levels of 
parental education (Statistics 2002). At the baseline interview, the patient's usual 
treatment regimen and what they usually do when the eczema worsens (this was 
defined as "stepping up" treatment for that patient) was established and recorded. 
The definition of what constituted "stepping up" treatment for their child was agreed 
at that interview between parents and the investigator. 
Diaries 
They/ their parents were asked to complete an electronic diary on a daily basis for a 
6 to 9 month follow-up period, recording severity of eczema and exposure to potential 
exacerbating factors (Appendix 9). Use of the electronic diary was demonstrated to 
participants at baseline where a trial run was carried out. Participants were requested 
to complete the diaries in the evening such that exposures from that day (not the 
previous evening) and eczema severity could be recorded. Participants were also 
given a booklet deSigned specifically for the study which explained how the diary 
functioned, how to respond to questions and also provided troubleshooting advice on 
the use of the diaries. The electronic diaries did not allow participants to complete the 
diaries after midnight on the day, neither did they allow partial daily completion. 
Unless participants answered yes to the question "Are you happy with your answers" 
and received the response "Your data has been submitted", no information would be 
stored from that day. 
Monthly reviews 
Participants were reviewed monthly and clinical assessments were carried out to 
determine overall disease control. Data from electronic diaries was downloaded 
monthly. At the end of the study period, a final clinical assessment was performed. 
These scores allowed correlation of clinically determined severity scores with patient 
determined "flare" scores in order to assist in their validation. 
Filaggrin status 
To determine filaggrin status it was necessary to obtain DNA from individuals 
entering the study. Following written informed consent, participants were asked to 
provide a saliva sample at enrolment. This was done using standardized techniques; 
for younger children, a sponge was used for sampling, while older children gave 
saliva samples into containers following instructions (Oragene). Identification of these 
containers was limited to the designated study number and date of birth. The 
containers were shipped to the Human Genetics Unit, University of Dundee. DNA 
was extracted by standard techniques and FLG genotyping for the common null-
alleles was carried out according to published protocols (Palmer, Irvine et al. 2006). 
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FLG genotype status were recorded and returned to the Nottingham-based senior 
investigators (SL or HW) again using the study number and dates of birth. 
Correlations between environmental data, filaggrin status and eczema flares were 
determined. 
Detailed personal data was kept by the lead researchers (SL and HW) and was not 
transferred to the laboratory researchers. It was therefore not possible for the study 
laboratory to link genotyping data back to participant's personal details. A single hard 
copy of the database linking genotype to phenotype was securely kept under the 
direction of the data controllers/senior investigators (SL and HW). Electronic 
databases were anonymous and did not contain any identifying data. 
Measurement of exposures: 
Eleven variables were included in the study (temperature, relative humidity, sun 
exposure, sweating, clothing, cleansing products/ washing, outdoor pollen level, 
extent and nature of exposure to household pets, dusty environments and swimming) 
which have been proposed to flare eczema (Table 5-1) Season was an additional 
variable; this was included as the study by Kramer et al demonstrated strong 
associations between seasonality and eczema flares. The seasons were defined 
using the UK Meteorological office guidelines as follows: spring (March 1- May 31), 
summer (June 1-August 31), autumn (September 1-November 30) and winter 
(December 1-February 28). These differ slightly from the definitions used for spring 
(March 11-May 15) and summer (May 16-September 14) in the German study 
(Kramer, Weidinger et al. 2005). 
Selection of the exposures for inclusion in the formal study was difficult; including too 
many variables would result in reduced precision and increased standard error. It 
would also be technically impractical to assess for interactions. It was equally 
important to include all the relevant exposures likely to contribute to disease flares. 
I have described the justification for the exposures recorded in Table 5-1. A number 
of factors suspected of causing disease worsening have been excluded. 
Stress also appeared to playa role in the pilot study, however to study the impact of 
this factor accurately on a daily basis would require too many daily questions. The 
burden on respondents would be too great and would be likely to reduce compliance. 
In order to analyse the relevance of this factor accurately, a formal study of stress in 
eczema would be required. Similarly, examining the role of foods would require in 
depth study which would preclude the examination of a range of factors and would 
merit a study on its own. 
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Table 5-1 Rationale for choice of variables for cohort study and methods of measurement of exposure 
Variable Rationale for choosing variable Variables to be Methods of measurement Frequency of 
analysed measurement 
Environmental 1. Weiland et al (ISAAC phase 1.(Weiland, Husing Daily maximum Outdoor temperature and Hourly 
temperature et al. 2004) Worldwide questionnaire study. 6-7y and minimum relative humidity measured by 
and 13-14y olds. Negative association between temperature, environmental monitoring 
eczema symptom prevalence and mean annual weekly change in centre, University of 
temperature mean Nottingham, Sutton 
2. Pilot study findings as outlined in Chapter 3 temperature Bonnington campus 
demonstrated disease worsening with 
I 
heat.(Langan, Bourke et al. 2006) Electronic data loggers-
3. Tupker et al. Influence of season on weal and (iButton, Maxim, Dallas). 
flare responses in eczema. More pronounced Measures temperature and 
i weal and flare reactions in winter (n=16).(Tupker, humidity 
Coenraads et al. 1995) 
4. Uter et al.(Uter, Gefeller et al. 1998) Irritant hand 
dermatitis increased in cold weather in large 
group of hairdressers 
Humidity 1. Weiland et al (ISAAC phase 1. Tendency Minimum indoor Measurements as for Hourly 
towards negative association between indoor relative humidity temperature. 
relative humidity and eczema.(Weiland, Husing et 
al. 2004) 
2. Sato et al.(Sato, Fukayo et al. 2003) 
I Questionnaire study comparing 200 adults 
working in ultra dry room compared to other 
I 
workers. Higher prevalence of eczema in ultra-dry 
room workers. I 
3. Denda et al.(Denda, Sato et al. 1998) Extremes 
of humidity contribute to disease flares 
- ~ ~
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-Variable Rationale for choosing variable Variables to be Methods of measurement Frequency of 
analysed measurement 
. Sweating with 1. Williams et al.(Wiliiams, Burr et al. 2004) Amount of Question regarding sweating. Daily 
exercise Questionnaire study. 42% exacerbated by sweating Did you/ your child sweat 
sweating with exercise. n=225 today? 
2. The pilot data- 56% reported exacerbations. Modified Likert score with a 
n=25. Questionnaire study range 
3. Itch when sweating reported by between 23 and from 0 (no sweating) to 4 
I 78% in previous questionnaire based studies (dripping 
I 
sweat, had to change clothes). 
Not relevant in infants 
Clothing 1. Diepgen et al.(Diepgen T J 1995) RCT diff Clothes worn Participants were asked daily if Daily 
fabrics. Synthetic shirts increased irritative directly against they wore wool or nylon 
capacity, cotton best tolerated. Rougher fabrics the skin clothing that day. If they 
more irritating. 55 eczema, 31 controls responded affirmatively, they 
2. Ricci et al.(Ricci, Patrizi et al. 2004) Study of silk were asked if they had worn I I 
i fabric in 31 children with eczema. Improved that fabric directly against their i 
eczema severity. 4 children, mean age 2 skin. This was then converted 
3. Williams et al.(Wiliiams, Burr et al. into a binary exposure 
2004 )Questionnaire study. Fabrics reported to variable whereby 
worsen eczema in 39% children, wool in 17%. the exposure was only positive 
N=225 if the fabric was worn 
4. The pilot study, eczema reported to flare with directly against the skin 
fabrics as follows: 48% wool, 24% fleece, 16% 
nylon. Questionnaire data from 25 patients 
--- --
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Variable Rationale for choosing variable Variables to be Methods of measurement Frequency of 
analysed Measurement 
Detergents 1. Williams et al. Cleansing products felt to induce Shampoo Participants were asked daily if Daily 
flares in 24.9%, of which washing powder freq exposure. Direct they had washed their hair that 
listed (% not stated}.(Wiliiams, Burr et al. 2004) exposure of the day. If they responded 
Questionnaire study 225 p skin to shampoo affirmatively, they were asked 
2. Sherriff et al.(Sherriff, Farrow et al. 2005} daily. if they washed their hair at the 
Increasing "hygiene scores" associated with same time as their bath or 
increased prevalence of eczema. ALSPAC study shower. If this was positive, 
exposure to shampoo was 
recorded that day. 
Pollen count 1. Burr et al.(Burr, Emberlin et al. 2003} ISAAC Grass and birch Midlands Asthma and Allergy Daily 
phase one. No association between high pollen pollen levels Research Association. 
counts and eczema prevalence. (28 centres, 11 Measures 
I 
countries. 13-14 year olds. Questionnaire 80,050 daily pollen using standardized 
children) techniques. This measuring 
2. Darsow et al.(Darsow, Vieluf et al. 1996} centre 
Correlation between +PT, raised serum IgE to is located in Leicester and 
same and +ve SPT. 79 patients eczema, 20 previous studies have 
controls demonstrated that there is 
3. Lewis et al.(Lewis, Corden et al. 2000} Grass sufficient lack of variation for 
pollen not birch pollen related to asthma flares these measures to be applied 
and A+E attendances to the whole of the East 
Midlands region. I 
---- ----
- ~ ~ ---
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-Variable Rationale for choosing variable Variables to be Methods of measurement Frequency of 
analysed measurement 
Other 1. Shah et al.(Shah, Hales et al. 2002) In vivo HDM avoidance Record at baseline of house Daily 
aeroallergens- challenge in 20 adult pt. Suggest that clinically measures dust 
house dust relevant HDM hypersensitivity present in 1/3 adult recorded mite reduction measures, i.e. 
mite atopics studied. Record of avoidance of furry toys and 
2. Gutgesell et al.(Gutgesell, Heise et al. 2001) 20 exposure to frequency of cleaning. Daily 
adults 1 year HDM avoidance no reduction in dusty recording of exposure to dusty 
severity scores environments environments 
3. Ricci et al.(Ricci, Patrizi et al. 2000) 41 children, 
HDM measures reduced severity scores over 1 yr. 
Other 1. Williams et al.(Wiliiams, Burr et al. 2004) Cats Exposure to Patients/ parents record their Daily 
aeroallergens- and dogs reported to induce flares in 8% and 5% animals- type and contact with animals in their 
animals respectively. Questionnaire study duration diaries, specifying the type of 
2. The pilot study, 36% reported flares on animal and whether the pet 
exposure to dogs and 32% to cats respectively. was the family's pet or an 
Horses perceived to cause flares in 28%. unfamiliar pet. Pet exposure 
Questionnaire study recorded as a binary variable 
positive with an unfamiliar pet 
only. 
Sun exposure 1. Deguchi et al reported worsening of facial Sun exposure Retrospective meteorological Daily 
erythema in adult patients following UV data of UV levels from 
exposure.(Deguchi, Danno et al. 2002) University of Nottingham 
I 2. T ajima et al report photoexacerbation of environmental monitoring site, 
eczema with abnormal UV responses.(Tajima, Sutton Bonnington 
Ibe et al. 1998) 
3. Russell et al reported photoexacerbation in 7 
patients with photosensitivity dermatitis/actinic 
reticuloid on a background of atopic 
eczema.(Russell, Dawe et al. 1998) 
4. UV therapeutically used for treatment of severe 
atopic eczema 
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Variable Rationale for choosing variable ~ a r i a b l e s s to be Methods of measurement Frequency of 
~ n a l y s e d d measurement 
Swimming Seki et al demonstrated sensitivity to lower chlorine Swimming in Question in daily electronic Daily 
concentrations in individuals with eczema compared to chlorinated diary 
! those with normal skin with reduced water holding swimming pool 
I capacity. (Seki, Morimatsu et al. 2003) I 
Seasons 1. Vocks et al studied a cohort of individuals in Seasons of the Seasons: spring, summer, Quarterly 
Davos and demonstrated an inverse year autumn and winter 
relationship between increasing outdoor 
I temperature and levels of itch (Vocks, Busch et 
i al. 2001) 
2. Kramer et al showed seasonal variations in a 
panel of children with eczema and proposed as 
a post hoc hypothesis that winter and summer 
types of eczema existed (Kramer, Weidinger et 
al. 2005) 
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Temperature and humidity 
Objective data of the temperature and relative humidity of the micro-environment to 
which the child was exposed were obtained by supplying each child/ parent with an 
ibutton© data logger (Maxim, Dallas, USA) on a keyring. This measured the daily 
maximum, minimum, mean and standard deviation of both the temperature and 
relative humidity. Data was downloaded from these devices every month, processed 
and then added to the study database by the accompanying software. Outdoor data 
from the local environmental monitoring centre in Sutton Bonnington was used for the 
outdoor data. Other measures were considered, e.g. twice daily recording of 
household temperature and humidity as used by Kramer et al (Kramer, Weidinger et 
al. 2005). However, this method is likely to be associated with missing data and is not 
an accurate measure of the individual's microenvironment, i.e. does not record 
temperature and humidity exposures when the child is in school. 
Sweating 
Patients/ parents were asked to score the amount of sweating on that day using a 
modified Likert score with a range from 0 (no sweating) to 4 (dripping sweat, had to 
change clothes). 
Clothing and shampoo 
Patients and their children recorded the duration and nature of exposure to clothing 
including wool and nylon and if this clothing was worn directly against the skin. 
Exposure was only considered positive if the fabric was worn directly against the 
skin. Parents were also asked to record whether they washed their child's hair that 
day and if so, whether this was at the same time as the child's bath or shower. Usual 
washing practices and products used were recorded at the baseline interview. This 
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posed less of a burden on participants than daily recording of washing products and 
was selected to be pragmatic. 
Household pets 
Patients/ their parents recorded exposures to household pets (type of pet, own pet or 
infrequent exposure) in the daily diary. This is a relatively weak way to measure 
exposure to pets. The ideal way to measure pet allergen exposures would be with 
personal air samplers, however this would be cumbersome, expensive and would 
pose too much of a burden on respondents. Static sampling, i.e. measuring pet 
allergen from dust samples is not an accurate way to assess actual exposure as it 
does not reflect air levels of pet allergen. Exposure to pets is also behaviourally 
driven so a portable personal sampler would be the only truly accurate was to 
assess this. Exposure to pets was only considered positive if it was not the patient's 
own pet, as tolerance to family pets is well recognised. 
Dusty environments and pol/en counts 
Patients were asked to record exposure to dusty environments on a daily basis in 
their diaries. Pollen levels were measured daily by a local aerobiology pollen 
monitoring centre using an automatic volumetric Burkard trap. This device was 
situated on the roof of the University of Leicester campus at a height of 12 metres. 
Leicester is an urban city with tree lined roads in the local vicinity, position reference 
52°38'N 1°5'W, with an altitude of 60 metres. The methodology used for collecting 
pollen used the standard methods of the National Pollen Monitoring Network 
described in the British Aerobiology Federation (BAF) guide. Pollen counts are 
expressed in grains/metre cubed and represent a daily average. A previous year long 
study examining pollen data in Derby and Leicester showed that both sets were 
comparable and that one can be used to forecast the other (Pashley CH 2007). As 
Nottingham is the same distance from Leicester as Derby, it is assumed that the 
pollen data will be representative for the local region. 
Sun exposure 
Sun exposure was assessed using retrospective data from the environmental 
monitoring site, University of Nottingham at Sutton Bonnington. One option 
considered was to ask a subset of patients (15) to wear personal dosimetry UV 
badges one per week for 4 weeks at the onset of the study to quantify their UV 
exposure over that period. In terms of additional information gained, this measure 
would not add much to the accuracy of the study. 
Maintenance of a high response rate 
Loss to follow up was minimised by initial fortnightly telephone reminders (120 calls), 
giving the patents/ parents an opportunity to discuss queries about diary completion. 
This approach, combined with review of diaries and guidance on how to complete 
them at monthly reviews, allowed maximization of data collection. 
5.3.4 Sample size 
There was no formal sample size justification for this study because of its exploratory 
nature. What was needed was sufficient data relating episodes of eczema to a range 
of putative exposure variables. There needed to be sufficient data for these 
exploratory analyses to give protection against misleading results arising from 
chance. Large numbers of participants were also needed to explore the interaction 
between risk factors. 
In the pilot study of 30 patients and 18 variables over a 28 day period, the 
completeness for pre-specified exposures ranged from 65% (holidays) to 83%, while 
measures of outcome were about 97% complete. 25 children (83%) completed the 
study. 
Based on the pilot study, the proportion of days on which an episode is recorded is 
0.23.The definitive study would prudently require 20 events/variable thus needing 
18x20/0.23 =1565 person-days. This would be achieved with only 5 individuals if 
data were complete (6 to 9 months follow-up is required to assess seasonal 
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effects). However, around 50 participants would still be needed for the patient to 
patient random effect reflecting differing susceptibility to be measured with a 
coefficient of variation of 20% and for cluster analysis of eczema types. 
In practical terms, the study numbers were restricted by resources, including the 
study duration, the numbers of children eligible for entry into the study, of which half 
were likely to agree to participate and the requirements to follow up participants 
through a long follow-up period. Bearing these constraints in mind, 60 children was a 
realistic number and was likely to give us sufficient numbers to allow for a contrast 
between winter and summer groups. Two previous studies, the pilot study and the 
study by Kramer et al managed to show some significant effects despite smaller 
numbers, 25 and 39 respectively, than the planned study and shorter follow-up 
periods, 28 days and 6 months respectively (Kramer, Weidinger et al. 2005; Langan, 
Bourke et al. 2006). The formal statistical analysis methods are discussed in detail in 
Chapter 7. 
5.3.5 Data management 
Data was extracted monthly from the dataloggers and electronic diaries to the study 
laptop. No patient identifiable data accompanied this data. At the end of the study, a 
second data extraction was done from each electronic diary by the manufacturers. 
This double-data entry and the automated nature of data extraction should prevent 
data errors. I performed interim data tabulations and analysis and carried out range 
and consistency checks to ensure data was accurate. Data from the baseline 
interviews was stored on the laptop in a separate Excel spreadsheet. All databases 
were married towards the end of the study and the results of filaggrin mutation 
analyses were added to this data to allow formal analysis. 
5.3.6 Ethics 
Written informed consent was obtained from the parents of all participants. Children's 
assent was also sought, when they were old enough to understand, using 
appropriate information sheets. 
Testing for filaggrin mutations involved obtaining a separate written informed 
consent, in other words, parents could consent to participate in the study with or 
without providing consent for mutation analysis. Saliva samples were anonymised 
and tested using published protocols. 
Confidentiality was maintained at all times. No personally identifiable data was stored 
on the study laptop. Identification of data was through identification numbers; the list 
of participants was secured separately in a locked filing cabinet. 
-76-
Chapter 6 The use of electronic diaries 
6.1 Background 
Diary data collection methods are a well established method of collecting patient 
reported outcomes (PROs) in clinical research. Their main advantage is that 
proximate data collection, for example on a daily basis, is associated with reduced 
recall bias. 
Traditional diary methods use pen and paper diaries to record PROs. However, 
recent studies and systematic reviews of their performance have highlighted 
important flaws which may be an important cause of bias. Issues include "backfilling" 
of paper diaries, sometimes termed "parking lot compliance". This is often suspected 
when paper diaries are completed with a row of identical outcomes for categorical 
outcome measures. Similarly, "forward filling" of paper diaries is well described. 
These issues were highlighted in a study by Stone et al comparing paper diaries with 
electronic diaries (Stone, Shiffman et al. 2003). The study compared actual 
compliance with reported paper diary compliance (measured using a concealed 
electronic device) and with electronic diary completion. In that study, participants 
reported completion of paper diaries per protocol 90% of the time compared to actual 
compliance of only 11 %. Indeed for 32% of the study days where diary completion 
was reported as 90%, the diaries had in fact not been opened. 
6.2 Comparisons of electronic and paper diaries 
Electronic diaries are a recent development in research. There is some evidence to 
support their use over paper diaries in clinical studies. Dale and Hagen reviewed this 
issue in a recent systematic review (Dale and Hagen 2007). They included only 
randomised controlled trials (RCTs) or quasi-randomised studies with direct 
comparisons of the two data collection methods. Their comparisons included the 
following fields: feasibility, protocol compliance, data accuracy and participant 
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acceptability. Nine studies were included in the review. In terms of feasibility, five 
studies reported technical problems including malfunction and problems with power 
leading to a loss of data in three of the five studies (Tiplady B 1997; Gaertner, Elsner 
et al. 2004; Lauritsen, Degl' Innocenti et al. 2004; Nyholm, Kowalski et al. 2004; 
Palermo, Valenzuela et al. 2004). One study reported an 80% reduction in the time 
needed for data handling with electronic devices (Tiplady B 1997). Five studies 
reported improved compliance using electronic diaries, while one study in adults 
reported better compliance with the paper diary method (Rabin, McNett et al. 1993; 
Rabin, McNett et al. 1996; Stone, Shiffman et al. 2003; Nyholm, Kowalski et al. 2004; 
Palermo, Valenzuela et al. 2004). Four of five studies reported "falsification" using the 
paper diary method (Tiplady B 1997; Stone, Shiffman et al. 2003; Gaertner, Elsner et 
al. 2004; Lauritsen, Degl' Innocenti et al. 2004). Three studies reported fewer errors 
using electronic diaries (Tiplady B 1997; Quinn, Goka et al. 2003; Palermo, 
Valenzuela et al. 2004). Of seven studies assessing participant acceptability, four 
reported a preference for electronic diaries while three showed no difference (Rabin, 
McNett et al. 1993; Rabin, McNett et al. 1996; Tiplady B 1997; Quinn, Goka et al. 
2003; Gaertner, Elsner et al. 2004; Lauritsen, Degl' Innocenti et al. 2004; Palermo, 
Valenzuela et al. 2004). Other significant differences highlighted by the authors 
include the increased costs of purchase of the devices and the increased set up 
times required. 
6.3 Choosing and piloting the electronic diaries 
Electronic diaries were chosen to record exposures and outcomes to increase 
compliance, reduce data errors and reduce the possibility of bias (Chapter 7). This 
method was also more likely to appeal to children more than paper diaries. This 
methodology represented a novel use of electronic PROs in dermatology, although 
they have been used for similar studies in respiratory medicine and rheumatology 
settings. Smart Patient Diary Cards (SPDC, Logos Technologies, Lymington, UK) 
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were used in this study. These were selected in preference to personal digital 
assistants (PDAs) due to concerns about the risk of loss of these devices. Other 
alternatives considered for this study included the use of mobile phones and the 
internet; two issues were a concern with these methods; firstly, the issue of data 
encryption and protection and secondly a concern that restriction to participants with 
access to these resources would incur selection bias. Other portable diaries were 
either less attractive interfaces or more expensive to source. The SPDC is a device 
specifically designed to record diary data. It has a small screen and a series of 
numbers and arrows which is suited to categorical responses and the use of visual 
analogue scales (Figure 6-1). 
Figure 6-1 The Smart patient diary card (SPDC) 
Legend to figure 6-1 
This figure shows an example of the type of electronic diary used in the study. Participants use the numbers top and 
bottom to answer the questions which use Likert scales and the keys on either side to go foreward 
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Set up stages involved designing a questionnaire which could be used on a daily 
basis to record relevant exposures and outcomes. This questionnaire was piloted 
amongst staff and volunteers from the paediatric eczema clinic, both adults and 
children. Subsequently, questions were uploaded onto a test device. This highlighted 
problems with the format of a number of questions, some of which needed to be 
abbreviated to fit on the screen. Piloting of the revised questions was carried out 
using the same panel. A series of further revisions followed before the final question 
series was completed (Appendix 9). Formatting "bugs" were uncovered when pilot 
testing the "final" series which took ten revisions to resolve; these included problems 
with non-functioning "skip" questions and ease of reading of the interface. The next 
step involved trial data downloading from the test device using a smart card. A 
training booklet was prepared to accompany the devices which complemented an 
initial training session on their use. The training booklet was given to all participants. 
A "smart card" for data download was maintained for each participant and this was 
used to download information from electronic diaries at each monthly review. A final 
data download was also carried out by Logos technologies. 
6.4 Electronic diary experience 
The SPDC was user-friendly and participants had no problems using the devices. 
However, despite installation of special long-life batteries to allow the devices to last 
for the length of the study, battery failure was a significant problem. Battery failure 
occurred in the event of either genuine battery failure or displacement of batteries. 39 
(65%) of participants required replacement diaries on at least one occasion; of these, 
25(42%) were replaced once, 13(22%) twice and 1 (2%) three times. Due to delays 
incurred by getting the devices reprogrammed and reissued to the participant, a 
pragmatic solution was reached whereby a replacement diary was issued when 
battery failure occurred. The disadvantage of that was that this resulted in 
participants having multiple diary numbers. A strict log of participant and diary 
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numbers was maintained to avoid error. On a few occasions, multiple diaries failed 
simultaneously leading to delays and lost data. Data extraction was a smooth 
process using smart cards; this was duplicated by the final diary download carried 
out by the manufacturers. There were no data entry errors or skipped questions as 
the diary format made this impossible. As responses were pre-coded and 
downloading was automated, transcription errors were not possible. 
In summary, the diaries were a user-friendly interface which allowed easy data 
download and avoided data errors. However, devices were expensive and 
associated with significant technical problems which lead to their use being more 
cumbersome than planned. Comparison with paper diaries is not possible in this 
study. Power failure is a frequently reported problem with the use of electronic diaries 
and this study is testament to that. 
On balance, the increases in data accuracy associated with the use of electronic 
diaries and reduction in recall bias merits the extra costs and technical difficulties 
incurred by their use. The reduction in bias and data errors is of critical importance in 
an observational study setting. 
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Chapter 7 Statistical methods 
7.1 Environmental factors 
The mean, standard deviation and range for all environmental variables were 
calculated for different environmental factors and examined graphically. High outdoor 
temperature was defined as greater than 22°C, which is equivalent to the 95 th centile. 
Low outdoor temperature was defined as less than 1°C, which is equivalent to the 5th 
centile. Similarly low relative humidity was defined as <40%, or the 5th centile. 
7.2 Missing data 
As this was an observational study requiring completion of electronic diaries daily for 
long periods of time, there was likely to be a substantial proportion of missing data. 
Kramer et al carried out a similar panel study in a group of children in Germany and 
excluded 14 children out of 56 (25%) due to poor completion of diary data.(Kramer, 
Weidinger et al. 2005) The researchers highlighted major differences between 
participants with missing data and those with higher degrees of compliance. Children 
with missing data were systematically different with lower parental school education 
(23% vs. 37% having at least one parent with a university degree) and had a slightly 
lower prevalence of acute eczematous lesions (50% vs. 57%). As a similar or higher 
degree of missing data was expected, a strategy was planned to assess miSSing data 
to try to minimise selection bias and the loss of power which would be incurred by 
case exclusion. A recent paper by Burton and Altman highlighted the poor quality of 
observational studies in terms of dealing with missing data and proposed guidelines 
for the reporting of miSSing covariate data (Burton and Altman 2004). These 
guidelines recommend that investigators should quantify the amount of missing data 
in the study (by case and by variable), outline the approaches used to handle the 
missing covariate data and explore the missing data comparing the characteristics of 
those with missing data to those with complete data. 
After considering the options, a pragmatic approach to the missing data was chosen 
highlighting the amount of missing data and comparing good responders to poor 
responders in terms of baseline characteristics to identify obvious sources of 
selection bias. As each individual's observations were being collected over long 
periods and all the data are correlated for each participant, losing a data point loses 
much less information than for independent data. Therefore after considering the use 
of imputation techniques such as multiple imputation by chained equations (ICE, 
available as a downloadable add-on for Stata. This program performs imputations 
using a model based approach based on chained regression equations), and 
obtaining independent statistical advice from an independent senior statistician 
(Professor Mike Campbell, Sheffield) with expertise in time-series analysis, it was 
concluded that it was reasonable to proceed with analysis using the Kalman filter 
option in Stata in order to handle missing data. The Kalman filter skips missing 
values, then obtains maximum likelihood estimators of the model parameters and 
then applies a smoothing process. ARMA will still fail however if there is substantial 
missing data and may lead to exclusion of some participants from analysis. 
7.3 Autoregressive moving average (ARMA) model 
The following autoregressive moving average (ARMA) model was used in which the 
error terms are allowed to be autocorrelated. 
Equation 7-1 ARMA model 
YI = Po + PI XI + P2 x ~ ~ + .... + PnXn + L'I 
e
l 
= .·1RIAIA(p,q) 
Legend for equation 7-1 
t 
/l. -regression coefficient associated with n exposure variables. xn=exposure variables. er=error term 
=ou come. I'n-
For this model ante-dependence of the response is entirely subsumed in the 
autocorrelations. An AR (1) structure was used, i.e. an ARMA (1,0,0) model, 
assuming that the error terms have a first order autocorrelation. The choice of model 
was determined by comparing the Akaike Information Criteria (AIC) for different 
model specifications; a first order specification was associated with a lower AIC than 
a second order autocorrelation for all but three individuals and therefore this was the 
preferred model. This model was used to assess the impact of variables on "bother" 
and "scratch" scores. The model generated regression coefficients and standard 
errors for each patient in relation to the different exposure variables. One patient's 
data was entirely excluded from analysis as the poor quality data made regression 
impOSSible. 
7.4 Analysis for the primary and secondary outcome measures 
Comparison of regression coefficients between patients on exposure to different 
variables was done using standard meta-analysis methods, i.e. treating each 
participant as a separate "study". The data was first examined for the primary 
outcome measure "bother" and then examined for the secondary outcome "scratch 
scores". If heterogeneity between participants was established, this indicated 
variation in individual susceptibility to exposures. 
Der Simonian & Laird's approach was used to pool estimated coefficients on the 
basis of a random effects model and to estimate the between-participant variance. If 
heterogeneity was demonstrated for different exposure variables, these variables 
were entered into a multiple regression model and coefficients estimated using the 
multiple regression model were likewise combined using the Der Simonian and Laird 
method to determine whether the association seen in univariate models may have 
been explained by a confounding variable, assuming that the confounding variable 
was included in the regression model. Examination of the association between the 
secondary outcome measure, "stepping up" of treatment was carried out using a 
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different technique as the binary nature of this outcome measure (yes/no) means that 
it does not meet the assumptions of the ARMA model (which assumes a Normal 
distribution for the errors). The technique used was a logistic regression with 
inclusion of lagged responses in the regression model, thus generating 
autocorrelated responses rather than autocorrelated errors as in ARMA. This was 
done by generating lagged responses for the outcome measure and including the 
lagged term within the regression model (Equation 7-2). 
Equation 7-2 
Legend for equation 7-2 
y=outcome, Pn=regression coefficient associated with n exposure variables, xn=exposure variables, PYt_,=lagged 
response variable 
The issue of multiple testing was also explored in relation to main study findings by 
exploring the impact of using 99% confidence intervals on associations with 
increased "bother" scores significant using 95% confidence intervals. The site-
specificity of reactions was also examined. Analysis was carried out to see whether 
exposure to aeroallergens such as grass, exposure to pets and dust was associated 
with worsening of facial and hand eczema and whether clothing exposure (wool or 
nylon worn next to the skin) was associated with worse eczema on the trunk and 
limbs. This was done by examining the data for associations between regression 
coefficients for responses to exposures and site-specific worsening as recorded in 
the electronic diaries as a follow-on question if the participant had stepped up their 
treatment that day. 
7.5 Testing of hypotheses 
Hypotheses were tested by generating point and interval estimates of regression 
coefficients corresponding to specific exposures. If the 95% confidence interval did 
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not include zero this was equivalent to a significance test performed at a two-tailed 
5% level. Testing the hypotheses required construction of three composite variables 
A (high outdoor temperature, >22°e, sweating and high grass pollen levels), B (dust 
exposure, low outdoor temperature, <1 °e, and low indoor relative humidity, <40%) 
and e (shampooing hair at the same time as the bath or shower and low outdoor 
temperature). The main effects of the composite variables A, B, and e were 
assessed, followed by estimation of the interaction between temperature and these 
variables if the main effect showed statistical significance. Power for the latter is likely 
to be low (as it nearly always is in studies not specifically designed to detect 
interactions). 
The final hypothesis was that combinations of exposures rather than individual 
exposures might be the important aspect in disease worsening and flares. This 
hypothesis was based on Rothman's "pie" model of causation, whereby disease 
causation or worsening may relate to several factors acting in concert rather than an 
individual factor.(Rothman KJ 1998) This theory is based on factors being sufficient 
to cause or, in the scenario of this study, to worsen disease. Sufficient causes can 
comprise a number of component causes which are not themselves necessary for 
disease causation or worsening. To test this hypothesis, a binary variable was 
created which was defined as being present if any three or more of the following 
exposures was experienced: dust, exposure to pets, shampoo, sweating, swimming, 
nylon next to the skin and a change in mean weekly temperature of greater than or 
equal to 3°e, and absent if this was not the case. The selection of change in mean 
temperature of greater than 3°e was an arbitrary point chosen following discussion 
with parents of children with eczema and colleagues with expertise in the 
management of eczema as being sufficient to trigger disease worsening. The 
association between the combined variable and the primary outcome measure was 
assessed using meta-analysis techniques as described previously. I also explored 
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the impact of each additional exposure contained within the combined variable, by 
treating the components of the variable as categorical, to determine graphically 
whether the relationship between worsening of disease and number of exposures at 
the level of the episode was linear. This was done using regression for one, two and 
three exposures and combining the regression coefficients using meta-analysis 
combining across patients as previously described. A line graph was then created 
and examined graphically with the hypothesis that each additional exposure would be 
associated with a linear increase in eczema severity. 
7.6 Comparing the performance of totally and well controlled weeks to 
monthly outcome measures 
The performance of the proposed definitions of disease control, totally and well 
controlled weeks (TCW and WCW) was examined by assessing the association 
between these measures and the measures of objective and subjective disease 
severity measured at monthly and three monthly intervals throughout the study, the 
three item severity score (TIS), the patient orientated eczema measure (POEM) and 
the children's dermatology life quality index (COLOI) respectively. This analysis was 
done at the level of the patient rather than the level of the episode as in time-series 
analysis. All of the regular measurements were converted into binary measures at 
arbitrary points as there are no clear guidelines on their correlations with clinical 
severity to define more and less severe disease. The cut off points to define more 
severe disease used were as follows: a POEM score of greater than 14, COLOI of 
greater than16 and a TIS score of greater than five. These scores were calculated for 
each individual by calculating an average of the monthly and three monthly scores 
taken throughout the study. The mean number of totally and well controlled weeks 
was calculated and compared amongst those with more and less severe disease for 
each score to determine whether there was a statistically significant difference 
between the groups. TCW and WCW were defined as in Figure 7-1. 
Figure 7-1 Proposed definitions of totally and well controlled weeks in eczema 
Totally controlled week (TCW) 
Treatment not "stepped up" 
Plus 
Zero days with scratch score >4 
Well controlled week (WCW) 
Treatment "stepped up" for ~ 2 2 days 
Plus 
~ 2 2 days with scratch score>4 
The average number of flares was also calculated for each individual to determine if 
this varied between groups with differing severity of eczema, using the same 
outcome measures to determine severity. 
7.7 Correlation between baseline perceptions and worsening on 
exposure 
The relationship between perceived worsening on exposure to an environmental 
factor as assessed in the baseline interview by parental perception of avoidance of 
exposure and observed worsening on exposure was assessed. This was done by 
examining regression coefficients for bother scores following specific exposures at 
the patient level and comparing this outcome between participants who had given a 
history or worsening or avoidance of specific exposures and those that had not. 
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7.8 Exploratory analysis to assess the validity of "summer" and "winter" 
types of eczema 
The hypothesis proposed by Kramer et al that winter and summer types of eczema 
exist where one group worsens in winter when the weather is cold and the other in 
summer when the weather is hot was also examined (Kramer, Weidinger et al. 2005). 
I used cluster analysis to assess whether distinct groups existed who responded in a 
different fashion during summer and winter. Two methods were used to generate the 
clusters, Ward's method and the complete linkage method. Clustering of patients was 
carried out using each patient's regression coefficients for "bother" scores in summer 
and winter. Dendrograms were then produced for both methods and examined 
visually to determine whether the summer and winter differentiation was valid and 
whether similar clusters were identified with each methodology. Dendrograms are 
two dimensional diagrams whereby the degree of similarity between individuals is 
used to group participants by response to both summer and winter. 
Results 
Chapter 8 Demographic details of participants 
8.1 Description of participants 
Sixty children completed the study. 146 participants were given information about the 
study of which 52 did not respond, 16 had insufficient eczema, one was not within the 
study age category, ten could not complete the diary and seven were not keen to 
participate. The baseline demographic details of participants are described in Table 
8-1. The median age for participants was 6.5 years (interquartile range (IQR) = 8.5 
years); the age range was 0.4-15.9 years. There were 32 boys (53.3%) and 28 girls 
(46.7%). The majority of participants, 38 (63%) were white European, the next largest 
proportion were Indian, n=8 (13%) with smaller numbers from other ethnic groups. 
Social classes 1 and 2 (assessed by parental occupation) were in the majority, n=26 
(43%) and similarly, when social class was assessed by parental education, n=23 
(38%) had a parenUcarer with a university degree or higher level of education 
(Statistics 2002). Median study duration was six months (IQR= 0.5 months). At 
baseline, the median POEM score was 13 (IQR=1 0) with a range from 2-28. The 
median COLQI was 9 (IQR=8, range 1-25). Median baseline TIS score was 3 
(IQR=2, range 1-8). As shown in Table 8-1, 15 (25%) had either previous systemic 
(azathioprine, cyclosporine or oral prednisiolone) or phototherapy treatment. 46 
children (77%) were recruited from hospital clinics while 14 were recruited from 
community clinics. However, many of the patients recruited from community clinics 
may have originated in the hospital clinic in the first instance. Average baseline TIS 
scores were 3.3 in the hospital cohort and 2.6 in the community clinic cohort 
(p=0.12). 40 children (67%) were from urban areas while 20 were from rural regions. 
-90-
9.2 Baseline beliefs 
I also determined parental perceptions and avoidance behaviour at baseline to 
determine if there was any determinable correlation with worsening on exposure. 
Parental perceptions as assessed at baseline were as follows: 42 (70%) were 
avoiding clothes (wool or synthetic), 51 (85%) of parents were avoiding cleansing 
products including shampoos and washing powders and 29% (48.3%) were avoiding 
furry pets as these were believed to worsen eczema. 31 (51.7%) believed that their 
child's eczema was worse in cold weather, while 6 (10%) felt the eczema was better 
in cold weather. Similarly for hot weather, 37 (61.7%) gave a history of worsening in 
hot weather and 9 (15%) described an improvement in eczema severity in hot 
weather. 
8.3 Filaggrin mutations 
Mutations in FLG were detected in ten of 54 children who had saliva tests (18.5%). 
Six opted not to have filaggrin tests done. Six children were heterozygous for the 
r501x null mutation, of whom four were white European and two were mixed race. 
2282del4 mutations were detected in four white European children of whom three 
were heterozygous and one was homozygous. No compound heterozygotes were 
identified and no FLG mutations were in children from other ethnic groups. The 
proportion of white European children with FLG mutations was 8/38 (21 %). 
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Table 8-1 Demographic details of participants in cohort study 
Characteristic Frequency Percentage (%) 
Age group (years) 
<2 8 13.3 
2-5.9 19 31.7 
6-11.9 18 30 
>12 15 25 
Gender 
Boy 32 53.3 
Girl 28 46.7 
Ethnicity 
White 38 63.3 
Indian 8 13.3 
Black Caribbean 4 6.7 
Mixed race 4 6.7 
Pakistani 3 5 
Chinese 3 5 
Social class by parental occupation 
1-2 26 43.3 
3-4 8 13.3 
5-7 11 18.3 
8-9 15 25 
Parental education 
None 6 10 
GCSE 22 36.7 
A level 2 3.3 
Higher education below degree 7 11.7 
Degree or higher 23 38.3 
History of asthma 
Yes 30 50 
No 30 50 
History of hayfever 
Yes 36 60 
No 24 40 
Previous systemic or phototherapy 
Yes 15 25 
No 45 75 
Total 60 100 
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Chapter 9 
Results of statistical analysis 
9.1 Environmental factors 
Temperatures during the study period ranged from -6.1 to 28.7°C. The daily mean 
temperatures for each season (Figure 9-1) were as follows: spring 10.2°C (range -1.8 
to 23.1), summer 15.5°C (range 5.8 to 28.5), autumn 11.7°C (range -1.7 to 28.7) and 
winter 6.6°C (range -6.1 to14.5). The daily mean outdoor relative humidity was 83.8% 
(range 61.1 to 100.0) with mean relative outdoor humidity by season as follows: 
spring 79.7% (range 61.1 to 100), summer 81.4% (62.1 to 86.5), autumn 85.1% (61.2 
to 100) and winter 85.6% (62.0 to 97.9). Mean solar radiation level during the study 
was 230.8 MJ/m2 (range -17.2 to 2496), Figure 9-2. Examining mean solar radiation 
by season, in spring mean radiation was 546.7MJ/m2 (86.5 to 1063.5), in summer 
662.7 MJ/m2 (124.2 to 1139.6), autumn 311.1 MJ/m2 (-3.8 to 744.4) and winter 119.0 
MJ/m2 (16.6 to 355.8). Mean grass pollen level was 7.9 grains/m3 (range 0 to 229), 
Figure 9-3. The grass pollen season lasted from May 18th 2007 to August 11 th 2007 
with a peak on June 9th of 229.0 grains/m3 (Figure 9-3) The mean birch pollen level 
was 2.7 grains/m3 (range 0 to 223.6) (Figure 9-4). The birch pollen season was 
shorter, lasting from April 5th 2007 to May 15t 2007 with a peak on April 15th of 223.6 
grains/m3 . 
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Figure 9-1 Mean temperature during study period 
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Figure 9-2 Mean radiation during the study period 
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Figure 9-3 Grass pollen level during study period 
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Figure 9-4 Birch pollen levels during study period 
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9.2 Missing data 
In terms of drop outs, only three participants dropped out in the first three months 
(6%), one per month (2% per month); four dropped out in month four (7%) and three 
in month five (5%). Overall, there were 10,940 observations across all participants. 
4354 diary observations were missing (39.8%) while 1079 (9.8%) observations were 
missing for indoor environmental observations. There was no missing data for 
outdoor environmental variables including pollen data. Comparing participants with 
large amounts of missing diary data (>50%) with those with more complete 
observations, there were no significant differences in age, severity of eczema, 
ethnicity, social class or parental education. No within-subject difference was 
observed between severity on the day before missing values (measured using 
"bother" scores) and the days before completed diary entries suggesting that severity 
on the day before (a proxy measure for severity on the day with missing diary entries) 
was not a good predictor of missing values (p=0.17). In good responders, there was 
199/1153 (17.3%) missing data in the first month of study across patients compared 
to 1889/6363 (29.7%) of observations missing after the first month. In the poor 
responders, 251/580 (43.3%) of observations were missing in the first time month 
compared to 2015/2844 (70.9%) after the first month of study (Figure 9-5). 
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Figure 9-5 Proportion of missing data in "good" and "poor" responders over the study period 
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This figure shows the percentage of data missing over time (months) in responders. Responders are divided into 
"good" and "poor" responders . "Poor" responders were defined as those with more than 50% of diary data missing 
through the study duration . Both groups demonstrated fatigue after month 1 but this was more pronounced in the 
"poor" than in the "good" responders . 
9.3 Results of relationship between environmental factors and eczema 
severity as measured using "bother" score 
9.3.1 Univariate analysis 
Table 9-1 shows the results of meta-analysis for the primary outcome measure 
"bother". In univariate analysis, heterogeneity was detected for the following 
variables: dust, swimming, maximum outdoor temperature , mean radiation, wool 
exposure next to the skin, sweating, grass pollen , spring , summer, autumn, winter 
exposure (shown in the forest plot Figure 9-6) and change in mean weekly 
temperature. 
No statistically significant heterogeneity was detected for the other variables and 
therefore it is reasonable to use the pooled estimates. Increased bother scores were 
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detected relating to wearing nylon next to the skin, exposure to unfamiliar pets (i.e. 
not the patient's own pet) and washing the patient's hair at the same time as bathing 
or showering and composite variable C (shampoo exposure and low temperatures, 
<1°C). The following variables were not significantly related to increased "bother" 
scores: minimum indoor relative humidity, birch pollen and composite variables A and 
B. It is important to note however that for composite variables A (hot temperature, 
>22°C, sweating and high grass pollen levels) and B (dust exposure with low 
temperature, <1°C and low relative humidity, <40%) there were few available data as 
the combinations of variables occurred infrequently. 
Table 9-1 Results of univariate and multivariate analyses for primary outcome "bother" using 
meta-analyses to assess heterogeneity 
Factor Summary Confidence Results of Tau Coefficient regression interval heterogeneity squared of coefficient 
variation Chi-squared 
test 
Univariate analysis 
Dust 0.344 0.046 to 0.642 <0.001 0.375 1.780 
Swim 0.081 
-0.119 to 0.281 0.002 0.112 0.872 
Minimum relative 
humidity 
-0.003 
-0.007 to 0.001 0.632 <0.001 0.657 
Maximum outdoor 0.001 
-0.016 to 0.017 <0.001 0.002 0.549 temperature 
Mean radiation 0.000 
-0.000 to 0.000 0.009 <0.001 0.482 
Wool next to 0.463 0.101 to 0.825 <0.001 0.304 0.434 
skin 
Nylon next to 0.342 0.143 to 0.540 0.05 0.094 0.398 
skin 
Pets 0.221 0.099 to 0.343 0.469 <0.001 0.370 
Sweating 0.178 0.039 to 0.316 0.03 0.057 1.340 
Shampoo 0.067 0.005 to 0.129 0.994 0.000 0 
Grass pollen 0.06 -0.034 to 0.154 <0.001 0.056 3.944 
Birch pollen 0.001 -0.006 to 0.008 0.742 <0.001 0 
Composite 0.035 -2.508 to 2.578 1.0 <0.001 0 
variable A 
Composite -0.330 -1.468 to 0.808 0.982 <0.001 0 
variable B 
Composite 0.303 0.039 to 0.566 0.188 0.093 1.006 
variable C 
Spring -0.049 -0.279 to 0.181 <0.001 0.431 -13.398 
Summer 0.220 -0.006 to 0.445 0.001 0.185 1.955 
Autumn -0.144 -0.552 to 0.233 <0.001 0.738 5.966 
Winter 0.082 -0.137 to 0.300 <0.001 0.199 5.440 
Change in 0.057 -0.117 to 0.231 0.001 0.158 6.974 
temperature 
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Factor Summary Confidence Results of Tau Coefficient 
regression interval heterogeneity squared of 
coefficient variation 
Chi-squared 
test 
Multivariate analysis 
Dust 0.531 0.230 to 0.832 <0.001 0.291 1.016 
Wool next to the 0.421 0.061 to 0.782 <0.001 0.291 1.281 
skin 
Nylon next to 0.232 0.034 to 0.430 0.101 0.074 1.173 
the skin 
Pet 0.110 -0.058 to 0.278 0.110 0.054 2.113 
Sweating 0.237 0.086 to 0.388 0.023 0.065 1.076 
Shampoo 0.070 -0.005 to 0.144 0.917 <0.001 0 
Composite 0.228 -0.053 to 0.508 0.172 0.113 1.474 
variable C 
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Figure 9- 6 Forest plot of the effects of grass on individual patient's "bother" scores in those 
with reasonably complete data (n=59) (univariate analysis) 
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Legend to figure 9-6 
The left s i d ~ ~ of the forest plot lists the individuals. The results for each individual are shown as squares centred on 
the rewesslon coefficient. A horizontal line runs through the square to show its 95% confidence interval. On the right 
hand side the r ~ g r e s s i o n n coefficient and its confidence interval are given as are the weights given to each individual. 
The o v ~ r a l l l estimate from the meta-analysis and its confidence interval are represented by the diamond. The centre 
of the .dlamond represents the pooled regression coefficient, and its horizontal tips represent the confidence interval. 
A vertical line representing no effect is also plotted.Significance is achieved at the set level if the diamond is clear of 
t ~ e e I . i ~ e e of no effect. In this figure, the diamond overlaps the line of no effect and therefore the pooled estimate is not 
significant. Heterogeneity is evident in the distribution of responses around the line of no response and the results of 
the Chi-squared test for heterogeneity shown bottom left, p<O.001. 
9.3.2 Multivariate analysis 
Multivariate analysis using the same ARMA methods and generating regression 
coefficients was used for variables which were significantly associated with 
worsening of eczema on univariate analysis (Table 9-1). Heterogeneity remained for 
the following variables: dust, wool next to the skin and sweating suggesting that there 
are significant differences in how individuals respond to these variables. 
Heterogeneity was no longer evident for nylon next to the skin suggesting that the 
heterogeneity might be related confounding by other variables in the unadjusted 
model. Dust, wool and nylon clothing and sweating were associated with worsening 
of bother after adjustment for possible confounding variables. None of the other 
variables were significantly associated with bother scores on multivariate analysis. 
Only the associations between increased "bother" scores and exposure to dust, 
unfamiliar pets and sweating persisted after applying 99% confidence intervals to 
associations significant with 95% confidence intervals in relation to adjusting for the 
possible effect of multiple testing. 
9.4 Results of relationship between environmental factors and eczema 
severity as measuring by "scratch" scores 
9.4.1 Univariate analysis 
Similar analysis was done for the secondary outcome variable, "scratch" scores 
(Table 9-2). Significant heterogeneity was detected for the following variables: dust. 
- I ( ) ~ ~
maximum outdoor temperature, mean radiation, wearing nylon against the skin, pet 
exposure, shampoo exposure, grass pollen, the four seasons (Figure 9-7 shows the 
heterogeneity in response to winter exposure) and composite variable C. No 
significant heterogeneity was detected for the other variables. Pooled estimates for 
the variables not showing heterogeneity show no significant associations between 
minimum relative humidity, change in mean weekly temperature, birch pollen 
exposure, composite variables A and B and scratch scores. Significant increases in 
scratch scores were seen for the following variables: swimming, wearing wool next to 
the skin, sweating and shampoo exposure. 
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Table 9-2 Results of univariate and multivariate analyses for secondary outcome "scratch" using 
meta-analysis to assess heterogeneity 
Factor Summary Confidence Results of Tau Coefficient 
regression interval heterogeneity squared of 
coefficient variation Chi-squared 
test 
Univariate analysis 
Dust 0.087 
-0.202 to 0.375 <0.001 0.361 6.906 
Swim 0.142 0.004 to 0.280 0.246 0.021 1.020 
Minimum relative 0.002 -0.002 to 0.006 0.533 0.000 0 
humidity 
Maximum outdoor -0.005 -0.021 to 0.011 0.001 0.001 -6.324 
temperature 
Mean radiation -0.000 -0.000 to 0.000 0.001 0.000 0 
Wool next to 0.283 0.113 to 0.453 0.834 0.000 0 
skin 
Nylon next to skin 0.232 -0.100 to 0.564 <0.001 0.620 3.394 
Pets 0.123 -0.083 to 0.329 0.001 0.177 3.420 
Sweating 0.147 0.037 to 0.258 0.300 0.013 0.776 
Shampoo 0.068 0.007 to 0.129 0.587 0.000 0 
Grass pollen 0.012 -0.069 to 0.092 <0.001 0.035 15.590 
Birch pollen 0.005 -0.012 to 0.023 0.12 0.000 0 
Composite 0.113 -2.526 to 2.751 1.0 0.000 0 
variable A 
Composite -0.498 -1.493 to 0.497 0.413 0.081 -0.571 
variable B 
Composite 0.326 -0.043 to 0.694 <0.001 0.446 2.048 
variable C 
Spring -0.019 -0.256 to 0.219 <0.001 0.505 -37.402 
Summer 0.138 -0.089 to 0.366 0.001 0.192 3.175 
Autumn -0.018 -0.361 to 0.324 <0.001 0.569 -41.907 
Winter 0.104 -0.137 to 0.345 <0.001 0.282 5.106 
Change in weekly 0.104 -0.009 to 0.218 0.808 0 0 
temperature 
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Factor Summary Confidence Results of Tau Coefficient 
regression interval heterogeneity squared of 
coefficient variation 
Chi-squared 
test 
Multivariate analysis 
Swim 0.175 -0.038 to 0.388 0.033 0.106 1.860 
Wool 0.116 -0.049 to 0.281 0.498 <0.001 0 
Sweat 0.190 0.060 to 0.321 0.153 0.032 0.941 
Shampoo 0.085 0.011 to 0.160 0.588 <0.001 0 
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Figure 9-7 Forest plot of the effects of winter on individual patient's "scratch " scores (regress ion 
coefficients) in those with reasonably complete data (n=44) (univariate analysis) 
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In this fig ure, the diamond overlaps the line of no effect and therefore the pooled estimate is not significant. Only 44 
individuals (of 60) had sufficient data to be included in the analysis. Heterogeneity is evident in the distribution of 
responses around the line of no response and the results of the Chi-squared test for heterogeneity shown bottom left, 
p<0.001 . 
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9.4.2 Multivariate analysis 
Multivariate analysis of the variables which were significantly associated with 
increased scratch scores on univariate analysis showed residual heterogeneity for 
swimming only (Table 9-2). Increased scratch scores persisted for sweating and 
exposure to shampoo. The associations between swimming and wearing wool next 
to the skin were no longer significant. 
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9.5 Results of analysis for effects of environmental factors on disease 
flares as defined by the need to "step up" treatment 
9.5.1 Univariate analysis 
Similar analysis was done for the other secondary outcome variable, "stepping up" 
treatment (Table 9-3). Univariate analysis showed heterogeneity between individuals 
for the following variables: dust, minimum relative humidity, maximum outdoor 
temperature, nylon next to the skin, shampoo, spring, summer and autumn. For the 
variables not showing heterogeneity, an association was detected between "stepping 
up" treatments and swimming. No association was detected for the other factors. It 
was however not possible to assess a possible relationship between composite 
variables A and B and "stepping up" treatment as the use of regression with lagged 
responses resulted in the loss of data. Multivariate analysis was not carried out for 
this outcome as only one of the exposures was associated with worsening of eczema 
on the univariate analysis. 
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Table 9-3 Results of univariate analyses for secondary outcome "treat" using meta-analysis to 
assess heterogeneity 
Factor Summary Confidence Results of Tau Coefficient 
regression interval heterogeneity squared of 
coefficient variation Chi-squared 
test 
Univariate analysis 
Dust 0.420 
-0.191 to 1.030 0.012 0.686 1.972 
Swim 0.420 0.046 to 0.795 0.589 0 0 
Minimum relative 0.280 -0.670 to 1.237 <0.001 9.51 11.014 
humidity 
Maximum outdoor 0.003 -0.031 to 0.037 0.028 0.03 57.735 
temperature 
Mean radiation -0.000 -0.001 to -0.000 0.444 0 0 
Wool next to skin -0.205 -0.661 to 0.251 0.692 0 0 
Nylon next to skin 0.051 -1.292 to 1.393 <0.001 7.428 53.440 
Pet 0.299 -0.108 to 0.707 0.353 0.063 0.839 
Sweat -0.132 -0.457 to 0.193 0.489 0 0 
Shampoo 0.074 -0.664 to 0.813 <0.001 3.604 25.564 
Grass pollen 0.054 -0.144 to 0.252 0.136 0.059 4.498 
Birch pollen -0.002 -0.016 to 0.012 0.136 0 0 
Composite variable -0.170 -0.680 to 0.340 0.988 0 0 
C 
Spring -0.060 -0.399 to 0.280 0.03 0.220 -7.817 
Summer -0.115 -0.676 to 0.447 0.003 0.607 -6.775 
Autumn -0.03 -0.400 to 0.341 0.02 0.263 -17.094 
Winter 0.269 -0.011 to 0.549 0.238 0.064 0.940 
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9-6 Comparison of associations between eczema severity using primary 
and secondary outcome measures 
The primary outcome measure "bother" and the secondary outcome measure 
"scratch" show many similar associations between exposure and eczema severity 
and also some unique associations (Table 9-4). Some similar findings were detected 
for the secondary outcome "stepping up" treatment, although due to methodological 
differences and the need to use measures other than ARMA for this outcome 
measure, true associations may have been missed. In the first two analyses, 
minimum indoor relative humidity, birch pollen levels and composite variables A and 
B showed no association with eczema severity for bother and scratch scores. 
Relative humidity and birch pollen also showed no association with the secondary 
outcome measure "stepping up" treatment. Dust, shampoo and exposure to wool 
were associated with increased severity for the outcome measures, bother and 
scratch but not for the other secondary outcome measure. 
-110-
Table 9-4 Comparison of associations using primary and secondary outcome measures 
PrimaJ'Youtcome measure "bother" 
Associated with increased severity No effect 
Univariate analysis Dust Minimum relative humidity 
Wool next to the skin Birch -.2..ollen levels 
Nylon next to the skin C o m ~ o s i t e e variable A 1 
EXQosure to pets Composite variable B£ 
Sweating Change in temperature 
Shampoo Maximum outdoor temperature 
Com-.2..osite variable C" Mean radiation 
Grass -.2..ollen 
Birch Rollen 
Seasons 
Swimminjl 
Multivariate analysis* Dust Exposure to pets 
Wool next to the skin Shampoo 
Nylon next to the skin ComQosite variable C" 
Sweating 
Secondary outcome measure "scratch" 
Associated with increased severity No effect 
Univariate analysis Swimming Minimum relative humidity 
Wool next to the skin Birch -.2..ollen 
Sweating Com2.osite variable A I 
Shampoo Com2.osite variable B£ 
Chan-.9..e in temperature 
Dust 
Maximum outdoor temperature 
Mean radiation 
Nylon exposure next to skin 
Exposure to pets 
Grass pollen 
Composite variable C" 
Seasons 
Change in temperature 
Multivariate analysis** Sweating Swimming 
Shampoo Wool next to the skin 
Secondary outcome measure "stepping up" treatment 
Univariate analysis Swimming Mean radiation 
Wool next to skin 
Pets 
Sweating 
Grass 
Birch gollen 
Maximum outdoor temperature 
Nylon next to the skin 
Shampoo 
Grass 2.ollen 
Seasons 
Dust 
< 
Minimum relative humidity , 
~ ~
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Legend for table 9-4 
*Factors associated with residual heterogeneity: dust, sweating and wool next to the skin 
**Factors associated with residual heterogeneity: swimming 
1Composite variable A: high outdoor temperature (>22°C), sweating and high grass pollen levels 
2Composite variable B: dust exposure, low outdoor temperature «1°C), and low relative indoor humidity 
«40%) 
3Composite variable C: shampooing the hair at the same time as shower or bath and low outdoor 
temperature «1°C) 
9.7 Site specificity of associations 
I hypothesised that specific exposures would cause site-specific flares. In particular, 
aeroallergens would be associated with flares of "air exposed" skin while clothing 
would be associated with flares of covered skin. The site-specificity of exposures was 
clearly demonstrated for a number of possible triggers (Table 9-5). No association 
was seen between dust or grass exposure and eczema of "air-exposed" sites. 
Exposure to pets was associated with flares of hand (p<O.001) but not face eczema 
(p=O.149) implying that direct contact may be relevant for disease flares. Looking at 
clothing, nylon contact with skin was associated with flares of both trunk (p=O.02) and 
limb eczema (p=O.03) while an association was only seen for wool contact of the 
trunk and not the limbs. 
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Table 9-5 Site-specific reaction to exposures 
Exposure Site Regression coefficient P value 
Dust Face 0.048 0.08 
Hands 0.024 0.31 
Pet Face 0.017 0.24 
Hands 0.078 <0.001 
Grass Face -0.002 0.39 
Hands -0.000 0.87 
Wool Trunk -0.066 0.03 
Limbs 0.013 0.62 
Nylon Trunk 0.031 0.02 
Limbs 0.09 0.03 
9.8 Correlation to perceptions 
There was no correlation between perceived worsening on specific exposures or 
specific avoidance as recorded in the baseline interview and worsening on exposure 
to these factors as assessed during the study at the patient level (Table 9-6). 
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Table 9-6 Correlation of responses to exposures to parental perceptions of "flare factors" 
Association Regression Confidence 
coefficient interval 
Perceived worsening in hot weather/ regression 
-0.013 
-0.046 to 0.207 
coefficient for maximum outdoor temperature 
Perceived worsening in summer/ regression 
-0.047 
-0.108 to 0.013 
coefficient for maximum outdoor temperature 
Perceived worsening in hot weather/regression 
-0.284 -0.720 to 0.153 
coefficient for worsening in summer 
Perceived worsening in summer/regression 
-0.403 -1.090 to 0.284 
coefficient for worsening in summer 
Perceived worsening in cold weather/regression 0.250 -0.040 to 0.539 
coefficient for worsening in winter 
Perceived worsening in winter/regression -0.021 -0.632 to 0.589 
coefficient for worsening in winter 
Pet avoidance/regression coefficient for pets 0.165 -0.461 to 0.790 
Shampoo or wash product avoidance/regression 0.178 -0.368 to 0.724 
coefficient for shampoo 
9.9 Results of hypothesis testing 
Hypothesis 1 
In hot weather, the combination of heat, sweating and grass pollen precipitates 
increased severity. 
Composite variable A was created to test this hypothesis. Neither the primary 
outcome "bother" not the secondary outcome "scratch" was associated with 
composite variable A (Table 9-1 and Table 9-2) and it was not possible to test this 
hypothesis for the other secondary outcome measure "stepping up" treatment. There 
is therefore no evidence to lead to rejection of the null hypothesis of a lack of 
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association between this combination of factors and worsening of eczema. However 
only five participants experienced this combination of exposures. 
Hypothesis 2 
In cold weather, the combination of cold weather, indoor aeroallergen exposure and 
reduced relative humidity from central heating lead to increased severity. 
This hypothesis was tested by the creation of composite variable B. Composite 
variable B was not associated with significant increases in either bother or scratch 
scores and it was not possible to test this hypothesis for the other secondary 
outcome measure "stepping up" treatment. There is therefore no evidence against 
the null hypothesis that there is no association between this combination of factors 
and worsening of eczema. However only ten participants experienced this 
combination of exposures. 
Hypothesis 3 
Detergents (soap, shampoo) can increase the propensity to increased severity 
(triggered by other factors) at all temperatures but possibly more in cold weather 
due to impaired skin barrier function. 
This hypothesis was tested by looking at whether washing the child's hair at the 
same time as the bath or shower was associated with significant increases in scratch 
or bother scores when outdoor temperature was low, <1 cC. An increase in both 
scratch and bother scores was observed with shampoo exposure. Composite 
variable C (shampoo and low outdoor temperature) was created to test this 
hypothesis. For the primary outcome measure, this variable was associated with 
increased severity of eczema without heterogeneity in responses providing evidence 
against the null hypothesis of no association. 
Hypothesis 4 
Patients with fi/aggrin mutations are more prone to the effects of climatic and 
environmental factors such as cold and heat than individuals who are wild type for 
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filaggrin. 
This hypothesis was tested by carrying out regression using the response to the 
exposure (regression coefficient) as the outcome variable and the filaggrin status as 
the explanatory variable. 
Only worsening in summer (p=0.01) was associated with the 2282del4 mutation. No 
associations were seen with the r501 x mutation. There is insufficient evidence to 
reject the null hypothesis as these associations may have occurred due to chance as 
a result of multiple testing. However, associations are also difficult to detect due to 
the low numbers of filaggrin mutations seen. 
Hypothesis 5 
Any combination of greater than or equal to three exposures at any time is 
associated with worsening of eczema. The exposures assessed were: dust, 
exposure to pets, shampoo, sweating, swimming, nylon clothing next to the skin and 
a change in mean temperature of more than 3°e from the previous weekly average. 
The hypothesis that any combination of greater than or equal to three of certain 
exposures would be associated with worsening of eczema was also explored. A clear 
association was seen with any of these combinations and worsening of eczema as 
assessed using the primary outcome, regression coefficient 0.159 (95% confidence 
interval 0.034 to 0.283). No heterogeneity was seen in responses, p=0.296, Tau 
squared=0.016. A linear association was also seen when data was analysed for the 
effect of each additional exposure as shown in Figure 9-8 below. This hypothesis will 
require further study as an a priori hypothesis looking at the impact of different 
exposures in different study populations. 
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Figure 9-8 Effect of additional cumulative exposures on "bother" scores 
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This graph shows the effect of each additional exposure on the "bother" regression coefficients with a linear trend . 
The bars represent the confidence intervals. 
9.10 How TCW and WCW perform in comparison to monthly outcome 
measures 
The definition of flares proposed was intuitively well understood by children and their 
parents. However, as this is a binary definition where flares are either present or 
absent, the sensitivity to detect change is lower than the primary outcome used and 
than the other secondary outcome (both 11 point scales) . 
The number of totally and well controlled weeks (TCW and WCW) were also 
compared between those with less and more severe eczema during the course of the 
study at the level of the patient. Individuals were divided into two groups each for 
average CDLQI , TIS and POEM during the study based on arbitrary cut offs of 
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greater than 16, greater than 5 and greater than 14 respectively. Associations were 
observed between POEM and TIS and number of TCW and WCW (Table 9-7). For 
COLOI, a higher average TCW and WCW was seen, which suggests a poor 
correlation with this measure, but as the former measure relates to quality of life and 
not disease control, this is not surprising. 
Table 9-7 Relationship between totally and well controlled weeks and average severity during the 
study 
Severity score Average number of weeks Confidence interval P value 
Totally controlled weeks 
Patient orientated eczema measure 
:514 0.006 0.005 to 0.007 <0.001 
>14 0.001 0.000 to 0.001 
Children'S Dermatology Life Quality index 
:516 0.004 0.004 to 0.005 <0.001 
>16 0.008 0.006 to 0.011 
Three item severity score 
:55 0.005 0.004 to 0.006 <0.001 
>5 0 0 
Well controlled weeks 
Patient orientated eczema measure 
:514 0.051 0.049 to 0.053 <0.001 
>14 0.007 0.006 to 0.009 
Children's Dermatology Life Quality index 
:516 0.041 0.040 to 0.043 0.008 
>16 0.048 0.042 to 0.054 
Three item severity score 
:55 0.045 0.043 to 0.047 <0.001 
>5 0.001 0.000 to 0.002 
-
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Similarly the relationship between average numbers of flares, as defined by the need 
to step up treatment, and the average of the severity scores, COLOI, TIS and POEM 
was assessed. This again showed clear associations with more flares in individuals 
with higher TIS and POEM scores (Table 9-8). No association was seen between 
higher COLOI scores and number of flares suggesting that this may be measuring a 
different aspect of eczema. 
Table 9-8 Relationship between mean number flares per individual per day and average severity 
during the study 
Severity Average number of flares per Confidence P 
score individual per day interval value 
Patient orientated eczema measure 
~ 1 4 4 0.168 0.165toO.170 <0.001 
>14 0.314 0.306 to 0.321 
Children's Dermatology Life Quality index 
:516 0.198 0.195 to 0.200 0.683 
>16 0.196 0.185 to 0.207 
Three item severity score 
:55 0.168 O. 165 to 0.170 <0.001 
>5 0.314 0.306 to 0.321 
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9.11 Exploratory analysis to assess the validity of "summer" and 
"winter" types of eczema 
The regression coefficients for the effect of summer and winter on the primary 
outcome measure "bother" were used to form clusters using Ward's and the 
complete linkage method. Cluster analysis was used to group participants into 
categories based on their responses to winter and summer. Ward's method uses an 
analysis of variance (ANOVA) approach to evaluate the distances between clusters. 
The complete linkage method by contrast determines the distances between clusters 
by the greatest distance between any two participants in the different clusters. 
Dendrograms were then used to displaying relationships among the clusters. A 
dendrogram shows the distances between participants in a tree-like structure. 
Dendrograms were produced for the response of eczema in winter and summer 
(Figure 9-9, Figure 9-10, Figure 9-11, Figure 9-12, Figure 9-13). The diagrams show 
individual responses to the seasons at the bottom of the diagram clustered by their 
similarity of responses. Dendrograms looking at both winter and summer responses 
show two major categories for responses to the seasons but this is much less clear 
when the complete linkage method is used than when Ward's method is used 
suggesting that this apparent clustering is not robust to the method used. This 
suggests that while there may be some validity in dividing participants into two 
groups for responses to seasons, more evidence is required to substantiate this 
clustering. 
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Figure 9-9 Dendrogram for response to winter using Ward's method 
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The dendrogram graphically presents the information concerning which participants responses are grouped together 
at various levels of dissimilarity in their regression coefficients for bother relating to the exposure winter. The 
clustering in this dendrogram was generated used the Ward 's method which attempts to minimise the sum of squares 
of any two clusters . At the bottom of the dendrogram, each individual is considered its own cluster identified by a 
generated cluster identification number. The height of the vertical lines and the range of the dissimilarity axis give 
visual clues about the strength of the clustering . Long vertical lines indicate more distinct separation between the 
groups as in this dendrogram. 
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Figure 9-10 Dendrogram for response to winter using the complete linkage method 
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Legend to figure 9-10 
This dendrogram was created using the complete linkage method of clustering which determines the distance 
between clusters by the farthest neighbour with in each cluster. The dendrogram shows much less distinct separation 
between groups. 
Figure 9-11 Dendrogram for response to summer using Ward's method 
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Figure 9-12 Dendrogram for response to summer using the complete linkage method 
Dendrogram of regression coefficients for responses to summer 
Cluster number 
Figure 9-13 Dendrogram for response to winter and summer using Ward's method 
Dendrogram of regression coefficients for responses to winter and summer 
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Chapter 10 
Discussion 
10.1 Summary of main findings 
Worsening of eczema was seen with exposure to nylon and wool clothing next to the 
skin, exposure to unfamiliar pets, shampoo, sweating and swimming. No association 
with worsening of eczema was seen for either minimum indoor relative humidity or 
birch pollen. Heterogeneity of responses between individuals was detected for many 
of the other exposures assessed including dust, grass pollen, maximum outdoor 
temperature and the four seasons. Site specificity was detected for responses to 
exposure to pets, wool and nylon clothing. In relation to the specific hypotheses 
tested, the null hypothesis that combined exposure to shampoo and cold outdoor 
temperatures was not associated with worsened eczema could be rejected. Analysis 
also showed that any concurrent combination of three or more of seven exposures 
likely to cause flares was highly associated with disease worsening. Indeed a linear 
relationship was observed between each additional exposure and eczema 
worsening. Specifically in relation to filaggrin mutations, only summer season showed 
an association with worsened eczema. This may have been a chance association or 
alternatively, other significant interactions may have been missed by chance due to 
the low prevalence of filaggrin mutations in the cohort. 
10.2 Main findings 
Combining the results from univariate and multivariate analyses for the primary 
outcome "bother", increased severity of eczema was observed in association with the 
following exposures: dust, wearing nylon and wool next to the skin, exposure to pets, 
shampoo exposure, the composite variable C (shampoo and cold weather) and 
sweating (Table 10-1). 
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Table 10.1 Summary of main study findings 
Outcome measures 
Primary Secondary 
"Bother" score "Scratch" score Flares of eczema 
Factor 
Dust Increased No change No change 
Swim No change Increased Increased 
Minimum relative No change No change No change 
humidity 
Maximum outdoor No change No change No change 
temperature 
Mean radiation No change No change No change 
Wool next to skin Increased Increased No change 
Nylon next to skin Increased No change No change 
Pet Increased No change No change 
Sweat Increased Increased No change 
Shampoo Increased Increased No change 
Grass pollen No change No change No change 
Birch pollen No change No change No change 
Composite variable No change No change No change 
A 
Composite variable No change No change No change 
B 
Composite variable Increased No change No change 
C 
Spring No change No change No change 
Summer No change No change No change 
Autumn No change No change No change 
Winter No change No change No change 
Footnote to explain table 10-1: 
"Increased" means that the exposure was associated with increased disease severity 
"No change" means that disease severity was unchanged with the exposure 
"Reduced" means reduced disease severity was associated with the exposure 
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Persistent heterogeneity was observed for responses to dust, swimming, grass 
pollen, wearing wool next to the skin, sweating, maximum outdoor temperature, the 
four seasons and change in weekly average temperature of greater than or equal to 
3°e. No association was seen for minimum indoor relative humidity, birch pollen and 
composite variables A and B. 
For the secondary outcome "scratch", increased severity was detected on exposure 
to swimming, wearing woollen clothing next to the skin, sweating and shampoo 
exposure. Persistent heterogeneity was detected for dust, maximum outdoor 
temperature, mean radiation, wearing nylon next to the skin, exposure to pets, grass 
pollen, composite variable e and seasons. No association was detected for dust, 
minimum relative humidity, maximum outdoor temperature, wearing nylon next to the 
skin, pet exposure, grass pollen, birch pollen, composite variables A, Band e, 
change in mean weekly temperature, seasons and mean radiation. For the other 
secondary outcome "stepping up" treatment, increased severity was seen only for 
swimming. No association was seen for dust, mean radiation, minimum relative 
humidity, maximum outdoor temperature, wearing wool or nylon next to the skin, 
exposure to pets, sweating, shampoo, birch and grass pollen and seasons. 
Persistent heterogeneity of response was detected for dust, minimum relative 
humidity, maximum outdoor temperature, wearing nylon next to the skin, shampoo 
exposure, spring, summer and autumn. A summary of the factors shown to have 
associations with worsening of eczema across all outcome measures is shown in 
Table 10-2. 
Table 10-2 Summary of factors associated with worsening of eczema 
Dust 
Exposure to unfamiliar pets 
Grass pollen 
Wool exposure 
Nylon exposure 
Sweating 
Swimming 
Shampoo 
Shampoo and cold weather 
Site specificity of a number of the associations was also seen. Exposure to pets was 
associated with flares of hand eczema while nylon exposure was associated with 
flares of eczema of the trunk and limbs and wool exposure was associated with 
worsening of truncal eczema. 
For the five hypotheses, only two null hypotheses could be rejected. Firstly the null 
hypothesis that shampoo exposure at the same time as the bath or shower in cold 
weather was not associated with eczema could be rejected. In regard to the final 
hypothesis, a combination of any three of seven likely variables was associated with 
worsening of eczema with no heterogeneity of responses between individuals. This 
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strongly suggests that the combination of a number of variables may be the key to 
disease flares. However this hypothesis requires further testing looking at different 
exposures in different study populations to see if this relationship is robust. 
Only summer season was associated with worsened eczema in people with 
2282del4 filaggrin mutations. This may be a chance association with multiple testing 
or associations may have been missed due to the low prevalence of filaggrin 
mutations. 
The performance of the proposed definitions for flares of eczema and totally and well 
controlled weeks (TCW and WCW) was also tested against the general control of 
eczema as assessed using monthly TIS and POEM scores and three monthly COLal 
scores. Average TIS and POEM scores correlated well with the average number of 
flares and TCW and WCW. No association was seen between average COLal and 
the average number of flares. Higher COLal scores were associated with greater 
numbers of TCW and WCW, which suggests that COLal may measure a different 
aspect of disease control than TCW and WCW. 
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10.3 Coherence with previous studies 
10.3.1 Aeroallergens 
In Chapter 2, I reviewed the published literature on what causes worsening of 
eczema. Previous experimental studies of the impact of house dust mite show 
associations between topical and inhaled dust mite and worsening of eczema in 
adults (Norris, Schofield et al. 1988; Tupker, De Monchy et al. 1996; Shah, Hales et 
al. 2002). In this study, dust exposure was associated with heterogeneous responses 
suggesting that individual children with eczema respond differently to dust exposure. 
The evidence for other aeroallergens from the literature is mainly from atopy patch 
test studies which have shown that eczema can be induced through topical 
application of aeroallergens. However, the associations between this experimentally 
induced eczema and clinical history and location of eczema are not clearly 
established (Bygum, Mortz et al. 2003). In this study, grass was associated with 
heterogeneous responses; worsening of eczema was seen using the secondary 
outcome measure "scratch" after multivariate analysis but not with the other two 
outcome measures. The responses to grass pollen did not show site specificity for air 
exposed sites. Birch pollen showed no association with worsening of eczema. 
10.3.2 Clothing 
In relation to clothing and worsening of eczema, previous studies by Diepgen et al in 
adults with eczema have shown the weave of fabrics is more important that whether 
the fabric is cotton or synthetic (Diepgen, Stabler et al. 1990; Diepgen T J 1995). In 
this study, nylon clothing was associated with worsening of eczema that was site 
specific. In other words, nylon clothing was associated with worsening of eczema on 
the trunk and limbs. Wool exposure was associated with worsening of eczema of the 
trunk but not the limbs. Wool exposure was associated with increased bother scores 
on univariate analysis but this disappeared after adjusting for possible confounding 
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factors. Wool exposure was associated with increased disease severity using the 
secondary outcome "scratch" scores with no heterogeneity between individuals. 
Diepgen's study differed from this study in that it was an experimental study involving 
the use of specially constructed ponchos and assessment of disease severity under 
experimental rather than "real-life" conditions. The authors also did not study eczema 
in children. 
10.3.3 Seasons 
In terms of the impact of seasonal factors on eczema, Vocks et al have shown a 
reduction in itch scores with increased mean daily temperature (Vocks, Busch et al. 
2001). This study has shown that the response to maximum daily temperature is 
heterogeneous and varies between individuals. Kramer et al have proposed a 
specific model of disease heterogeneity to environmental factors in eczema, 
specifically that there are winter and summer types of eczema which respond 
differently to outdoor temperature (Kramer, Weidinger et al. 2005). In this study, 
variation has been demonstrated in people's responses to outdoor temperature and 
the seasons. The dendrograms used to examine responses to different seasons lend 
some support to the model proposed by the aforementioned authors, but are not 
sufficient to confirm these associations. This possible association was not tested as a 
pre-specified hypothesis. 
10.3.4 Irritants 
A number of other important factors included in this study were the impact of irritants, 
specifically shampoo, swimming and sweating. There is some previous evidence that 
irritants may be important in eczema severity and that these factors might show 
seasonal variation (Tupker, Coenraads et al. 1995; Tupker, Coenraads et al. 1995; 
Seki, Morimatsu et al. 2003). However, the previous studies were not eligible for 
inclusion in Chapter 2 as they did not assess the impact of irritants on eczema 
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severity. The study by Seki et al showed that individuals with eczema could tolerate 
lower levels of chlorine exposure than individuals without eczema. This study 
indicates associations between eczema worsening and irritant exposure. Specifically, 
associations were seen between washing a child's hair at the same time as the bath 
or shower and worsening eczema. It was also possible to demonstrate interactions 
between this response and low environmental temperature, which is an anecdotally 
and clinically reported association. Swimming in chlorinated pools was associated 
with disease worsening as assessed using daily scratch scores and the need to "step 
up" treatment. It was associated with heterogeneity of response when the primary 
"bother" score was the outcome used. 
10.3.5 Exposure to pets 
Worsening of eczema on exposure to pets has been inadequately studied in the past 
as I noted in Chapter 2. Specifically no-one has studied the association between 
exposures to pets other than the family pets and worsening of eczema. This is 
relevant as patients develop tolerance to family pets, which may not extend to 
unfamiliar or infrequently exposed pets. In this study, an association was observed 
between exposure to unfamiliar pets and worsening of eczema. Furthermore, site-
specificity was seen for this association, whereby exposure to pets was associated 
with worsening of hand but not facial eczema. 
10.3.6 Filaggrin mutations 
Interactions were observed between worsening of eczema in summer season and 
one of the filaggrin mutations, the 2282del4 mutation. No interactions were observed 
between the r501 x mutations and worsening of eczema with exposures. No previous 
study has assessed the impact of filaggrin mutations and worsening of eczema on 
exposure to environmental factors and therefore it is not possible to compare the 
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results with those from other research. The low prevalence of filaggrin mutations in 
the cohort will mean that this study is not powered to adequately assess interactions. 
10.4 Strengths and limitations 
10.4. 1 Originality 
This is an original study addressing a highly important issue, the role of 
environmental factors in eczema. The study has been carried out in a methodical 
fashion, with a pilot feasibility study, systematic reviews to identify research gaps, 
proposals of definitions of flares in eczema and followed by a formal planned study. 
This study has a number of novel components which will have improved the quality of 
the information. These include the use of specially programmed electronic diaries 
which are likely to have reduced data entry errors and recall bias, improved 
compliance and removed data download errors. Electronic dataloggers were also 
used to record climatic factors accurately. This is a novel concept, which allows 
recording of indoor climatic factors and study of the child's microenvironment. A 
previous study has assessed the impact of indoor temperature and relative humidity 
in the home, but as children spend a large proportion of their time in school and other 
indoor settings, these environmental factors have not been captured by previous 
study designs. 
This study also assessed the importance of filaggrin mutations in regard to 
responses to environmental factors. These possible gene-environment interactions 
have not previously been studied. Although the low prevalence and relatively small 
sample size precluded full assessment of the role of these mutations, this study did 
afford the opportunity to explore environmental interactions with filaggrin mutations 
for the first time. 
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10.4.2 Study duration 
One of the further advantages of this study is the long study period, which due to 
staggered entry allowed study of the seasonal effects of environmental variables 
across participants. No previous similar study has had a similar duration or 
incorporated all of the seasons. This therefore was a unique opportunity to study the 
impact of environmental factors on eczema. 
10.4.3 Study design and analysis 
The prospective observational study design allowed observation of time course of 
eczema and temporal associations between exposure and worsening of disease. It 
was also possible to test site-specificity of the effect of exposures to determine 
whether particular exposures were associated with worsening at specific sites. 
Individuals effectively acted as their own controls as the ARMA regression was 
carried out on an individual basis before meta-analysis. This reduced the impact of 
confounding factors and made it was possible to examine inter-individual variation in 
response to exposures. Although there was some missing data, an inevitable 
occurrence in any study of long duration, the quality of data collected was high and 
the fact that the data is not independent means that missing data at a single time 
point is less important. All of these factors combined lead to the conclusion that this 
study is likely to be associated with good internal validity. 
10.4.4 Hypothesis testing 
The use of a cohort design meant that it was possible to test and examine multiple 
hypotheses. A number of pre-specified hypotheses were tested including the 
possible gene-environment interactions of filaggrin mutations. 
10.4.5 Possible sources of bias 
One of the main problems with long duration cohort or panel studies is the possibility 
of selection bias if there are differential losses to follow up between different groups. 
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Similarly, selection bias may arise in this study if there are differential completion 
rates between groups who differ in important ways. This issue was also explored in 
relation to baseline characteristics of "poor" responders «50% diary completion 
rates) and "good" responders and also in relation to exposures predicting the 
likelihood of missing data. No important differences were seen in terms of age, 
gender, social class, parental education or the baseline severity of eczema. The only 
exposure associated with missing data was maximum outdoor temperature. This may 
well be a chance finding from multiple testing. If this were due to poorer diary 
completion during vacations, one would also expect an association with mean solar 
radiation. A further source of selection bias relates to differences between persons 
who were screened and did not participate and those who participated in the study. 
This may have lead to over-representation of individuals of higher socioeconomic 
status. The issue of multiple testing was also explored in relation to main study 
findings by exploring the impact of using 99% rather than 95% confidence intervals 
for associations with increased "bother" scores as it was not possible to use 
statistical methods such as the Bonferroni correction in this post hoc situation. The 
associations between increased "bother" scores and dust, exposure to unfamiliar 
pets and sweating persisted; other associations no longer persisted but this criterion 
may be too stringent given the relatively small sample size. 
Fatigue is a major problem in panel studies, where overall completion rates reduce 
with time. This phenomenon has been clearly shown in this study where in both 
"poor" and "good" responders, response rates reduced after the first month. This was 
much more markedly seen for the "poor" responders than the "good responders" but 
was evident in both groups. This suggests that for future observational studies, 
consideration should be given to the use of a month "run in" period to identify 
participants with good compliance. 
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In terms of information bias, observer bias is not likely to be a major problem as the 
primary analysis was based on self-assessment of the severity of eczema. 
Responder bias is more likely, if parents perceive associations between exposures 
and worsening of eczema and are thus more likely to record worsening of eczema. I 
believe this is unlikely to be a major problem as diary completion was undertaken 
daily over a long follow up period. Parental bias is also unlikely to be the only 
explanation because no association was seen between parental perceptions of flare 
factors or avoidance factors determined at the baseline interview and associations 
observed during the study. Another possible source of information bias relates to the 
use of proxy respondents. For young children, aged 8 years or less, parents 
completed the diaries on behalf of the children. This may lead to poor recording of 
some exposures. For example, if children are in a nursery during the day, parents 
may not be aware of all daily exposures. Every effort was made to reduce this 
element by clear explanations to parents and by requesting diary completion by the 
person most likely to be aware of all exposures. Another possible issue relates to 
measurement of exposures for factors such as dust exposure. No direct measure 
was taken of household dust or dust mite levels; it is likely therefore that the question 
will only detect individuals in very dusty environments and therefore extreme levels of 
exposure rather than day-to-day house dust mite exposure. 
10.4.6 Confounding 
A confounder is a factor which is associated with the exposure and the outcome and 
may be responsible for either observed associations or missing real associations. In 
this study, the roles of factors which may cause worsening or flares of eczema were 
assessed. Some possible confounders not studied are the effects of exposures such 
as stress or bacterial infections previously reported to cause worsening of eczema. It 
was decided not to include these factors as stress can only be adequately studied by 
asking multiple relevant questions; such a requirement would have increased 
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respondent burden significantly and is likely to have an associated reduction in 
compliance rates. Study of bacterial infections was not the main focus of the study 
and would have required laboratory testing in addition to the study procedures. This 
would have complicated the study without significantly enhancing it, as detecting 
Staphylococcus Aureus from the skin of people with eczema is not specific for clinical 
infection (Leung, Schiltz et a!. 2008). I also did not differentiate between whether 
individuals were from urban or rural locations as the study would have been 
inadequately powered to examine this and it was not one of the study primary 
objectives. 
10.4.7 Random error 
Random error is always a possible source of chance associations or missed 
associations. For example in relation to environmental interactions with the filaggrin 
2282del4 mutation, multiple testing may have led to the observed worsening with 
summer season as a chance phenomenon. However, equally, as only ten of the 
participants had filaggrin mutations, significant interactions may well have been 
missed due to low numbers. 
10.4.8 Specification of the wrong hypothesis 
It is possible that the five hypotheses tested as a priori hypotheses in this study may 
not have been the key hypotheses in relation to worsening of eczema. However, two 
of the null hypotheses could be rejected. The other null hypotheses may either have 
been the wrong choice of hypotheses or the low prevalence of exposures may have 
lead to missing significant associations by chance. It is acknowledged that 
hypothesis 1 and 2 may have been too complicated thus leading to low prevalence of 
the specified combined exposures. Specifying simpler hypotheses in these cases 
may have shown different results. 
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10.4.9 Methodological issues 
One of the issues affecting this study was a methodological issue precluding the use 
of ARMA for analysis of the binary variable, "stepping up" treatment as the binary 
nature of responses cannot be assumed to be normally distributed. This required the 
use of logistic regression on an individual basis followed by meta-analysis of the 
regression coefficients across individuals which was not the ideal means to study 
time-series data. This process may have impacted on the ability of this outcome 
measure to show associations between exposures and disease worsening. 
One of the disadvantages of panel studies is that they are slow to carry out and the 
investment of time can lead to them being relatively expensive. However, it would be 
very difficult to study associations between exposures such as seasonal associations 
and worsening of eczema using shorter studies. This issues was highlighted in the 
study by Kramer et ai, whereby, the non-inclusion of the winter season in their study 
(study period March to September) meant that it was difficult to truly infer "winter" 
types of eczema (Kramer, Weidinger et al. 2005). A longer study period was 
essential to study these associations in detail and this was weighed against the 
increased costs incurred. 
10.5 Clinical importance of findings 
Causation is never possible to prove in the context of an observational study 
although it is possible to demonstrate associations and then to determine if these are 
likely to be clinically relevant. The findings of this study imply that parents don't often 
correctly guess what makes their child's eczema worse. The findings of this study 
suggest that nylon clothing, dust, exposure to unfamiliar pets and shampoo use need 
to be enquired about and minimised. The data also implies that children with eczema 
respond in different and clinically relevant ways to certain exposures such as dust, 
grass pollen and hot outdoor temperature. The data do not support a very important 
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role for filaggrin mutations in how people react to external exposures, but the study is 
not sufficiently statistically powered to assess this fully and hence, important 
interactions may have been missed by chance. Data also suggests that it is the 
combination of concurrent exposures which is associated with disease worsening 
rather than individual exposures. 
An issue which determines the generalisations of the findings is that of external 
validity. The study population may not be representative of the population attending 
general practitioners with eczema. By definition, if participants are recruited from 
hospital and community outpatient clinics, they may have more severe eczema and 
may be more susceptible to the effects of environmental exposures. However, in 
order to effectively study flares without too long a study duration, the study population 
needed to have sufficient disease severity to experience flares during the study 
period and therefore this decision was made pragmatically prior to the onset of the 
study. Another issue related to external validity is the issue that participants who 
agree to participate in a study for between six and nine months which involves daily 
diary completion and monthly assessments may be different to the general 
population and this may reduce the external validity. Again, this was believed to be 
essential to study these associations effectively and worth the reduction in external 
validity. 
10.6 Recommendations for future research 
The findings of this study highlight the need for further research in a number of key 
areas. A larger gene-environment study is required to look at possible gene 
environment interactions with filaggrin mutations. These studies will require larger 
number of participants to ensure that there is sufficient statistical power to look at 
these possible interactions. Further study is also required of the theory that multiple 
concurrent exposures are critical to disease flares in eczema. Specifically, it would be 
useful to assess this in different populations with different combinations of exposures. 
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A key area highlighted by this research is the possible role of shampoos in eczema 
worsening, particularly in cold weather. More research is required into the impact of 
different formulations using a clinical trial for example. If this is a generic association 
with all available shampoos, more work will be required in conjunction with the 
pharmaceutical industry to create a more suitable product for use in eczema. 
10.7 Conclusions 
This study suggests that the proposed definitions of flares and totally and well 
controlled weeks perform well in comparison to other measures of disease severity. 
The following factors were shown to be associated with disease worsening in 
children with eczema in this UK study: clothing (wool and nylon), sweating, shampoo, 
swimming, dust, contact with unfamiliar pets and high grass pollen levels. The 
implications of the findings of this study for clinical practice are that that worsening of 
eczema may be more complicated in that multiple exposures acting in concert may 
be associated with worsening of disease. This study strongly suggests that parental 
perceptions of the causes of flares may not be reliable for use in clinical practice. 
This study has also shown for the first time that shampoo exposure may be 
associated with eczema worsening and that this is more pronounced in cold weather. 
There was insufficient evidence to support the other hypotheses tested in this study 
but this may be explained by low prevalence of these exposures. 
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Chapter 11 Lessons learned from this research 
11.1 Writing 
Medical papers: 
I have published five papers from this study. A further two papers are being 
preparation and submitted. The project I completed for my MSc project has been 
accepted as an original publication by the British Medical Journal. My writing has 
improved significantly since commencing research. For example, in the first paper I 
wrote, I had less clarity about what should go in each section and had "mini-reviews" 
within my introduction and discussion sections. I am much clearer now about the 
division of papers using the standard IMRAD (introduction, methods, results and 
discussion) format. 
Protocol and ethics submissions: 
The discipline of writing my own protocol and preparing the ethics submission were 
useful to improve the study design and to obtain independent peer review of the 
proposal. The process obliged me to address specific issues such as how I would 
explain my study to a lay audience, what exposure and outcome variables I would 
collect and why I had chosen them. The peer review process gave a fresh 
perspective on the protocol and highlighted potential weaknesses and important 
omissions. For example, one of the peer reviewers noticed that sunlight was not 
included as an exposure variable and suggested that this was a key exposure 
variable. The protocol was subsequently modified to include this variable. The 
COREC form was quite a challenge to complete, but the process did improve the 
preparatory stages of the study as outlined above. 
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Choosing study instruments: 
The use of novel electronic diaries is advantageous in terms of improving compliance 
and the accuracy of the data collected (Hyland, Kenyon et al. 1993; Jamison, 
Raymond et al. 2001; Palermo, Valenzuela et al. 2004). The disadvantages are the 
lack of control over the timing of the project due to dependence on external 
programmers to prepare the devices. An additional disadvantage is the cost 
incurred, approximately £250 per device. In comparison, paper diaries are easier to 
prepare and produce; there is a wealth of experience in their design and use and 
they are relatively inexpensive. A major concern, however is that the information in 
paper diaries does not accurately reflect exposures and outcome status (discussed in 
detail in Chapter 6). This is due to a number of factors: missing data, poor 
compliance, retrospective data entry (thus incurring recall bias), and poor handwriting 
leading to erroneous conclusions. The main advantage with the electronic devices is 
improved compliance and the prevention of retrospective data entry. 
Using electronic dataloggers gives highly accurate individual data representing the 
temperature and humidity in the child's micro-environment. This is a much more 
accurate representation than, for example, measuring household climatic conditions 
twice daily (Kramer, Weidinger et al. 2005; Langan, Bourke et al. 2006). Using the 
latter approach, even with full parental compliance, only household conditions will be 
taken into account. As children spend large proportions of time outside the home, for 
instance at school or outdoors, the data would poorly reflect exposures thus 
compromising the validity of the data. These electronic devices have potential uses 
for future clinical research in a variety of areas. 
Designing study instruments: 
DeSigning the electronic diary questions was an entirely new process for me. I had 
assumed that as I had experience designing paper diaries and a clear idea of what I 
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wanted to study, that this would be a straightforward process. It is much clearer to 
me now that the use of high technology equipment in a study requires learning 
completely new skills. These skills include adapting questions to suit the electronic 
format; questions must be closed-ended, must fit on the screen and be legible and 
must be readable and "user-friendly". I also had to intensively study the tool to look 
for "bugs". The initial pilot device did not use the skip-format I had requested and 
when buttons were repeatedly pressed (as children will do!), the machine gave 
unreadable responses. I therefore had to intensively re-test the diaries and 
developed a close working relationship with the company preparing the device. In 
this case, using electronic diaries delayed the start by several months and required a 
lot of persistence to bring the tool to perfection. In terms of the "ibutton" dataloggers, I 
tested these in a variety of settings. This type of testing showed me that humidity 
readings were unreliable when the devices were kept in my pocket and that the 
"ibuttons" were easy to lose when they were kept loose. As a result of this, I ordered 
key ring holders for the ibuttons so that they could be worn externally and thus 
reduce the chance of loss of the dataloggers. 
11.2 Attitudes and approach 
Patience and persistence 
The research processes are associated with significant delays at all stages, including 
securing funding, applying for ethical approval and designing and preparing tools to 
use in the project. I am satisfied that I have learned patience and persistence through 
these experiences. 
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Appendix 
Appendix 1 How investigators have defined disease flares in eczema 
Author Intervention Follow Single or Primary Severity Definition of Symptoms Signs Treatment Duration Comment 
(year) (s) up multiple outcome of AD flare used 
relapses 
Composite Scales 
Days of 
Double blind treatment IGAS ~ 4 . .
with Same 
Papp RCT pimecroli Moderate Corticosteroi methods as pimecrolimus 1 year Multiple d (CS) 3 No Yes Yes Yes 2004 1% cream mus1 % or or severe days. 7 days Kapp and 
vs. vehicle 1% CS CS free Wahn 
Double blind IGAS ~ 4 . .RCT Incidence Majority Corticosteroi Kapp pimecrolimus of flares 
2002 1% vs. 1 year Multiple at 6 moderate d(CS)3 No Yes Yes Yes 
vehicle (CS months disease days. 7 days 
for flares) CS free 
Double blind 
RCT IGAS ~ 4 . .
pimecrolimus Ranked Majority Corticosteroi Wahn 1% vs. I year Multiple flares of moderate d (CS) 3 No Yes Yes Yes 2002 vehicle (CS AD in 6 disease days. 7 days for flares) months CS free 
L ___ 
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Author Intervention Follow Single or Primary Severity Definition of Symptoms Signs Treatment Duration Comment 
(year) (s) up multiple outcome of AD flare used 
relapses 
Double blind 
'I RCT 0.1% 
betamethaso 
ne valerate Number Assessed for 3 days vs. 
I of scratch Scratch steroid 1% Mild and Thomas hydrocortison 18 Multiple free days moderate score>2 for 3 Yes No No Yes usage but 2002 weeks and consecutive not used in e ointment 
number of AD days definition of for 7 days 
relapses flare 
Arbitrary score thresholds 
Modified 
Open study Costa Severe Assessed 12 weeks severity 
relapse 70% patient George baseline, 12 48 score. Severe symptoms 
1993 weeks TL-01 weeks Single Visual pre- No Yes No No but not in 
3/week, analogue phototherapy definition of Costa score 24/12 F/Up score relapse 
(patient) 
Open 
randomised 
parallel 
group trial. Number Granlund Compared 8 1 year Multiple of days in Severe SCORAD> Yes Yes No No 2001 week cycles remission 50% baseline 
of either 
cyclosporine 
or UVAB 
i 
l ______ ~ ~____ 
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Author Intervention Follow Single or Primary Severity Definition of Symptoms Signs Treatment Duration Comment 
(year) (s) up multiple outcome of AD flare used 
relapses 
Open-label Single SCORAD 
Bunikowsk study of 12 (discontin Cytokines S C O R A D ~ 8 0 0
i 2001 cyclosporine weeks uedin IL-6, IL-8 Severe % baseline Yes Yes No No 
case of and TNF-A 
relapse) a 
Open-label Disease Atakan study of 36 Single severity Severe S C O R A D ~ 7 5 5 Yes Yes No No I 1998 Sandimmun weeks % baseline 
i Neoral® score 
SCORAD> 
Ehlers Double blind 10 15 points 
2001 sugar days Single SCORAD Moderate above Yes Yes No No 
challenges baseline 
Double-blind 
RCT twice 
Berth- weekly 
Jones fluticasone 20 Single Time to Moderate T I S ~ 4 4 No Yes No No propionate weeks relapse to severe 2003 
vs. placebo 
base 
Open study: Symptoms Two Disease and steroid 
Granlund treatment 32 Length of activity use periods of 6 Multiple Severe No Yes No No 1995 weeks remission score>75% recorded 
weeks baseline but not in 
cyclosporine definition 
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Author Intervention Follow Single or Primary Severity Definition of Symptoms Signs Treatment Duration Comment 
(year) (s) up multiple outcome of AD flare used 
relapses 
: Open-label 
stabilisation IGAS ~ 3 3 and followed by 
score 2 to 3 double-blind Single Risk of for any 2 of Steroid use maintenance relapse in Moderate recorded Hanifin RCT study of 48 (withdraw maintena to severe erythema, Yes Yes No No but not in 2002 weeks n from itch, twice weekly 
study) nce AD papulation/ definition of fluticasone phase induration/ relapse propionate 
oedema 0.05% cream 
vs. vehicle 
i Double-blind 
I randomized Primary Mild to Flares are 
vehicle- not 
controlled efficacy severe specifically 
, 
I 
variable AD parallel 6 was the affecting defined Siegfried group study although 
2006 of month Multiple number of at least I G A S ~ 4 4 No Yes No No the authors 
pimecrolimus s individual 5% of define use swho body 1% cream 
remained surface of a "major 
with topical flare-free flare 
corticosteroid area regimen" 
s for flares 
Behavioural scales 
Double blind % of days Disease Symptoms 
Meurer RCT of 24 on which Moderate state assessed pimecrolimus Multiple topical CS requiring CS No No Yes Yes but not 2002 weeks to severe 
cream 1% was use for ~ 3 3 used in 
vs. vehicle received days definition 
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Author Intervention Follow Single or Primary Severity Definition of Symptoms Signs Treatment Duration Comment 
(year) (s) up multiple outcome of AD flare used 
relapses 
Open case Need to use Some 12 Response potent topical children Zaki series 
1996 treated with weeks Single to Severe CSt further No No Yes No part of 
cyclosporine max treatment systemic multicentre treatment study 
Double blind % of days ~ 3 3 days in RCTof which CS Meurer pimecrolimus 24 Multiple on which Moderate considered Yes No Yes Yes 2004 weeks topical CS 1% vs. necessary by I 
vehicle used investigator 
Number Cut off on 
I of study IGA not Double blind days ~ 3 3 days in clearly RCTof which CS Gollnick pimecrolimus 26 Multiple without Mild or considered Yes No Yes Yes defined but 2008 weeks topical CS moderate authors 1% cream 
use for necessary by references 
vs. vehicle 
major investigator previous 
flare studies 
CS = corticosteroid; FIUp = follow-up; SCORAD = Severity Scoring of Atopic Dermatitis; TIS = Three Item Severity score; IGAS = Investigator Global Assessment Score 
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Appendix 2 Search strategy for systematic review of flare factors for eczema 
1. exp Dermatitis, Atopic/ 
2. atopic dermatitis.mp. 
3. atopic eczema.mp. 
4. exp NEURODERMATITIS/ 
5. neurodermatitis.mp. 
6. infantile eczema.mp. 
7. childhood eczema.mp. 
8. Besniers' Prurigo.mp. 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. environment$.mp. or exp ENVIRONMENT/ 
11. climate.mp. or exp CLIMA TE/ 
12. weather.mp. or exp WEA THERI 
13. exp METEOROLOGICAL FACTORS/ or meteorological.mp. 
14. temperature.mp. 
15. humidity.mp. or exp HUMIDITY/ 
16. seasons.mp. or exp SEASONS/ 
17. wind.mp. 
18. exp AL TITUDE/ or altitude.mp. 
19. air temperature.mp. 
20. (damp or wet).mp. 
21. $allergen$.mp. or exp ALLERGENS/ 
22. irritant$.mp. or exp IRRIT ANTS/ 
23. sunlight.mp. or exp SUNLIGHT/ 
24. ultraviolet.mp. or exp ULTRA VIOLET RA YS/ 
25. wool.mp. or exp WOOL! 
26. exp Clothing/ or cloth$.mp. 
27. pollen.mp. or exp POLLEN/ 
28. exp Animals, Domestic/ 
29. *CA TS/ or cat$.mp. 
30. *DOGS/ or dog$.mp. 
31. house dust mite.mp. or *Pyroglyphideczema/ 
3:2. *HOUSING/ 
33. exp Food! 
34. 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 
26 or n or :28 or 29 or 30 or 31 or 32 or 33 
35. 9 and 34 
36. tlare$.mp. 
37. exacerbation$.mp. 
3R. relaps$.mp. 
39. remissionS.mp. 
40. worscS.mp. 
41. *RECURRENCE/ 
4:2. 36 or 37 or 38 or 39 or 40 or 41 
·n. 35 and 4:2 
44. ['C\ic\\.pt. 
45. 43 not 44 
-1 ~ 7 7
Appendix 3 Summary of results of the evidence for factors being associated with eczema flares by "flare factor" 
Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
FOODS 
Sampson DBPCFC. 113 severe 4 moto Elimination diet Symptoms, 56% children Unclear if skin 
1985 USA Randomised eczema 24.5 for 1-2 weeks severity and challenge +ve (101 symptoms equated 
(Sampson order years prior to admission duration challenges positive in to a flare of eczema 
and Ho No washout (up to six assessed 63 patients), of which 
1997) allergens, based using 84% had rash. All 
on history, SPT or standardized symptomatic within 
RAST test) scoring sheet two hours of 
DBPCFC:Two ingestion. Results for 
challenges given placebo challenge 
, daily, one active, not given. 42% of 
i 
one placebo in positive reactions to 
randomized order egg, to peanut in 
19% and milk in 11 %; 
other allergens 
accounted for lower 
percentages 
I 
, 
! 
,- ------
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Author! Study type Number of Age Measures of Outcome Results Comments year! participants range exposure measures 
country 
Pike 1989 Individualised 66 children 0.6-16.8 Few food diets Visual DSPCFC all negative Parental UK(Pike, few food diet with severe years, (based on eczema score despite 12 (18%) identification of Carter et al. (n=65) eczema, mean commonly (unvalidated) having long term provoking foods is 1989) followed by 54% of age 4.2 allergenic Diary cards benefit from dietary unreliable 
serial whom had years substances, (itch, redness exclusion. 
reintroduction previous history from and sleep 
of foods in dietary parents and foods disturbance 0-
diet intervention frequently 3) 
! 
responsive ingested) for 
children median of 26 
(n=20). days (range 19-
DSPCFC in 44), serial 
subset reintroduction 
I (n=10). (n=20). Parental 
Randomised recording of 
I order of active "exacerbating 
and placebo foods". DSPCFC 
challenges. (n=10) of foods 
I Washout (1 described as I 
, 
week) exacerbating 
, 
eczema by 
parents. 
-- ~ ~
----
-JSl)-
Author! Study type Number of Age Measures of Outcome Results Comments 
year! participants range exposure measures 
country 
Van Bever DBPCFC to 25 children 5 Elemental diet via Clinical All improved during Authors state no 
1989 food and food severe months nasogastric tube scoring <4 elemental diet phase. exacerbation of 
Belgium additives and eczema to 13.8 for 1-2 weeks as hours after Food 46.8% of eczema after 
(Van Bever, food additives years inpatient. challenge. challenges +ve, 51 % challenge (all 
Docx et al. (tartrazine, DBPCFC given Symptom skin reactions resolved <4 hours). 
1989) sodium via nasogastric score Food additives 
benzoate, tube (19 (redness, 39% +ve. Most 
sodium challenged with hives, developed rashes. 
glutamate, food, 5 with food swelling, No reactions to 
sodium and additives and itching) placebo 
metabisulfite, 1 with food 
acetylsalicylic additives only). 
acid and Two challenges 
tyramine) per day, one 
I Randomised active and one 
I order. placebo. 
I 
No washout 
I 
: i 
i 
! 
" 
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
Sloper DBPCFC with 64 children 0.5-15 Elimination diet Daily 74% improved during Authors report 
1991 (Sloper, washout (1 with eczema years (milk, eggs and symptom elimination period. worsening with 
Wadsworth week) recruited foods implicated score (0-3). Cow's milk median cow's milk and 
et al. 1991) from in history) for >3 Unpublished itch score increase tomato (actual 
outpatient weeks (median clinical 1.4 (-2 to 12.5), results not given). 
clinics and length of scoring p<0.01, median sleep No worsening with 
advertiseme avoidance 4.6 system. A score increase 9 (-6 egg but 36% 
nt in months) followed reduction of to 9), p<0.05; Egg incomplete. 
eczema by DBPCFC (194 skin core of 3 median itch score Questionable if 
magazine. challenges given, (range 0-80) increase 0.8 (-4 to change in score of 
! Varying range 1-11). considered 12) NS. Significant 3 points clinically i 
severity Challenges given significant. association between significant. 
as 1 tin daily for 1 positive challenge 
week of specific and improvement on 
food type elimination diet, 
followed by 1 p<0.001. No 
week washout. relationship between 
history of food-
induced eczema and 
positive challenge. 
I 
I 
I 
L 
---
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
Oranje 1992 Case control 91 patients 0-5 Skin application Unvalidated 67% FICH +ve of No definition of 
Netherlands study of food with eczema years food tests (SAFT) severity score whom 33% had what change in 
(Oranje, provocation (severity not using food flared during or score constituted a 
Aarsen et al. using skin given) and allergens applied shortly after SAFT. flare. The authors 
1992) application 16 healthy on gauze in Finn FICH +ve to eggs in state that most 
food tests controls chambers (milk, 44 (72%), to milk in flares were 
(SAFT) to egg, soy, peanut 29(47%) and peanut urticarial. 
i trigger food butter and other in 21 (34%) of FICH Eczematous flare 
! immediate foods if clinically +ve individuals. ups were seen in 
contact suspected). Oral Placebo responses 33% of FICH +ve 
hypersensitivit food challenge not given. No positive individuals. 
y (FICH). No tests in patients responses in controls 
randomisation with inconclusive 
SAFT results 
Oranje 1992 Case control 52 eczema, 0-5 Skin application Unvalidated Contact urticaria in 50% had 
Netherlands study of food 22 control years food tests (SAFT) severity score 25/52 (egg), 16/52 correlation between 
(Oranje, van provocation where foodstuffs milk and 11/52 food contact or 
T oorenenber using skin applied to back of peanut. 10.5% (4/38) ingestion and 
gen et al. application patient using exacerbation of eczema worsening. 
1992) food tests pieces of gauze, eczema after SAFT. 
(SAFT). No oral food Placebo responses 
randomisation challenge tests in not given. No positive 
i patients with responses in control 
inconclusive group. 
SAFT results 
-----
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
Devlin 1992 Double-blind 12 children 1.9 to Three tartrazine Change in Median eczema 1 worsened during 
UK(Devlin placebo severe 6.9 50mg and unvalidated symptom score three weeks of 
and David controlled eczema and years glucose score. tartrazine weeks tartrazine 
1992) challenges parental challenges Severity was (216) vs. placebo exposure. P=O.46 
with tartazine. history of comprising weeks assessed weeks (154), median for possibility of 
I Randomised tartrazine in random order. before and change in score (+4) result arising from 
I order. No worsening 24-48 hours vs. (-6); not chance. Small 
washout eczema. after the statistically study 
challenge. significant, p>O.1 
Positive 
challenge was 
where 
tartrazine 
weeks had 
highest 
scores or 
greatest 
increase in 
scores 
\ I 
I 
I 
I 
I 
~ ~
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-Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
. Beyer 1998 DBPCFC 17 children 1-10 Milk and egg free Clinically 41 % +ve challenge Authors 
Germany No with eczema years diet for 5 days determined 18% worsening of demonstrate 
(Beyer, Renz randomisation with followed by exacerbation eczema. Placebo change in 
et al. 1998) No washout suspected DBPCFC. of eczema challenges all lymphocyte 
allergy to Increasing doses within 48 negative subpopulations with 
egg or of hens egg (up hours after reduction in total 
cow's milk to 30ml); cow's challenge. number and 
9 controls milk allergen (up Lymphocyte percentage 
to 200ml) or populations lymphocytes 
, placebo given at assessed by (activated T cells 
30 minute flow and B cells) after 
intervals until cytometry. challenge in food-
clinical symptoms sensitised children 
or the maximum independent of 
dose was outcome of food 
reached. challenge. 
Reekers Elimination 37 17-64 Elimination diet SCORAD 17/37 worsened Polyclonal T cells 
1999 diet followed outpatients years excluding all birch (increase of (median increase in with Bet v1 in 
Germany by DBPCFC eczema and pollen-related 15 points SCORAD 21 in responsive and 
(Reekers, Randomised hypersensiti food for 4 weeks significant) responders). Results non-responsive 
Busche et al. order. vity to birch followed by Proliferation for placebo challenge patients. Increased 
1999) No washout pollen and DBPCFC (one assays before not given. CLA+ve 
no history of active challenge elimination lymphocytes only in 
food only) with 60g of diets using responder group. 
hypersensiti carrots, 20g of birch pollen. Authors suggest 
I vity hazelnuts and Observation that CLA positivity 
60g of apple and period of 2 in responsive 
a placebo hours after patients may 
1 _____ challenge challenge explain skin homing 
-164-
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Author! Study type Number of Age Measures of Outcome Results Comments 
year! participants range exposure measures 
country 
Vieluf 1999 Part 1 Open Part 1. 64 Part 1. Part 1. Series of Change in 96 positive reactions Unclear what 
Germany oral moderate to 1-66 foods including SCORAD, not in 44 patients to degree change in 
(Vieluf, provocation severe years "provocation diet" given in detail foods in part 1. 23 SCORAD 
Wieben et al. tests (OPT) to eczema on day 6 with flare ups of eczema significant 
1999) foods, part 2 additive rich with food additives in 
Double-blind Part 2.30 foods part 1, first symptoms 
placebo- people with occurring 30 minutes 
controlled eczema with Part 2. Part 2. Food after provocation. 7 
OPT to food a history of 3-68 additives in reacted to 1, 9 to 
additives reactions to years gelatine capsules two , 1 to three and 2 
Not additives in increasing to 4 FAs in part 2 
randomised doses for up to 8 Results for placebo 
hours with not given 
observation for 16 
hours. Challenge 
given to people 
with a history of 
adverse reactions 
to food additives 
, 
! or to additive-rich 
foods on day 6 
I 
I 
I 
I 
~ . ~ ~ ~ ~
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
Worm 2000 Elimination 50 18-72 Low Worsening of Elimination diet: 63% Only 6 +ve 
Germany diet, open outpatient years pseudoallergen modified improved (26/41 who DBPCFC. No long 
(Worm, challenge, eczema diet for 6 weeks Costa >10 completed diet) term F/up 
Ehlers et al. DBPCFC with (multiple followed by open points. Fall of Open challenge: 
2000) food SPT +ve), challenge (n=26) >35% 19/24 +ve; DBPCFC: 
additives. 15 in responders, improvement. 6/15 +ve, 1/15 +ve 
Randomised responders then by DBPCFC response to placebo. 
order to low (n=15) in No immediate 
Washout 48 pseudo- responders to responses. 
hours after allergen diet open challenge. 
each underwent Challenge with 
provocation DBPCFC food additives 
combined in one 
I administration or placebo. 
Observation for 
48 hours after. 
Ehlers 2001 Elimination 30 2-47 Sugar elimination SCORAD No change in No control group 
Germany diet (sugar- outpatient years diet for 1 week (>15 SCORAD or pruritus 
(Ehlers, free diet for 1 eczema followed by increase) levels active vs. 
Worm et al. week prior to DBPCFC with ECP levels placebo challenge 
2001 ) challenges either sucrose or Pruritus levels 
and continued placebo in 
during random order 
challenges), 
DBPCFC 
Randomised 
order 
Washout ! I I 
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
. country 
Breuer 2004 Elimination 12 children 3-9 Elimination diet SCORAD, 4 had worsening of Challenges varied. 
Germany diet followed moderate to years for 4 weeks IgE to birch eczema P=0.018. No 3 patients had 
(Breuer, Wulf by DBPCFC severe excluding all birch pollen and relation to specific immediate 
et al. 2004) Randomised eczema pollen-related birch pollen IgE in responders vs. reactions requiring 
No washout foods followed by related foods. non-responders. No oral steroids, these 
DBPCFC (n=9). Clinical +ve placebo patients did not 
Challenge with assessment challenge develop 
either verum for up to 6 eczematous 
containing birch hours after reactions 
pollen related last dose. 
food or placebo; 
successive doses 
I 
I given until full 
! dose or reaction 
with 10 minute 
intervals between 
doses on day 1 . 
I On day 2, the full I 
I , 
dose was given i 
i 
! 
together. 
I Washout period 
I I 
of 1 day 
I 
I 
-----
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
Worm 2006 DBPCFC in Questionnai 18-65 DBPCFC in SCORAD 1/9 showed Poor response to 
Germany people re sent to years people with (>15 worsening of eczema questionnaire but 
identified as 13,300 history, SPT or increase) with study suggests that 
having individuals RAST suggestive a negative food allergy is not 
eczema with in of food allergy. placebo an important cause 
either a population. Active challenge response of exacerbations of 
history or 13% (1739) with 50g of unselected adults 
investigation responders vegetables and in the population. 
suggestive of of whom 28 fruit, 10g of 
allergy to that had active hazelnut and 
food eczema. peanut, 20g of 
Tests done fresh flour, 200ml I 
in 9 patients of cow's milk and 
1 egg 
--- - -- ~ ~ - - -- - - - - - -------- - - - - - - --
HOUSE DUST MITE 
Tupker1996 Double-blind 20 patients 18-30 Inhalant Costa score, Worsening 9/20 Unclear if 
Netherlands randomised with eczema years challenge with Itch score 1-4 (scores not given in worsening 
(Tupker, De placebo and positive HOM over 80 Changes in results), 4 <8 hours constituted flare of 
Monchy et al. controlled SPTto minutes. severity or of challenge, 5 eczema. Costa and 
1996) study HOM Interval of 1 localization of sustained. itch scores not 
week between eczema Preceded by fall given (description 
random order noted. FEV1 >15% (n=8). only: 3 
active and FEV1 1 response to exacerbation 
placebo placebo existing areas only, 
challenges 3 new areas only 
and 3 combination) 
- -- ----- --
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-Author! Study type Number of Age Measures of Outcome Results Comments 
year! participants range exposure measures 
country 
Norris 1998 Double-blind 34 eczema 16-65 Dp and control Clinical 1!3 deterioration Only one site 
UK placebo- 12 atopic, 6 years solution to grading score. Significant tested 
(Norris, controlled endogenous alternate system, difference compared 
Schofield et exposure eczema antecubital or measurement to placebo only seen 
al. 1988) tests to popliteal fossae of area, VAS for mildly, not 
Dermatophag twice daily for 5 itch uninvolved skin, 
oides days p<0.01 
pteronyssinus 
(Dp) solution. 
Not 
randomised 
Shah 2002 Double-blind 20 17-62 Op and control SASSAD 6 patients increased Blinding may not 
UK placebo- outpatients years solution to score in SASSAD and VAS have been 
(Shah, Hales controlled with eczema antecubital antecubital scores. complete (different 
et al. 2002) exposure of varying fossae twice fossae Stimulation indexes coloured solutions). 
tests to Dp severity daily for 4 days VAS Itch (0- challenge positive vs. Only one site 
, solution 100) challenge negative tested 
I Randomised PBMC (p=0.004). No 
to different proliferation response to placebo 
sides assays 
OTHER AEROALLERGENS 
Wananu Double-blind 30 eczema 2-14 years SPT,APT Clinical 90% APT +ve in No severity 
kul 1993 placebo 30 controls aeroallergens: severity eczema group assessment tool 
Thailand controlled (respi ratory house dust mite, assessment 3 patients in eczema used. Eczema in 
I (Wanan atopy patch atopy) cockroach, mold (subjective) group had flare of other sites may not 
ukul, test (APT) mix and grass eczema (antecubital be related 
Huipras series. mix on tape and popliteal fossae). 
ert et al. Not stripped skin No reaction to 
1993) randomised placebo 
- ~ ~
-
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
Bygum 2003 Case control 23 19-29 APT various Reading of No convincing Trigger for flare up 
Denmark atopy patch moderate to years potential tests and relationship between unclear 
(Bygum, test study. severe (cases) allergens correlation +ve APT, history and 
Mortz et al. Randomised eczema including Dp, to distribution of 
2003) 25 healthy 18-30 grass, cat, milk prospective eczema. 2 patients 
non-atopic years and pityrosporum history. flare up of eczema 
controls (controls) ovale. Clinical during APT. No 
severity reaction to placebo 
(su bjective) 
WASHING POWDER 
I Andersen Randomised 25 mild to 17 to 59 Randomised SCORAD, No difference Authors comment 
i 1998 double-blind moderate years double blind Corticostero between eczema on low numbers 
Denmark crossover trial eczema crossover; each id quantity severity in either and short duration 
(Andersen, of washing involving period one month Patient study period, p>0.99 
Bindslev- detergents clothing duration record itch 
Jensen et al. enzyme vs. covered and 
1998) non-enzyme body sites intensity 
containing using 
detergents arbitrary 
scale (0-3) 
___ - I 
SUNLIGHT 
Deguchi Case series. 74 patients 15 to 47 UVB and UVA Measureme 14 patients (39%) Improvement with 
2002 Japan No placebo, facial years phototests (n=36) nt of abnormal papular sunscreen 1-2 
(Oeguchi, no control eczema on unexposed erythema response to UVB with weeks in patients 
Danno et al. group (>50% skin of back and papules normal or reduced with abnormal UVB 
2002) surface) Histological minimal erythema response 
indurated assessment doses. Histology 
erythema confirmed eczema 
I for >6 mo 1 _____ 
-------
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-Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
- - ---
TEXTILES 
----_.-
Seymour Randomised 85 infants <20 Cloth vs. Scoring Significant difference Change in nappy 
1987 controlled with eczema months cellulose core system for in nappy rash score rash only not 
USA trial,26 and 87 nappies vs. eczema cellulose with eczema severity 
(Seymour, weeks. Three controls cellulose nappies modified absorbent core vs. 
Keswick et types of were with absorbent from cloth nappies at 5 of 
al. 1987) nappy: home recruited core Queille. 8 visits. Significant 
laundered from Score for correlation between 
cloth nappies, advertiseme nappy rash nappy rash and 
conventional nts and (0-4 ). eczema severity 
cellulose core physician Graded outside the nappy 
1 and cellulose referral. every two area only in those i 
core Varying weeks for 6 wearing cloth 
containing degrees of weeks and nappies. 
absorbent severity then 
gelling monthly 
material 
Diepgen Randomised 55 eczema, Mean age Cotton,3 Comfort Comfort 8.4 cotton Only significant 
1990 controlled trial 31 controls 24.8y synthetic textiles score (1- vs. 7.3, 3.66 (S), 3.3 difference for fabric 
Germany of poncho-like (severity not varying 10), (S). Difference roughness. 
(Diepgen, shirts in 4 given) roughness. maximum between cotton and 
Stabler et al. different Repeated comfort=10, synthetic fabrics with 
; 1990) materials: wearing of maximum coarser weave with 
cotton and ponchos discomfort= reduced comfort in 
synthetic 1 the coarser fabrics 
fabrics of for those with 
different fibre eczema compared to 
structure controls. 
--
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-Author! Study type Number of Age Measures of Outcome Results Comments 
year! participants range exposure measures 
country 
Diepgen Randomised 20 eczema, Mean age Seven different Visual More discomfort with No difference in 
1995 controlled trial 20 patients 25.3 types of fabrics: analogue rougher weave fabric comfort between 
Germany comparing with (eczema), three jersey knits scale: very (warp vs. jersey, those with eczema 
(Diepgen T J ponchos in psoriasis 27.2 years (one cotton, two comfortable, p<0.01 ). and two other 
1995) seven vulgaris and (psoriasis) polyester) and comfortable, Reduced comfort groups with 
different 20 control and 28.4 four warp knit slightly with sweating in all sweating. 
I fabrics. participants years polyester fabrics. uncomfortab groups (p<0.0001), i 
I 
I with no skin (controls) Each individual Ie and very worst at maximum I 
disease underwent an 100 uncomfortab sweating. Ponchos 
Watt stress on an Ie (4 made from polyester 
ergometric categories with similar fineness 
bicycle wearing in each). to cotton were 
i the ponchos tolerated as well as 
I 
I cotton in eczema 
group 
BACTERIAL INFECTIONS 
David 1986 Cohort study 190 children 7 weeks Bacterial infection Clinical 164 episodes of Impossible to 
UK(David 21!2 years with eczema to 17 as defined by assessment infection and 20 exclude role of 
and attending years 1.Presence of of severity episodes of possible other factors, 
Cambridge outpatient (median pustules, purulent of eczema infections in 40% of although response 
1986) department. age 3 discharge, crusting every 3 patients to antibiotics 
years) with or without months or 15% of episodes lead supports role of 
weeping and sooner if to hospital infection. No 
2.Response to oral unexpected admissions clinical severity 
antibiotic or topical deterioration scoring system 
antiseptic treatment of eczema used 
- --
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
SEASONALITY 
Vocks 2001 Observational 2,106 16-74y Meteorological data Daily I nverse correlation of Group score used. 
I Germany ecological participants (15 variables) average itch group daily average Participants 
(Vocks, study score itch score with contributing to 
Busch et al. 7 years temperature (r=- group changed 
2001 ) 0.235) over time 
Kramer 2005 Panel study 39 children 8.7-9.7 Patient daily record Daily itch Winter (improved itch Subtypes identified 
Germany 6 months with eczema years of exposure and extent by 22% and extent by in post-hoc 
(Kramer, (17 including twice of eczema 65% per 15°C analysis. Study did 
Weidinger et excluded daily household temperature rise) not include winter 
al. 2005) due to poor temperature and (n=21) and summer period (March to 
diary humidity levels. types (increased itch September) 
completion Outdoor by 16% and extent by 
or absence temperature and 19% correlated with 
of eczema) humidity, pollen grass pollen) 
count and radiation identified (n=18). The 
correlation for pollen 
existed when grass 
pollen counts were 
higher than 46 per 
m3. There was no I 
association with birch 
I pollen levels 
I 
--
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Authorl Study type Number of Age Measures of Outcome Results Comments 
yearl participants range exposure measures 
country 
-STRESS 
--
Gil 1987 Case series 44 eczema 2-21 Life events Symptoms Pearson correlation Once-off evaluation 
USA (Gil, years checklist, AD score sheet, coefficients: Relation of all measures in 
Keefe et al. problem total and %BSA AD distress and selected group 
1987) eczema distress symptoms (r=0.5) 
scores and life events 
(r=0.03). Relationship 
between family 
environment 
characteristics and 
eczema severity (less 
severity in 
independenU 
organised vs. 
moral/religious ). 
King 1991 Prospective 50 eczema, Mean Diary completed for Eczema Relation stress and Volunteers I 
(King and case-control 30 controls age two weeks subjectively self-rated severity included. Control 
Wilson 1991) study eczema recording daily scored daily (r=0.2), anxiety and group were 
Australia 30.6 emotional states (1-3 ). tension (r=0.3). psychology 
years, and skin condition. Depression Relation between students 
controls and stress stress and skin 
27.6 recorded condition on the 
years daily. following day (r=0.28, 
p=0.04) (reciprocal). 
I 
Depression was 
I predicted by the skin 
condition on the ! 
I 
previous day 
I (p=0.0005 
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Abbreviations for appendix 3 
SCORAD: SCORing atopic dermatitis score 
AD: atopic dermatitis 
OPT: oral provocation tests 
DBPCFC: double blind placebo controlled food challenges 
HDM: house dust mite 
Dp: Dermatophagoides pteronyssinus 
SASSAD: Six area six sign atopic dermatitis severity score 
FEV1: Forced expiratory volume in 1 minute 
FICH: Food immediate-contact hypersensitivity 
SPT: Skin prick tests 
RAST: Radio-allergosorbent test 
APT: Atopy patch test 
PBMC: Peripheral blood 
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Appendix 4 Psychometric properties and scale quality criteria considered in the systematic 
review of outcome measures in eczema 
------- ------------,----
Name of 
quality item 
I 
I 
Definition of 
I item 
I 
-, ---,--- ---- ----:-------_ .. ,. 
i ! Measurement 
I of quality item 
I 
Criteria for 
i "adequate" 
rating 
Criteria for 
! "acceptable" 
I rating 
Does the scale measure the hypothetical construct (objective severity of 
eczema) it should? 
~ - - - - - - - , - - - - - - - - - , - - - - - - ----- -
Construct 
validity: 
(a) 
convergent 
I (b) 
divergent 
Content 
validity 
(a) Are 2 
outcome 
i measurements 
that are 
presumed to 
measure the 
same construct 
correlated? 
:-------,-,-
(b) Are 2 
outcome 
measurements 
that are 
presumed to 
measure different 
constructs not 
I related? 
Can the domains 
measure the 
construct in 
question? Are the 
items 
representative of 
the domain they 
are supposed to 
measure? 
- '-,-----'------
(a) and (b) 
Confirmatory 
factor analysis, 
Structural 
equations 
modeling 
(correlation of 
coefficients) 
Rating by 
experts and 
I consumers 
I Are the different 
Internal I domains/items of Cronbach 0* 
I consistency i the scale 
: I nterobserver 
reliability 
• interrelated? 
- ------,-------------
I 
I Do 2 or more 
independent 
I investigators 
achieve the same 
: result? 
i (a) Correlation I coefficient 
r------
: (b) Kt 
, 
r-- - --_. --" 
(c) Coefficient of 
: variation 
(d) ANOVA (% 
variance 
explained by 
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I 
i (a) Correlation 
coefficient >0.70 
(b) Correlation 
i coefficient ~ 0 . 7 0 0
Expert/consu mer 
. says yes for at 
i least 90% of all 
I 
, items 
, ~ 0 . 9 0 0 (individual 
patients) 
I 
I 
~ 0 . 7 0 0 (groups) 
(a) >0.80 
(b) >0.60 
(c) <20% 
(d) <10%) 
(a) Correlation 
coefficient 0.60-
0.69 
(b) Correlation 
coefficient 0.71-
0.85 
Expert/consumer 
I
, says yes for 70% 
to 89% of all 
I items 
0.70-0.89 
(individual 
patients) 
I 0.60-0.69 
I (groups) 1 (a) 0.60-0.80 
(b) 0.41-0.60 
I (c) 20% to 30:;: 
. (d) 10% to 2 0 ~ ~
Name of Definition of 
quality item item 
L-,--
T est-retest 
reliability 
I 
I 
1
002 
I assessments by 
; one investigator 
I • 
In the same 
patient yield the 
same result? 
Measurement 
of quality item 
observer) 
(a) Correlation 
coefficient 
Criteria for 
"adequate" 
rating 
(a) 0.90 
(b) Percentage 
variation I (b) <5% 
(c) ~ ~ e f f i c i e n t t of I ( ) < 10°1 
vanatlon c 10 
~ - - - - - - - - - , , ·.------------TI-------------T-----------
I 
Sensitivity to 
change 
Can clinically 
relevant changes 
be detected by 
this 
measurement? 
: Correlation of 
I changes in 2 or 
. more outcome 
I measurements 
! of the same 
>0.80 
I construct 
······-r----------------+--,--
lis the 
measurement 
practical enough 
I Acceptability 
to be applied in: 
(a) everyday 
clinical practice 
i Time to administer 
I 
i (a) <3 min 
Criteria for 
"acceptable" 
rating 
(a) 0.80-0.90 
I 
I(b) 5% to 10% 
(c) 10% to 20% 
0.60-0.80 
(a) 3-5 min 
I (b) clinical trials ! (b) <7 min ; (b) 7-10 min 
- - - - - - ~ - - ~ - - - - - ~ - - - -
*The Cronbach a value assesses the extent to which the items and domains of an outcome 
can be treated as measuring a single latent variable (range, -00 to 1.0; higher values reflect 
better internal consistency) (Kline 2005) 
t The K value is the chance-corrected agreement between 2 observers (range, -1.0 to 1.0; 
higher values reflect higher interobserver reliability) (Rosner 2000) 
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Appendix 5 Table of references for systematic review of outcome measures in eczema 
Angelova-Fischer, Bauer et af. 2005 
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Bahmer, Schafer et af. 1991 
Balkrishnan, Housman et af. 2003 
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Charman, Varigos et af. 1999 
Charman, Venn et af. 1999 
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Charman, Venn et af. 2005 
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Hanifin, Thurston et af. 2001 
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Hon, Leung et af. 2006 
Hon, Ma et af. 2003 
Housman, Patel et af. 2002 
Jenner, Campbell et af. 2004 
Kagi, Joller-Jemelka et af. 1992 
Kunz, Oranje et af. 1997 
Mastrandrea, Pecora et af. 2005 
Oranje, Stalder et af. 1997 
Pucci, Novembre et af. 2005 
Rajka and Langeland 1989 
Schachner, Lamerson et af. 2005 
Schafer, Dockery et af. 1997 
Schneider 1994 
Severity scoring of atopic dermatitis: the SCORAD index. 1993 
Silny, Czamecka-Operacz et af. 2005 
Sowden, Berth-Jones et af. 1991 
Sprikkelman, Tupker et af. 1997 
Staab, Kaufmann et af. 2005 
Sugarman, Fluhr cI af. 2003 
Tofte 1998; 
Van Leent. Graber et af. 1998 
yan Joost, Heule et af. 1994 
Verwimp 11M 1995 
\\' olkerstorfer, de \\' aard \an der Spek et af. 1999 
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Appendix 6 Characteristics of validation studies on outcome measures in eczema included in 
the systematic review 
Study characteristics I I 
Study population 
I 
No. of 
participants 
Setting -
Outcome No. of Geographic Community/primary Per Age validation location care - Total study (range) measure studies Secondary/tertiary (range) 
I 
I care I ) 
ADAM 1 Australia Secondary/tertiary 171 171 0-16 Y care 
ADASI 1 Germany Secondary/tertiary 
care 
16 NS 1-34 Y 
ADSI 0 - - - - -
BCSS 1 The Secondary/tertiary 82 NS 0-67 Y Netherlands care 
Australia, 
United 
States, All secondary/tertiary 1801 20- 0-43 Y EASI 5 Europe, care 1550 
South 
America 
FSSS 0 - - - - - I 
Australia, 
United 
States, All secondary/tertiary 1751 201- 0-17 Y IGADA 2 Europe, care 1550 
South 
America 
Leicester 1 United 
Secondary/tertiary 123 NS 0-60 Y 
index Kingdom care 
I 
United Community, n = 2; 
NESS 5 Kingdom, secondary/tertiary 651 70-290 1-63 Y 
China care, n = 3 
OSAAD 2 Europe, 
All secondary/tertiary 70 32-38 0-38 y 
United States care 
1 
United Primary and 453 NA 1-62 Y I POEM Kingdom secondary care 
I All secondary/tertiary 52 6-30 1-54 Y RL score 3 Europe care 
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i Study characteristics 
----+--------. - ~ - - - - - ~ ~ ~ - ~ - - ~ - - ~ - -
No. of 
Outcome ! validation 
measure I I studies 
Geographic 
location 
Setting -
Community/primary 
care -
Secondary/tertiary 
care 
1------C----- - - l - - ~ ~ --r-------
SA-EASI 12 I United States I All secondary/tertiary I care 
---r----- --- -- r-, --- 1 ___ -
SASSAD 3 
I 
r · - - ~ - - - ~ - - - - ~ - - -
SCORAD i 14 
I 
r ~ - - - - , - - - - - ~ ~ - - - ~ ~
SIS 10 
r SSSl4 . 
I 
- r ~ ~
TBSA 10 
r ~ - - - - - ~ ~ - - - ~ ~ - r - ~ - - ~ ~
, 
TISS 12 
WAZ-S 10 
I 
United 
, Kingdom, 
! Australia 
Europe, 
China, 
I Canada 
I 
- T - - - ~ - - - -
I 
- - T - ~ - - - ~ ~
I Europe 
i 
--i---------
I 
Primary, n = 1); 
secondary/tertiary, n = 
2 
I Community n = 4· I " 
i secondary/tertiary 
: care, n = 11 
Study population 
No. of 
participants 
Per 
Total study 
(range) 
I 96 47-49 
! 
Age 
(range) 
0-12 Y 
6-85 3-63 Y 
i 1346 19-201 I 0-67 Y 
I 
! 
ADAM, Atopic Dermatitis Assessment Measure; ADASI, Atopic Dermatitis Area and 
Severity Index; NA, not applicable; ADSI, Atopic Dermatitis Severity Index; BeSS, 
Basic Clinical Scoring System; SIS, Skin Intensity Score; TBSA, Six-area Total Body 
Severity Assessment. 
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Appendix 7 Summary of psychometric properties of objective disease severity measures in eczema 
Outcome Content Content Construct Construct Internal Interobserver Test-retest Sensitivity to Time to Mean Recommendation 
validity- validity- validity- validity- consistency reliability reliability change perform score 
expert consumer convergent divergent (mins.) 
ADAM • • • X X 0 X X - 44% Not recommended 
ADASI • • 0 X X 0 X X 2-10 38% Not recommended 
ADS( • • X X X X X X - 25% Not acceptable 
Bess • • 0 X X • X X - 44% Not recommended 
EASI • • • • 0 0 0 • - 81% Recommended 
FSSS • • X X X X X X - 25% Not acceptable 
(GADA • • • X X X X • - 50% Acceptable 
Leicester • • X X X X X 0 - 31% Not recommended 
index 
NESS • • 0 • X • X X I 56% Acceptable 
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OSAAD X X 0 • X • X 0 5 25% Not acceptable 
POEM X • • 0 • N/A • 0 1-2 71% Recommended 
RL score • • X X X 0 X X <1-4 31% Not recommended 
SA-EASI • • 0 0 • N/A X 0 - 57% Acceptable 
SASSAD • • 0 X X • 0 0 <2-10 56% Acceptable 
SCORAD • • • • X • 0 • :oslO 81% Recommended 
SIS • • X X X X X X - 25% Not acceptable 
SSS • • 0 X X 0 X 0 1-5 44% Not recommended 
TBSA • • X X X X X X - 25% Not acceptable 
TISS • • • • X 0 X X - 56% Acceptable 
WAZ-S X • X X X X X X - 13% Not acceptable 
ADAM, Atopic Dermatitis Assessment Measure; ADASI, Atopic Dermatitis Area and Severity Index; ADSI, Atopic Dermatitis Severity Index; BeSS, BasIc 
Clinical Scoring System; NA, not applicable; SIS, Skin Intensity Score; TBSA, Six-area Total Body Severity Assessment. 
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Guide to appendix 7 
., Criterion is adequately met (100%); 0, criterion is acceptably met (50%); X criterion is inadequately met (0%). 
Recommendations are based on all items except time needed to perform measurement: Highly recommended, score greater than 90%, measurement is 
valid and reliable; recommended, score of 70% to 90%-measurement meets most validity criteria; acceptable, score of 50% to 69%, but not 
recommended-validity criteria only partly met; not recommended, score of 30% to 49%-significant validity criteria are not met or have not been evaluated"; 
not acceptable, score of less than 30%-measurement is invalid or has not been validated. 
t Weighted mean (weighted by the number of study participants) if psychometric property was assessed in more than one study; criterion judged as 
inadequately met if no studies identified on a psychometric property. 
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Appendix 8 Eczema study questionnaire 
Child's date of birth:' / / (dd/mm/yy) 
Sex: Boy D Girl D 
Ethnicity: 1 White 
3 Black-African 
5 Indian 
7 Bangladeshi 
2 Black-Caribbean 
4 Black-other 
6 Pakistani 
8 Chinese 
9 Other - please specify: 
Your child's eczema 
1. How long has your child had eczema for? 
---------------------
2. What kind of moisturiser does your child normally use? 
1) ____________________ _ 2) __________________ __ 
3) ____________________ _ 4) ____________________ __ 
3. What topical steroids does your child use? 
1) ____________________ __ 2) ____________________ __ 
4. How do you normally treat your child's eczema every day? (Name creams 
and how often use you use them) 
5. When your child's eczema gets worse, what treatments do you usually use? 
6. How long do you use them for? 
7. Does your child use any other treatments (other than topical steroidsl 
emollients) for their eczema (e.g. wet wraps, tacrolimus, and antihistamines)? 
IYes : No 
If yes, please say what: ______________________________________ _ 
-1 S4-
8. Has your child been on any of the following treatments for their eczema? 
Phototherapy/light treatment 0 
Cyclosporine, Neoral 
Azathioprine, Imuran 
Steroids taken by mouth 
o 
o 
o 
9. Has your child ever had asthma? Yes 0 No 0 
10. Has your child ever had hay fever? Yes 0 No 0 
Environmental factors 
11. Are you avoiding any types of clothes because of your child's eczema? 
Yes 0 No 0 
If yes, which type(s) of clothes? 
12. Are you avoiding any cleansing products (shampoo, shower gel etc) 
because of your child's eczema? 
Yes 0 No 0 
If yes, which ones? _____________________ _ 
13. Do you avoid contact with animals because of your child's eczema? 
Yes o No o 
If yes, proceed to q14 
14. Which types of animals do you avoid? ____________ _ 
15. Are there pets at home? 
If yes, specify type and 
Yes 0 No 0 
number ____________________ __ 
16. Is there carpet in yourl your child's bedroom? Yes 0 No 0 
17. Are there furry toys in your/ your child's bedroom? Yes D No D 
18. How often do you dust and Hoover your child's room each month? 
Daily o 
Every few days 0 
Weekly 0 
Every few weeks 0 
Once a month or less 0 
19. Does the eczema get worse in summer (June, July, and August)? 
Yes 0 No 0 
20. Does the eczema get worse in winter (November, December, and January)? 
Yes 0 No 0 
21. How does cold weather affect you! your child's eczema? 
Not at all 0 
Makes it better 
Makes it worse 
o 
o 
22. How does hot weather affect you! your child's eczema? 
Not at all 0 
Makes it better 
Makes it worse 
Home details: 
o 
o 
23. Does your child regularly share a bedroom? Yes 0 
If yes, proceed to q24 
No 
24. How many people does your child share his! her bedroom with? 
25. Does your child regularly share a bed? Yes 0 No 0 
o 
26. How many brothers and sisters does your child have? _______ _ 
27. How many people live in your house? ___________ _ 
Main household earner's occupation 
28. What is your occupation? __________ _ 
-\ ~ 6 6
29. If you have a partner, what is your partner's occupation? 
Your occupation Your partner's occupation 
Present occupation _____ _ Present occupation ______ _ 
Previous occupation _____ _ Previous occupation ______ _ 
Never employed D Never employed D 
30. What is the highest educational qualification of the main care giver? 
None D 
GCSE, 0 level or equivalent D 
A-level or equivalent D 
Higher education below degree D 
Degree/ higher degree D 
Other: _________________ __ 
Thank you very much for completing this questionnaire. 
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Appendix 9 Diary questions 
Dail questions 
No Question Next step I Notes 
0 WELCOME SCREEN Proceed to 
Please enter your data for <day/month/year>. Press tick to Q1 
continue 
1 How much did you (your child) scratch today? Proceed to 
Please give a number from 0 to 10 ( 0= not scratched at all; 10= Q2 
scratched all of the time) 
2 How much bother did your (your child's) eczema cause today? Proceed to 
Please give a number from 0 to 10 (0= no bother at all; 10= the Q3 
most bother you can imagine) 
3 Where did your (your child's) eczema get worse? (can pick more Proceed to Need to be able 
than one) Q4 to select more 
1 ) Hands than one choice 
2) Face 
3) Arms or legs 
4) Some of your trunk (back and tummy) 
4 How much time did you (your child) spend outdoors today? Proceed to 
1) Less than 15 minutes Q5 
2) Between 15 and 30 minutes 
3) Between 30 minutes and 2 hours 
4) More than 2 hours? 
5 What parts of your (your child's) skin were not covered by Proceed to Need to be able 
clothes during this time? (can pick more than one) Q6 to select more 
1 ) Hands and face than one choice 
2) Face only 
3) Arms or legs 
4) Some of your trunk (back and tummy) 
6 What was the most you (your child) sweated today? Proceed to 
1 ) Not at all Q7 
2) A little 
3) Damp forehead and/or underarms only 
4) Wet hair and damp underarms 
5) Dripping with sweat 
- - I 
7 Did you (your child) sweat because of playing sport? Proceed to I 
1 ) Yes Q8 
2) No 
8 Did you (your child) wear woollen clothes today? If Yes 
1 ) Yes proceed to 
2) No Q9. If No 
proceed to I 
Q11 
-- . 
9 Did you (your child) wear it next to the skin? If Yes 
1 ) Yes proceed to 
2) No Q10. If No 
proceed to 
Q11 
10 How long did you (your child) wear it for? Proceed to 
1 ) Less than one hour Q11 
2) More than one hour, up to a half day 
3) More than a half day, up to a full day 
11 Did you (your child) wear nylon or synthetic clothes today? If Yes 
1 ) Yes proceed to 
2) No Q12. If No 
proceed to 
Q13 
12 Did you (your child) wear it next to the skin? If Yes 1 ) Yes proceed to 2) No Q13. If No 
proceed to 
Q14 
13 How long did you (your child) wear it for? Proceed to 1 ) Less than one hour Q14 2) More than one hour, up to a half day 
3) More than a half day, up to a full day 
14 Were you (your child) in close contact with any animals today? If Yes 
1) Yes proceed to I I ! 2) No Q15. If No 
proceed to 
Q18 
15 What type of animal was it? (can pick more than one) Proceed to Need to be able 1) Cat Q16 to select more 2) Dog than one choice 3) Hamster, guinea pig or gerbil 
4) Rabbit 
5) Horse 
6) Other 
16 How long for? Proceed to 
1 ) Less than one hour Q17 
2) More than one hour up to two hours 
3) More than two hours 
17 Was it your own pet? Proceed to 
1 ) Yes Q18 
2) No 
18 Were you (your child) in a very obviously dusty place today? If Yes 
1 ) Yes proceed to 
2) No Q19. If No 
proceed to 
! Q20 
19 How long for? Proceed to 
1 ) Less than one hour Q20 
2) More than one hour up to two hours 
3) More than two hours 
, 
J 20 Did you (your child) go swimming today? Proceed Q21 
1 ) Yes 
2) No 
21 Have you had to step up your treatment today because your Proceed Q22 
(your child's) eczema was worse? 
1 ) Yes 
2) No 
22 Did you wash your (your child's) hair today? If yes, 
1 ) Yes proceed to 
2) No Q23. If no, 
proceed to 
24 
23 Did you wash it at the same time as your bath or shower? Proceed to 
1 ) Yes Q24 
2) No 
24 Thank you for entering your data. Are you happy with your If Yes, 
answers? proceed to 
Yes Q25 and data 
-\89-
No is saved. If 
No, return 
back to QO 
and Data is 
not saved 
25 Your data has been submitted. You need to enter your data Finish. 
again on <date> 
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